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SUMMARY  
 
In addition to the so-called small molecule drugs, proteins and peptides are of increasing 
interest for pharmacotherapy, due to several advantageous properties. In general, those 
compounds are administered parenterally. However, non-invasive routes of administration 
represent a great part of research. Amongst others is the pulmonary application of proteins 
and peptides for local delivery in the case of pulmonary diseases, such as idiopathic 
pulmonary fibrosis, where the alveolar epithelium is affected.  
To ensure an intracellular delivery, nanoparticles in a size range of 150 nm were prepared via 
charge-mediated coacervation, characterized for their physicochemical properties and loaded 
with several model-proteins and -peptides. The material used for nanoparticle preparation was 
chosen to be positively and negatively charged starch derivatives, which were synthesized 
from potato starch. 
Although nanoparticles in that size range are known to show an increased cell uptake, they do 
not show a high deposition in the deep lung. Thus, an advanced carrier system consisting of a 
fast dissolving microparticle matrix with embedded starch nanoparticles was developed and 
characterized. Due to its aerodynamic properties, that carrier system was able to deposit a 
high fraction of the applied dose in the deep lung (~50%), while at the same time 
demonstrating (in in vitro models) the ability to facilitate uptake of starch nanoparticles into 
cells of the alveolar epithelium after fast dissolution of the microparticle matrix.  
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KURZZUSAMMENFASSUNG 
 
Aufgrund zahlreicher Vorteile, stellen Proteine und Peptide eine vielversprechende 
Erweiterung der Pharmakotherapie dar, weg von sogenannten small molecule drugs. Die 
nicht-invasive Applikation solcher Wirkstoffe steht heutzutage im Fokus der Forschung. 
Unter anderem zählt hierzu die pulmonale Applikation von Proteinen und Peptiden für die die 
lokale Gabe bei bestimmten Lungenerkrankungen wie z.B. der idiopathischen pulmonalen 
Fibrose, bei der vor allem das Alveolarepithel betroffen ist.  
Um ein intrazelluläres Delivery zu gewährleisten wurden Nanopartikel durch 
ladungsvermittelte Koazervation im wässrigen Medium mit einem Größenbereich um die 150 
nm hergestellt und charakterisiert. Im Anschluss wurden die Nanopartikel mit verschiedenen 
Modell-Proteinen und -Peptiden beladen. Das Material für die Nanopartikel bestand dabei aus 
negativ und positiv geladenen Stärkederivaten, welche aus Kartoffelstärke synthetisiert 
wurden.  
Da Nanopartikel in diesem Größenbereich zwar eine Aufnahme in die Zelle erleichtern, 
allerdings keine hohe Depositionsrate in der tiefen Lunge erreichen, wurde im Rahmen dieser 
Arbeit ein spezielles Drug Delivery System, bestehend aus in einer sich schnell auflösenden 
Mikropartikel Matrix mit eingebetteten Nanopartikeln, entwickelt und charakterisiert. Durch 
seine aerodynamischen Eigenschaften ist das Drug Delivery System fähig einen Großteil der 
applizierten Dosis in der tiefen Lunge zu deponieren (~50%), als auch, nach der schnellen 
Auflösung der Mikropartikel Matrix, die Aufnahme der Nanopartikel in das Lungenepithel (in 
vitro) zu gewährleisten. 
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1. STATE OF THE ART 
1.1 PROTEINS AND PEPTIDES AS ACTIVE PHARMACEUTICAL INGREDIENTS 
Historically speaking, active pharmaceutical ingredients (APIs) such as acetylsalicylic acid or 
paracetamol have been commonly characterized by a small molecular weight. However, 
modern drug discovery approaches most often lead to drugs with a hydrophobic character and 
a high molecular weight, resulting in poor water solubility and low permeability over 
epithelial barriers, respectively.1, 2 In recent times, the use of so-called biopharmaceuticals, 
including nucleic acid- and protein- based APIs with complex chemical structures have begun 
to find favor in therapeutic settings; such entities have shown faster and higher success rates 
in phase two and three clinical trials compared to conventional APIs.3, 4 This is especially 
important for pharmaceutical industry with clinical trials being the most expensive part of 
development. 
Due to the fact that this thesis is about drug delivery systems (DDS) for protein and peptide 
delivery, the focus of this chapter lies on protein- and peptide-based APIs. Nucleic acid based 
APIs will not be explained, so the reader is referred to several literature reviews about this 
topic.5-8 
 
1.1.1 THE STRUCTURE OF PROTEINS AND PEPTIDES 
Proteins and peptides are biomacromolecules consisting of amino acid residues. The main 
difference between proteins and peptides is their size, represented by different numbers of 
constituent amino acids. While peptides in general consist of a linear chain of 20-30 amino 
acid monomers (primary structure), proteins generally have more than 100 residues, also 
showing different protein folding and resulting higher levels of structure (secondary, tertiary, 
quaternary structure), as can be seen in Figure 1.1. 
Proteins and peptides in the human body are mainly composed of 22 different amino acids. 
Amino acids consist of an amine group (-NH2) and a carboxyl group (-COOH) that are both 
linked to a carbon atom which is also bound to a hydrogen atom and a variable moiety. The 
primary structure is constructed of so-called peptide bonds between the carboxyl group of one 
amino acid and the amine group of another.9 The secondary structure is mainly formed by two 
motifs: the α-helix and the β-sheet. Additionally, random coils with no clear spatial 
arrangements occur (displayed as turquoise strands in Figure 1.1). For the formation of a 
tertiary or quaternary structure, several peptide chains building multiple subunits are 
combined to form the final protein, e.g. in enzymes. The process of folding is highly complex 
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and cannot be done easily by chemical synthesis. As a result, biotechnology-based methods 
are often used as manufacturing tools.9 
 
 
Figure 1.1: Different protein folding, shown by the example of the HIV-1 NEF protein, a 
non-receptor tyrosine-protein kinase that plays a role in many biological processes. 
 
Unlike proteins, peptides mostly only possess a primary structure. Due to disulfide bond 
formation, they sometimes express a secondary structure,9 as known from vasopressin 
(antidiuretic hormone) or insulin.  
 
1.1.2 PROTEIN AND PEPTIDE THERAPEUTICS 
Proteins fulfil various functions in the human body, ranging from stabilizing tissues and 
organs (e.g. collagens), to transport, storage of molecules, mediation of receptors, and 
catalysis of metabolic reactions (enzymes). As a result, they often exhibit post-translational 
modifications, such as phosphorylation, acetylation or glycosylation, which activates the 
protein and allow it to carry out its specific function. In contrast, most peptides work as 
signaling agents and are classified as hormones.9  
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In many cases, diseases are the result of missing or malfunctioning proteins. The idea of 
protein- or peptide-based APIs is often therefore to replace these compounds. Currently, 
proteins and peptides represent a large fraction of compounds in drug development pipelines, 
due to their predictable activity profiles and their highly selective mode of action. 
Additionally, several formulations incorporating protein or peptide APIs are already on the 
market, as illustrated in the following. 
Insulin is the oldest example of a peptide-based API, used for the treatment of diabetes 
mellitus type 1 - a metabolic disorder resulting from an absolute insulin deficiency, caused by 
either defects in insulin action, secretion, or both. Before the discovery of insulin by Banting 
and Best in the 1920s, this disease in its most severe form often led to death.10 Today, insulin 
is usually administered via subcutaneous injection. Different modifications of the molecule, 
resulting in long-acting and short-acting insulin derivatives, allow for mimicry of the 
physiological secretion of insulin by the pancreas.10 
The small peptide-derivative leuprorelin is a luteinizing hormone-releasing hormone (LH-RH) 
agonist which was first synthesized by Takeda Chemical Industries in 1974,11 being 80 times 
more potent than natural LH-RH.12 It is used today in the treatment of e.g. advanced and 
metastatic prostate cancer - as part of androgen deprivation therapy (ADT), acting to suppress 
testicular steroidogenesis - when administered continuously. This first formulation, which was 
associated with the need for frequent dosing via subcutaneous or intramuscular 
administration, was soon replaced by a depot formulation, allowing for dosing at one-month 
intervals. Further developments, using various DDS allow for application at a three-monthly 
or even six-monthly (Eligard® 45mg; Atrix Laboratories) intervals.13 ADT in general and the 
advanced depot leuprorelin medication in particular, replaced orchiectomy, an irreversible 
surgical castration, which was one of the rare and unpleasant treatment options in the 1940s.  
With the progress in biotechnology, the use of monoclonal antibodies for the treatment of 
various inflammatory diseases has seen a rapid increase in popularity. One example is 
adalimumab (Humira®), a recombinant fully humanized monoclonal antibody, used for the 
treatment of moderately to severely active rheumatoid arthritis (an immune-mediated, chronic 
inflammatory disease characterized by chronic synovitis). Adalimumab binds specifically to 
the pro-inflammatory cytokine TNF-α, neutralizing cytokine activity. It can either be used as 
monotherapy or in combination with so-called disease-modifying anti-rheumatic drugs 
(DMARDs) such as methotrexate.14 
It can therefore be seen that in a wide range of diseases with diabetes, cancer and 
inflammatory diseases representing just a few examples - proteins and peptides are 
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successfully used as API. The use of proteins and peptides in such contexts may act to provide 
a treatment where none was available before, or to further improve the outcome of existing 
therapy options, considered inefficient from a modern perspective. However, the delivery of 
proteins and peptides is a complicated task, as discussed further below.  
 
1.1.3 NEEDS IN PROTEIN DELIVERY  
Parenteral application is the typical route to deliver proteins and peptides and is the least 
expensive and quickest strategy for commercialization, however owing to their complex 
structure, proteins and peptides are susceptible to degradation. Degradation results  in protein 
unfolding and thus a loss of function,15 which may also be accompanied by an unwanted 
immune response in vivo. The maintenance of the spatial structure of proteins is therefore of 
great importance. For peptides, besides their short half-life, the most important property to 
either maintain or enhance is their ability to gain intracellular access, as they often have their 
target inside the cell. One strategy employed to overcome stability or pharmacokinetic issues 
associated with proteins or peptides is to chemically modify the molecular structure, as known 
for example from the use of protein analogs15 or via acylation16-18 or PEGylation.19, 20 
However, care must be taken during modification not to reduce efficacy or to cause 
immunogenicity. As an alternative to changing the chemical structure, the use of DDS based 
on micro- or nanoparticles could be applied for protein and peptide delivery. Here, the protein 
can be used in its original form, and will be protected during storage and delivery by the DDS. 
The application of nanotechnology in the form of DDS (‘nanotechnology enabled DDS’) 
could even enhance protein uptake into or permeation over epithelial barriers, allowing for 
non-invasive administration and avoiding the requirement for injection. Nevertheless, as high 
salt concentrations, heat, shear stress or extreme pH values during preparation might be 
detrimental to the protein/ peptide structure, mild manufacturing processes have to be chosen, 
that do not degrade the protein or peptide during DDS preparation and loading. 
In summary, the successful formulation of proteins and peptides requires a thorough 
understanding of the physicochemical and biological properties of the protein-/peptide-based 
API. This includes knowledge of physical and chemical stability, as well as of the 
characteristic pharmacokinetic profile.  
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1.2 NANOPARTICLES FOR MEDICAL APPLICATIONS 
The following section gives an overview on the topic of nanotechnology, as background to 
further discussion on nanotechnology enabled DDS.  
 
1.2.1 A PHARMACEUTICAL PERSPECTIVE ON NANOTECHNOLOGY 
Although the concept of nanotechnology was defined by Taniguchi in the 1970s, a universally 
agreed upon interpretation of this term is still unavailable. Typically, a material can be 
considered as ‘nano’ if it exists in a size range of 1 nm to 100 nm, with special physical and 
chemical properties or biological effects that differ from its larger-scale counterpart. In the 
field of pharmacy the definition is even broader, including particles up to 1000 nm in size. 
A broad range of industrial sectors apply nanotechnology and nanoparticles: From food 
agriculture21 to electronics,22, 23 renewable energy,24, 25 and health care26-29 to just mention a 
few.  
However, there is also a public fear of nanotechnology, with toxicity arising from materials in 
the nano-size range being an important concern to be addressed.30 Worst case scenarios from 
e.g. studies on combustion particles and their effect on the environment or human health are 
indeed important for risk assessment but should never be extrapolated to nanoparticles with a 
deliberate use in humans as for the field of nanomedicine. Here, nanotechnology is applied for 
medical purposes in order to produce the safest possible product, manufactured from high 
quality raw materials by the best manufacturing processes, and regulated by a quality control 
of the highest standards. The European Technology Platform on NanoMedicine has defined 
nanomedicine as: “The application of nanotechnology in health care, exploiting the improved 
and often novel physical, chemical, and biological properties of materials at the nanometric 
scale”.31 Figure 1.2 demonstrates the specific position of nanomedicine within the broad field 
of nanoparticles and illustrates the diversity of such nanoparticles.  
In general, there are two main groups of nanoparticles used for medicinal applications. The 
first group basically consists of plain nano-sized API particles, so-called nanocrystals. The 
second group is based on DDS. Here, the API is incorporated into a carrier matrix of 
excipient(s), usually made up of polymers or lipids. The latter can vary considerably – from 
simple structures, to highly complex systems, such as core-shell and also multilayer 
structures. In the following, when the term nanoparticle is used, it refers to these kind of 
nanoparticles used within the field of nanomedicine.  
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Figure 1.2: Overview of nanoparticles with different origins and with a focus on 
nanomedicine. NP: nanoparticle; API: active pharmaceutical ingredient; DDS: drug delivery 
system. NP type used in this thesis (*); modified with permission from Barthold et al.32 
 
As safety is a huge issue, the material chosen for nanoparticle preparation generally must have 
pharmaceutical acceptance, meaning that it is of high purity, and is biocompatible and 
biodegradable (if necessary). Such properties provide a good starting point for evaluating the 
safety profile of the final formulation. Materials which fulfil these criteria generally have 
GRAS (Generally Recognized As Safe) status, if not already used as excipients in FDA- (US 
Food and Drug Administration) or EMA- (European Medicines Agency) approved products. 
Materials with a high toxicity are not considered for nanoparticle preparation. One approach 
that may help in the evaluation of safety of future nano-products was introduced by Lehr and 
Groß.33 Here, the intrinsic toxicity of the nano-product compounds is evaluated as a first 
parameter, followed by consideration of their solubility and biodegradability as second 
parameter. According to those parameters, a product can be classified into classes from I to 
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IV, with class I representing non-toxic bulk materials with high solubility/ biodegradability. 
By comparison, class II also represents non-toxic bulk materials, but with low solubility/ 
biodegradability. A product that belongs to class III or IV shows a toxic behavior in its bulk 
form being highly soluble/ biodegradable (III) or not (IV). For class I materials, additional 
safety testing could be set aside, whereas additional testing might be advisable for class II and 
class III products. Class IV products, however, require exhaustive safety testing. 
An earlier system for the risk assessment of final nanoparticle formulation was proposed by 
Keck et al. in 2013.34 The Nanotoxicology Classification System (NCS) is designed to 
categorize formulations based firstly on size and biodegradability, and secondly on 
biocompatibility. Again, there are four categories of increasing risk. Particles above 100 nm 
in size that are biodegradable are in class I, whereas particles which are not biodegradable 
belong to class II. Class III and IV deal with particles below 100 nm. To differentiate here, 
class III particles are again biodegradable, whereas particles in class IV are not. While the 
NCS considers characteristics such as formulation size and biodegradability, the initial 
toxicity of material is not considered – here therefore, the further developed system of Lehr 
and Groß may find application as a complementary tool.  
 
1.2.2 ADVANTAGES OF NANOPARTICLES AND THEIR MARKET SITUATION 
The first nanoparticles for pharmaceutical applications, at that stage called nanoparts, were 
synthesized by Birrenbach and Speiser in the 1970s.35 However, materials and preparation as 
well as analytical techniques used at that time, had to be optimized or even newly developed 
to suit the high demands of a pharmaceutical application. Nevertheless, from the 1990s 
onwards, various nanoparticulate formulations have been approved by the FDA or the EMA 
and are currently on the market.36, 37 In the following section a number of selected examples 
will be discussed; further information about nanoparticle formulations on the market can be 
found in literature.36 
APIs are not always ideal drug candidates showing a high solubility and permeability, and an 
excellent safety profile. Using nanoparticles for drug delivery may therefore improve the 
performance of non-ideal APIs in several ways.36 Most modern drugs in fact show low water 
solubility. Nanoparticles show increased dissolution kinetics, which can lead to higher 
bioavailability of the API.38 The issue of poor API solubility has mainly been overcome by 
using Nanocrystal® technology, where the size of API particles is reduced via wet-milling into 
the nano-size range, leading to improved water solubility of the product and hence 
bioavailability.39-41 The first marketed drug, developed with the Nanocrystal® technology was 
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Sirolimus (Rapamune®) in 1999.40, 42 Sirolimus, a potent immunosuppressive agent used for 
the prevention of graft rejection in organ transplantation is highly hydrophobic, shows low 
water solubility, and hence has a low bioavailability. However, an orally administered 
nanoparticle formulation, based on the Nanocrystal® technology, shows fast dissolution 
kinetics and an improved bioavailability.  
Another issue that can be addressed by using nanoparticles is the possibility of tuning release 
kinetics of an API via encapsulation into a carrier matrix (a DDS).37 A prolonged release of 
drug over a certain period of time can be achieved, meaning a reduction in dose frequency. A 
further benefit could lie in reduced side effects, which are dose dependent, as has been shown 
by Bawa:37 adverse effect, seen for traditional formulations, can be reduced by adjusting the 
release kinetics via tunable sizes and surfaces of nanoparticles, as has been seen for the 
liposomal formulation of AmBisome®,43-45 which was approved by the FDA in 1997. A 
bottleneck preventing widespread use of the drug amphotericin B is its toxicity which further 
compromises its fungicidal activity. However, the encapsulation into liposomes lowers the 
toxic effects and improves drug therapeutic efficacy.43-45 
The importance of DDS is also derived from their targeting potential and ability to overcome 
biological barriers. Some DDS for example are able to cross the blood-brain-barrier,46, 47 
although practically all macromolecules and most of the small-molecule drugs are not able to 
cross. An indirect targeting mechanisms of nanoparticles has also been described by Maeda 
and Matsumara:48 a higher endothelial fenestration and architectural anarchy compared to 
healthy tissue has been found for tumor capillaries, making a passive tumor-targeting of 
nanoparticles possible. This phenomenon has been called the EPR (enhanced permeation and 
retention) effect. Liposomes of up to 400 nm have been shown to be able to permeate tumor 
vessels.49 Such observations have led to the conclusion that injected agents of the right size 
are able to accumulate in tumor tissue, if not previously recognized and cleared by the 
immune system. This point addresses another important aspect of surface characteristics of 
nanoparticles: nanoparticles with a hydrophilic surface (e.g. conferred via PEGylation) have a 
higher chance of escaping immune cell detections50 allowing for circulation for a longer 
period of time in the bloodstream. An example for this delivery strategy is the marketed and 
previously mentioned formulation Doxil®/Caelyx®. Doxil/Caelyx®, is a formulation of the 
API doxorubicin, which is an intercalating agent used in cancer therapy. The formulation is 
based on PEGylated liposomes, also known as STEALTH® liposomes.51 STEALTH® 
liposomes are not recognized by the immune system, therefore showing a prolonged blood 
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circulation time.52 Further, the formulation has shown a decreased toxicity compared to free 
doxorubicin.53 
A similar effect based on passive targeting is called ELVIS, “Extravasation through Leaky 
Vasculature and the subsequent Inflammatory cell-mediated Sequestration”, introduced by 
Yuan et al. with respect to rheumatoid arthritis.54 It can be suspected that such effects are also 
applicable in other inflammatory tissue, when several pathophysiological features such as 
vascular leakage and activated inflammatory cells are shared - indeed an accumulation of 
particles in inflamed areas of the intestinal epithelium has also been observed.55, 56 In contrast 
to passive targeting, active targeting via modification of the carrier’s surface with appropriate 
ligands binding to specific pathological sites in the body is also possible. 
To summarize, nanoparticles offer several advantages including enhanced solubility of drug 
compounds, reduced side effects, and passive/active targeting possibilities. They can not only 
serve as delivery agents but also protect the drug from degradation and can furthermore 
control drug release and enhance permeation through cell membranes.57  
Although there are only a few formulations on the market yet, the impact of reformulated or 
novel nanoparticle-based formulations on medicine and health care is more than promising. It 
should be emphasized, however, that the bench to bed-side process is a long and slow one. 
Although liposomes have been widely studied since the 1960s, the first liposomal formulation 
only reached the market in the 1990s (AmBisome®). Solid nanoparticles were studied later, 
and are currently in clinical trials, but are still some way from reaching the market.58 
Obviously, nanoparticle-based formulations that are currently on the market are quite simple, 
compared to what nanoparticle-based DDS can offer (multicomponent systems). However, 
the full characterization that is required from FDA and EMA in the case of nanoparticles is 
still quite challenging. Nanoparticles do not yet count as well-established formulations (as do 
tablets, inhalables, creams, etc.), due to their special properties conferred by their nano-size. 
As mentioned, people are inherently concerned of nano-toxicity. It is of no help that there are 
no clear regulatory and safety guidelines directly related to nanoparticles for medicinal 
applications. Responsible institutions are thus very careful in selecting the right analytical 
tools for every formulation as repetition of the Contergan® scandal is absolutely not wanted. 
Contergan® was primarily prescribed as a sedative drug, however, after it became an over-the-
counter API it was later also used against morning sickness in pregnant women. Shortly after, 
thousands of infants were born with phocomelia, severe malformations of the extremities. 
Unfortunately, at that time, pharmacovigilance was still in the early stages of development. 
Only after that scenario, people began to think carefully about the safety of medicines leading 
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to the development of more precise drug regulations and control over drug use and 
development. Therefore, successful nanoparticulate formulations should be based on a sound 
knowledge of the API (in the context of this project, the protein/peptide), the excipients, their 
biocompatibility, biodegradability and toxicity.59 Further, consistent quality must be ensured 
by appropriate manufacturing processes and a sound characterization of the formulation.  
 
1.2.3 ROUTE OF ADMINISTRATION 
Biodistribution is guided by the application route, as are parameters including onset of action, 
efficacy and elimination. A first step in the development of a formulation for administration 
via a specific route is to decide whether local or systemic delivery is preferable. Usually local 
delivery is favored, although not always the easiest choice as the target can be hard to reach. 
So far, nanoparticles for medicinal use are administered parenterally, including via 
intravenous (i.v.) application. This route has the advantage of always demonstrating a 100% 
bioavailability as no absorption via an epithelial barrier is necessary. This route is most 
famously employed for cancer therapy, as nanoparticles are able to accumulate in tumor tissue 
due to their passive targeting (EPR effect). However, the drawbacks of this route of 
administration are the invasive character, the need of medical personnel for application and 
the assurance of sterility for the applied medicine, which makes production usually quite 
expensive.  
By contrast, the most well-renowned non-invasive route of administration is the oral route. 
Production is cheap, and people are usually quite eager to swallow tablets/ capsules or liquids 
compared to receiving an injection. Unfortunately, there are drawbacks such as variations in 
pH, sometimes to extreme levels (e.g. in the stomach), the potential for variation in drug 
absorption depending on whether dosing is performed in a fed or fasted state (food effect), the 
mucus layer, which acts as a barrier to oral absorption, and the enzymatic environment. Often, 
sensitive drugs are destroyed in that environment and nanoparticles are often not able to cross 
the mucus barrier, meaning no or only low absorption into the circulation. Nanoparticles with 
special properties, however, are able to show some penetration.60 Additionally, some 
therapeutically interesting formulations based on nanoparticles could be used for the treatment 
of inflammatory bowel disease (IBD)61 or for uptake via M-cells for vaccination.62 
Another non-invasive route of administration is the skin. As its purpose is to prevent 
unintentional permeation, delivery via the intact skin is not that easy. Microneedles for 
vaccination63, however, or needle-free vaccination through the use of nanoparticles have been 
reported recently.64 
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Furthermore, the lungs are an interesting target for drug delivery via nanoparticles, for both 
local and systemic delivery. This is discussed in more detail below. 
 
1.3 THE PULMONARY ROUTE OF ADMINISTRATION  
Diseases like Chronic Obstructive Pulmonary Disease (COPD), asthma, lung cancer, cystic 
fibrosis (CF), and also idiopathic pulmonary fibrosis (IPF) locally affect the lung. To achieve 
here a maximum effect with at the same time reducing side effects, a direct and local 
application to the lung is favored (air-to-lung-delivery). Moreover, pulmonary delivery to 
obtain a systemic effect is of increasing interest (lung-to-blood-delivery). A few drug 
candidates delivered via the lung have already been selected for clinical trials: 
dihydroergotamine as non-oral treatment of migraine65 is one of them. As patients with 
migraine often suffer from nausea, a formulation for oral delivery is difficult; inhalation of the 
API is therefore preferred under this condition. 
Regarding non-invasive delivery of proteins and peptides, the lung and especially the deep 
lung (also called alveolar region), consisting of a very thin layer of tissue for high efficiency 
gas exchange66, is an important epithelial barrier. Due to a low level of resident degrading 
enzymes, drug delivery directly to the lung or via the lung into the circulation can occur 
without much enzymatic or metabolic loss (as is well-known to occur for example for the oral 
route of administration), making administration via this route very attractive. One famous 
example of a protein formulation pulmonary delivery is the inhalable insulin formulation 
called Afrezza® from Mannkind Inc., that was approved by the FDA in June 2014.67  
 
1.3.1 THE HUMAN LUNG AND ITS CLEARANCE MECHANISMS  
With around 100 m2 of surface area, the lung represents one of the biggest exchange 
interfaces of the human body with its surrounding environment.68 The large surface area on 
the one hand enables efficient gas exchange (oxygen uptake vs. carbon dioxide excretion), but 
on the other hand also provides a gateway for microorganisms and particles contained within 
the inhaled air. Therefore, to protect this area, several barriers are prominent in the lung. The 
most prominent are the respiratory epithelia (cellular barrier), together with the mucus 
(conducting airways) and the pulmonary lining fluid (deep lung) as non-cellular barriers.69 
Both types of barriers vary along the respiratory tract in terms of structure and composition. 
The fate of an inhaled particle after deposition in the lung is illustrated in Figure 1.3.  
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Figure 1.3: Fate of a particle after deposition in the lung; (1) first contact with the lung lining 
fluids; (2) uptake into / across the pulmonary epithelium; (3) clearance; modified with 
permission from Ruge et al.69  
 
Depending on the specific pulmonary location, different clearance mechanisms exist. In the 
conducting airways, the mucociliary clearance is most prominent, whereas in the deep lung it 
is macrophage clearance.70 Mucociliary clearance has the ability to entrap particulates within 
the mucus and propel them out of the human lungs at rates between 3 and 25 mm/min.71, 72 
This speed varies according to pulmonary condition73 and airway caliber, but a maximum 
lung-residence time of about 6 h can be predicted.74 In the deep lung, the clearance depends 
on the phagocytic stimuli elicited by deposited particulates, which in turn is a function of their 
shape, surface chemistry and size. Between 50 and 75% of inhaled particulates are cleared 
within 2-3 h after deposition, and nearly 100% are removed after 25 h.70 The alveolar 
clearance rate, however, may be influenced by a number of pulmonary conditions. Thus, a 
time frame of up to 6 h could be estimated for non-biodegradable nanoparticles to deliver 
their cargo. 
    
Conducting airways 
The mucociliary clearance is an effective system to entrap and remove particulates contained 
in inhaled air. Cellular and non-cellular barrier elements again cooperate, to allow for 
operation of this system. A pseudo-stratified columnar epithelium is formed by ciliated, 
secretory and basal cells that build the bronchial airway epithelium.66 The apical membranes 
of such cells are further joined by tight junctions, giving the epithelium its barrier properties.75 
The pulmonary mucus (pulmonary lining fluid of this particular region) on top of the 
epithelial cells is made of 90-95% water, mucins (glycoproteins), lipids, proteins, DNA and 
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cells.76, 77 It consists of two different layers:66 the lower layer shows aqueous sol-like 
characteristics. It allows the cilia to beat and recover so that the thick viscous upper layer can 
be propelled towards the proximal airways in a continuous way. Subsequently, the mucus can 
be transferred to the digestive tract for further gastric metabolism and elimination.66, 78 The 
upper layer is a viscous gel layer containing mucins that form a complex mesh-like structure 
with a high capacity to entrap particulates.76, 77 These mucins are built of a polypeptide 
backbone, with high levels of O-glycosylated tandem repeats, leading to a negative charge at 
physiological pH.79, 80 There are five major mucins expressed in the respiratory tract: MUC1, 
MUC4 and MUC16 (cell-membrane tethered mucins), as well as MUC5AC and MUC5B 
(main gel-forming mucins), which are secreted by submucosal glands and goblet cells onto 
the luminal surface of the airways.81, 82 The latter two mucins are primarily responsible for the 
viscous mesh-like size structure of the pulmonary mucus.83 The pore size of the mucus is 
highly heterogeneous and ranges between small pores of just 100 nm up to large voids of 
several µm in size.84 Thus, water, ions and small molecules are able to diffuse through the 
mucin mesh, whereas larger particulates at some point are hindered due to steric interactions 
with the rigid walls. Additionally to the size filtering effect, electrostatic and hydrophobic 
filtering effects enable the immobilization and clearance of particulates, even smaller than the 
pore size of the mucus mesh. These effects are based on the interactions of negatively charged 
mucins85 and hydrophobic regions located in the non-glycosylated regions of the mucins,79 
with particulates.  
 
Deep lung  
The alveolar region represents a major target of many inhaled therapeutic agents. Two 
epithelial cell types constitute the alveolar epithelium: due to their flattened shape 
(approximately 0.2 to 0.3 µm thick in the cell periphery78), Alveolar Type I (AT-I) cells 
provide an exceptional platform for gas exchange and cover about 90% of the entire alveolar 
surface. Alveolar Type II (AT-II) cells are cuboidal in shape and are responsible for the 
synthesis and release of pulmonary surfactant (composed of a complex mixture of lipids and 
proteins that reduce the surface tension in the alveoli, preventing their collapse).86, 87 They 
further serve as progenitors for ATI cells and are important for cell renewal. Both cell types 
are able to form tight junctions88, 89 and represent a significant barrier, although nanoparticles 
smaller than 100 nm may efficiently cross the alveolar epithelium.90 Endocytic pathways 
provide an opportunity for bigger particles to be internalized.91 Another cell type present in 
the deep lung are the macrophages, which patrol on top of the epithelium, having the ability to 
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engulf and degrade particles in a size range of 1-5 µm.83 Nanoparticle uptake by alveolar 
macrophages (mediated by hydrophilic proteins contained in the pulmonary surfactant) has 
also been described, showing different absorption patterns depending on the nanoparticle 
coating.92, 93 When considering the prospect of delivery to the lung, it is important to keep in 
mind that these described aspects of barrier function and clearance must be preserved, as they 
are of the highest importance for maintaining human health. Thus, the aim is to design a 
system with the ability to avoid clearance and penetrate or pass barriers without significant 
interference with such clearance mechanisms and barrier integrity.  
 
1.3.2 PARTICLE DESIGN 
It can be seen that the biological barriers within the lung represent a challenge for pulmonary 
drug delivery. However, a better understanding and characterization of the pulmonary barriers 
in recent years has given the opportunity to enhance and improve drug delivery to the lung.94 
Nanotechnology enabled DDS in particular have the potential to improve pulmonary drug 
delivery. This can be achieved through the ability to rationally design nanoparticles with 
optimal surface chemistry, size and shape for overcoming those barriers.  
Designing mucus penetrating particles, which are able to escape the mucus entrapment by 
means of a hydrophilic polymer coating (PEGylation) which results in particles with a neutral 
or slightly negative charged surface,77, 95, 96 has helped in improving particle uptake in the 
lung. Guluronate oligomers have been shown to alter the network architecture in mucin 
matrices, thus leading to an enhanced nanoparticle mobility in both native and highly purified 
mucus matrices.97 These strategies could for example be most suitable for drug delivery to the 
lung in diseases with increased or pathologically thickened mucus.  
In the alveolar region, the clearance of particles occurs mostly by way of alveolar 
macrophages.98 Furthermore, it is known that the macrophage clearance is faster for 
microparticles than for nanoparticles.99 Therefore, nanoparticles could be designed in 
different sizes that might help to avoid macrophage clearance.  
Traditionally, the focus of pulmonary drug delivery has been on improving lung deposition of 
inhaled therapeutics. Thus, most of the factors influencing particle size during aerosol 
generation and subsequent drug inhalation have been well-described.77, 78 In this respect, a 
dramatic improvement of deposition can be achieved with most modern aerosol delivery 
devices.100 The design of particles additionally plays an important role in such effective 
deposition – particles with a certain shape or in an acceptable size range for sufficient 
aerodynamic properties may enable deposition in the alveolar region. However, nanoparticles 
17 
 
in a pharmaceutically relevant size range of approximately 100-200 nm are not suitable for a 
high deposition in the deep lung.101 Thus, a carrier system with optimum aerodynamic 
properties (generally in the lower µm size range) is necessary to improve the delivery of 
nanoparticles to the alveolar region. Several investigations have been made in that context, in 
which the delivery of nanoparticles via dry powder carriers seems to be the most promising. 
One approach is to combine the high alveolar deposition of microparticles with the slower 
clearance by alveolar macrophages of nanoparticles For example, Ely et al. used an active 
release mechanism of nanoparticles from carrier particles by an incorporated effervescent 
technology.102 Another concept is utilized by so-called large porous Trojan particles, 
introduced by Tsapis et al. Also here, nanoparticle-in-microparticle systems are formed and 
administered. Upon deposition, the microparticles quickly dissolve, releasing the incorporated 
nanoparticles again.103  
Although nanoparticles represent a great chance for improved pulmonary delivery (e.g. 
enhanced cell uptake, avoidance of macrophage clearance), they cannot be administered as 
such but need an advanced carrier system, necessary for high deposition in the deep lung.  
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2. AIM OF THE WORK  
 
Biopharmaceuticals, such as proteins and peptides, currently represent a large fraction of 
compounds in drug development pipelines, due to their highly selective mode of action and 
predictable activity profiles. Nevertheless, a widespread application of potential protein 
therapeutics is restricted due to limitations in both drug disposition and pharmacokinetic 
properties. Their success, amongst other factors, will depend on formulation and delivery 
strategies that can address these limitations. 
This thesis was part of a joint research program entitled COMPACT (Collaboration on the 
Optimization of Macromolecular Pharmaceutical Access to Cellular Targets), which is a 
European project funded by the Innovative Medicines Initiative (IMI) and the European 
Federation of Pharmaceutical Industries and Associations (efpia). COMPACT focuses on two 
major aims: first of all, the identification and characterization of transport pathways across 
biological barriers and across cell membranes (work packages (WPs) 4-7), and secondly the 
construction and characterization of DDS for proteins and peptides (WP 1) or nucleic acids 
(WP 2). Within the COMPACT consortium, the motivation of this thesis was the 
development and characterization of a nanotechnology enabled, novel and safe DDS for 
pulmonary protein and peptide delivery. 
One of the most important points to be addressed in this respect is the excipient used for the 
DDS. The material should be biocompatible, biodegradable, and easily accessible. 
Furthermore, the material should be suitable for the nanoparticle preparation process. Charge-
mediated coacervation in aqueous medium was chosen as the preparation procedure for 
nanoparticle formation. This process is mild, fast, straight-forward and easy to upscale, e.g. by 
using microfluidics. Further, no additional excipients, such as stabilizers, are necessary. As 
the alveolar epithelium seems to play a major role in diseases such as IPF, this site of action 
was chosen as target in this project. Due to the low deposition of NPs in the deep lung, the 
final pulmonary formulation should be based on a delivery system, consisting of 
microparticles with embedded nanoparticles, suitable for a high deposition in the alveolar 
region. The microparticle matrix should further be highly water soluble to ensure a fast 
release of the nanoparticles, which are then ready for cell uptake. 
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The major aims and corresponding work of this thesis can subsequently be divided into four 
sections: 
 
Chapter 3  Starch derivatives as excipients for nanotechnology enabled pulmonary drug 
delivery systems: polymer characterization, improvement of synthesis and 
purification 
Chapter 4  Starch vs. chitosan nanoparticles – preparation and physicochemical 
characterization 
Chapter 5  Aerosol delivery of nanoparticles to the deep lung – nanoparticles embedded in 
microparticles 
Chapter 6  In vitro biopharmaceutical evaluation of the novel carriers 
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3. STARCH DERIVATIVES AS EXCIPIENTS FOR 
NANOTECHNOLOGY ENABLED PULMONARY DRUG DELIVERY 
SYSTEMS: POLYMER CHARACTERIZATION, IMPROVEMENT OF 
SYNTHESIS AND PURIFICATION 
 
 
 
 
 
 
 
 
 
The author of the thesis made the following contribution to this chapter:  
Planned, designed and performed all experiments, analyzed all data from the mentioned 
studies, interpreted all experimental data and wrote the chapter, if not stated otherwise. 
The XRPD studies were kindly performed by Dr. Robert Haberkorn at the Department of 
Inorganic Solid State Chemistry.  
 
The synthesis of the two α-starch polymers, used for nanoparticle preparation, was kindly 
performed by Dr. Carolin Thiele.  
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3.1 INTRODUCTION 
DDS (shown in Figure 1.2) are prepared from a wide range of different materials. The most 
common ones are polymers of synthetic or natural origin, with both types showing advantages 
and disadvantages.104 The most studied synthetic polymers are polyesters, such as poly (ɛ-
caprolactone) (PCL), poly (lactic acid) (PLA), poly (lactide-co-glycolide) (PLGA) and their 
derivatives.105 PLGA is a well-known material. Being biocompatible, with GRAS status for 
some applications, and offering a controlled release of its cargo, it is an ideal material for 
DDS preparation. The delivery of proteins, however, requires special care and attention. The 
release of the cargo at the desired site of action is one point, but with particular respect to 
proteins and peptides the DDS should further be able to protect the complex structure from 
degradation during DDS preparation and loading, storage and on exposure to physiological 
conditions following application. In the latter context, PLGA is mainly degraded by 
hydrolysis in vivo, leading to acidic degradation products that could be detrimental to the 
encapsulated cargo.106 
The importance of new natural or semi-synthetic polymers as DDS components is increasing 
in line with the considerable current interest in material sustainability. Natural polymers, 
especially polysaccharides are among the most studied polymers as components of DDS for 
biopharmaceuticals.107, 108 Within this group, dextran-,109-111 alginate-,112 and chitosan-based 
systems have all been well-explored.113-117 In addition, starch is an excellent bio-polymer for 
nanotechnology enabled DDS. It is a commonly employed excipient in pharmaceutical 
industry, used for example in tableting processes,118-121 as well as an excipient in novel DDS 
for nasal122 and other site-specific123, 124 applications. Regarding its toxicity, starch consists 
of linear amylose and branched amylopectin - both polysaccharides consisting of α-(D)-
glucose units, which have been evaluated as safe and without the need for restrictions on daily 
intake.125 Starch is further GRAS listed and included in the FDA Inactive Ingredients 
Database. Its excellent biocompatibility is further underlined by its biodegradability not only 
by hydrolysis, but also by α-amylase, an enzyme commonly present in the human body.  
Additionally, the molecular structure of starch allows for different chemical derivatizations, 
due to the presence of a high amount of hydroxyl groups; this in turn leads to the possibility 
for numerous new applications. Santander-Ortega et al. previously prepared NPs from propyl 
starch for the dermal application of small molecule drugs.126 However, as this starch 
derivative was not water soluble, ethyl acetate had to be used as a solvent for particle 
preparation. Further, the use of a high speed homogenizer makes the utilized preparation 
method challenging for the encapsulation of proteins. The synthesis of a water soluble, 
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negatively charged starch derivative for complex formation with cationic cyclodextrins as 
targeted cancer therapy was investigated by Thiele et al.127 Another study, using positively 
charged, water soluble starch-derivatives for better pDNA transfection was carried out by 
Yamada et al.128  
The properties of the excipient for DDS preparation is of great importance in order to ensure a 
good quality of the used material as well as compatibility with a protein or peptide cargo. As 
charge-mediated coacervation in aqueous medium was the method of choice for NP 
preparation, the focus was set on water soluble starch derivatives. Thus, negatively and 
positively charged α-starch-derivatives that were used for nanoparticle preparation were 
characterized for their degree of substitution, purity, and their weight average molecular 
weight. Additionally, different syntheses were carried out to optimize both the synthesis 
procedure and purification method; the products of this optimization work were also 
characterized. 
 
3.2 MATERIALS AND METHODS 
3.2.1 MATERIALS 
Potato starch, partially hydrolyzed with a molecular weight (Mw) of 1 300 000 g/mol and an 
amylose content of approximately 33% was a kind gift from AVEBE (Netherlands). (2,2,6,6-
tetramethylpiperidin-1-yl)oxidanyl (TEMPO), N,N’-dicyclohexylcarbodiimide (DCC), 1-
hydroxybenzotriazole (HOBt) and 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-
methylmorpholinium chloride (DMTMM) were obtained from Sigma Aldrich (USA). 
Ethylenediamine was purchased from Acros Organics (USA). All other reagents were of 
analytical grade. 
 
3.2.2 STARCH OXIDATION – SYNTHESIS OF NEGATIVELY CHARGED STARCH 
Potato starch was oxidized to produce a negatively charged starch derivative, in the following 
referred to as NegSt. Briefly, 20 g of dried potato starch was weighed into a 1 L glass beaker, 
suspended in 800 mL of purified water and heated at 95 °C for 1 h. After cooling down to 
room temperature (RT), the catalyst TEMPO was added to the suspension (4 mg/g potato 
starch). Adequate volumes of sodium hypochlorite solution (12%) were then added (1 
mL/min). The pH was kept at 8.5 during the reaction by adding 1 M sodium hydroxide 
solution. Sodium borohydride (0.5 molar equivalents relative to sodium hypochlorite) was 
then slowly added to stop the reaction. The resulting solution was stirred overnight. After 
filtration the next day, the solution was extensively purified by ultrafiltration (Vivaflow 200; 
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5 kDa Hydrosart membrane, Sartorius Stedim Biotech GmbH, Germany) and lyophilized for 
two days (Alpha 2-4, Martin Christ GmbH, Germany) before storing at RT until usage. 
 
3.2.3 COUPLING OF ETHYLENEDIAMINE WITH DCC/HOBT  
To obtain the positively charged starch derivative (PosSt), NegSt was coupled with 
ethylenediamine. To achieve this, 13 g of the free acid form of NegSt, obtained by ion 
exchange, was first dissolved in 650 mL DMSO at 50 °C under a reflux condenser overnight, 
with stirring. The coupling agents DCC and HOBt (each 1.5 molar equivalents relative to the 
degree of oxidation of NegSt) were then added and stirred for 24 h. Afterwards, 
ethylenediamine was slowly added (10 molar equivalents relative to the degree of oxidation of 
NegSt) and the reaction was allowed to proceed for another 48 h (end product termed PosStα) 
or 72 h (end product termed PosStβ). After filtration, the solution was either lyophilized, 
subsequently dissolved in 1%  acetic acid (HOAc), extensively ultrafiltered (Vivaflow 200; 5 
kDa Hydrosart membrane, Sartorius Stedim Biotech GmbH, Germany) and lyophilized for 
two days (PosStα and PosStβ) or precipitated with ethanol (EtOH), washed and then 
lyophilized (PosStγ and PosStδ). PosSt was stored at RT until further use. An overview of the 
different materials and their synthesis specifications can be found in Table 3.1. 
 
Table 3.1 
Different PosSt derivatives and details of their synthesis. Coupling was performed with 
DCC/HOBt. 
 
PosSt NegSt 
[Dox] 
Reaction time 
[h] 
Method of purification 
α 36 48 ultrafiltration 
β 52 72 ultrafiltration 
γ 25 48 precipitation 
δ 21 48 precipitation 
 
3.2.4 COUPLING OF ETHYLENEDIAMINE WITH DMTMM  
As a second coupling reaction, the coupling of ethylenediamine to NegSt via DMTMM was 
carried out, according to Kunishima et al.129 Here, 250 mg of NegSt was first dissolved in 
6.25 mL milliQ water. Afterwards, 18.75 mL of DMSO was added, to obtain a solvent 
mixture of 1:4 (water:DMSO). Further, 0.68 mmol DMTMM (conjugation reagent, adapted 
from Yamada et al.128) was added under stirring and the resulting mixture was further stirred 
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for 30 min to activate the carboxylate groups. After 30 min, 10 equivalents of 
ethylenediamine relative to the degree of oxidation of NegSt were added and the reaction was 
allowed to proceed for another 72 h at RT. The mixture was then filtered and precipitated with 
EtOH. The resulting product, termed PosStδDMTMM was then lyophilized for two days. 
PosStDMTMMδ was stored at RT until usage.  
An overview of all syntheses can be found in Scheme 3.1. 
 
 
Scheme 3.1: Synthesis of negatively charged starch (NegSt) and positively charged starch 
(PosSt); (A) coupling reaction with DCC/HOBt (PosSt); (B) coupling reaction with DMTMM 
(PosStDMTMM); potato starch is illustrated as amylose. 
 
3.2.5 SYNTHESIS OF FLUORESCENTLY LABELED POSITIVELY CHARGED STARCH  
For later characterization and cell interaction studies, PosSt was labeled with green Bodipy® 
FL-C5 NHS Ester. Briefly, 30 mg of polymer was dissolved in 5 mL purified water and 
diluted slowly with 5 mL of methanol. A 2 mL volume of Bodipy® FL-C5 NHS Ester solution 
in methanol (0.5 mg/mL) was then added slowly to obtain a molar ratio of 50:1 (starch:dye). 
The sample was stirred for 1 h at RT under light protection, and then precipitated with 1 M 
sodium hydroxide and ethanol. Washing was performed with ethanol:methanol (1:1) until the 
supernatant was fluorescence free. Labeled positively charged starch, referred to as PosStF, 
was then dissolved in purified water, freeze dried and stored in the fridge under light 
protection until usage. 
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3.2.6 CHARACTERIZATION OF SYNTHESIZED STARCH DERIVATIVES 
The degree of oxidation of NegSt was determined with the Blumenkrantz assay, a 
colorimetric method based on detection of uronic acid content.130 The degree of oxidation was 
calculated as follows: 
 
𝐷𝑒𝑔𝑟𝑒𝑒 𝑜𝑓 𝑜𝑥𝑖𝑑𝑎𝑡𝑖𝑜𝑛 [%] =
𝐴
ɛ ∗ 𝑑 ∗ 1 000 000
𝑚(𝑁𝑒𝑔𝑆𝑡) 𝑖𝑛 50 µ𝐿
∗ 100 
 
A: absorbance; ɛ: extinction coefficient (26700 [Lmol-1cm-1]); d: cuvette length (1 [cm]); m: 
mass [mg]. 
 
 
1H-NMR spectra were collected at RT on a Bruker Biospin spectrometer NMR Magnet 
System 400 MHz Ultrashield plus (Bruker, USA) in D2O (64 scans). Fourier transform 
infrared (FT-IR) measurements were carried out in solid state with a Spectrum 400 FT-IR/FT-
NIR spectrometer (PerkinElmer, UK) between 700 and 3600 cm-1. The weight average 
molecular weights of starch derivatives were analyzed by gel permeation chromatography 
(GPC, HLC-8320 GPC, Tosoh, Japan), equipped with online viscometer (ETA-2010, PSS, 
Germany) on SUPREMA 1000 and 30 columns (NegSt) or SUPREMA-MAX 1000 and 30 
columns (for PosSt; PSS, Germany) at a flow rate of 1 mL/min at 35 °C in 1 M sodium nitrate 
(NegSt) or 1% formic acid (PosSt). The calibration was done with Pullulan and PVP 
standards, respectively.  
For X-ray powder diffraction (XRPD), samples were analyzed by a diffractometer of the type 
Bruker D8 Advance, equipped with a 1D-detector 'Lynxeye' using variable divergence slit and 
Cu Kα radiation. 
 
3.3 RESULTS AND DISCUSSION 
3.3.1 OXIDATION OF POTATO STARCH  
The raw material used for the oxidation was a partially hydrolyzed potato starch with an 
amylose content of approximately 33% and a molecular weight of 1 300 000 g/mol. For the 
synthesis, a TEMPO-mediated system was used, which enabled the selective C6-oxidation 
(primary hydroxyl group) of potato starch.131  
TEMPO (I) is a stable radical, which is oxidized to the nitrosonium ion (II), the actual 
oxidizing species, under the influence of hypochlorite. During the oxidation process of potato 
starch, the hydroxyl group is oxidized via an aldehyde to the carboxylate, while the 
nitrosonium ion (II) is reduced to the hydroxylamine (III). The regeneration of the 
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nitrosonium takes place in situ with the help of the oxidant hypochlorite.131 Here, the 
hydroxylamine reacts with another nitrosonium ion to reform the stable TEMPO radical. This 
process is shown in Scheme 3.2.  
 
 
 Scheme 3.2: Mechanism of TEMPO-mediated oxidation of potato starch. 
 
For the synthesis, a ratio of 4 mg of TEMPO per 1 g of starch was chosen, as a higher amount 
probably leads to the degradation of the polymer (as suggested by Thiele132). For the 
oxidation of the hydroxyl group to the aldehyde, as well of the aldehyde to the carboxylate, 1 
molar equivalent of hypochlorite is required. Different molar ratios of sodium hypochlorite 
were used (1.5, 1.25, 1, 0.75) to obtain a product with different degrees of oxidation.132 A 
degree of oxidation below 100% was expected, as some of the primary alcohol groups are 
necessary for formation of the α-1,6-glycosidic bond in amylopectin.  
After the reaction, sodium borohydride was slowly added to selectively reduce aldehyde 
groups back to hydroxyl groups, without reducing the carboxyl groups.  
 
3.3.2 CONJUGATION OF ETHYLENEDIAMINE WITH DCC/HOBT 
The oxidation of potato starch was carried out as a first step for two reasons. One reason is the 
need for a negatively charged starch derivative for the further development of a 
nanotechnology enabled DDS prepared via charge-mediated coacervation in aqueous 
medium. Additionally, the use of NegSt as a precursor for modification with ethylenediamine 
allows for a selective coupling reaction between carboxyl groups of NegSt and amine groups 
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of ethylenediamine, meaning that protection of hydroxyl groups is unnecessary. Conversion 
of the carboxyl group via an activated ester to an amide (as possible  for example with the 
DCC/HOBt system - Scheme 3.3) also does not lead to toxic side products or impurities, as 
usually known from paper industry, where the synthesis of cationic starches is usually 
performed with epoxyalkylamines133, 134 or halogenalkylamines.135  
The conjugation of ethylenediamine with DCC/HOBt in DMSO was adopted from Sheehan136 
and König,137 who have used the reaction for peptide bond formation. Furthermore, this 
method was used by Thiele for the synthesis of amino-functionalized pteroates (folic acid salt) 
and for their coupling with oxidized starch.132 As a free carboxylic group is necessary for the 
reaction, the carboxyl group was transferred into the free acid form with the help of an ion 
exchanger (Dowex 50 WX2-200). Successful coupling could already be observed during 
synthesis, by the formation of the non-water soluble dicyclohexylurea (not shown in Scheme 
3.3).  
 
 
Scheme 3.3: Mechanism of coupling: ethylenediamine with DCC/ HOBt. 
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3.3.3 CONJUGATION OF ETHYLENEDIAMINE WITH DMTMM 
An alternative coupling reaction between carboxyl groups of NegSt and amine groups of 
ethylenediamine was performed using DMTMM (adopted from Kunishima129) instead of 
DCC/HOBt. The conjugation with DMTMM is shown in Scheme 3.4. In a first step, an 
activated ester is produced by the reaction of a NegSt carboxylate anion with DMTMM. In 
order to achieve this, the reaction mixture was stirred for 30 min to activate the sodium 
carboxylate groups. The formed activated ester is then subjected to attack by the amine group 
of ethylenediamine, forming an amide bond. Reaction conditions, such as solvent choice, 
reaction time and molar ratio of DMTMM:NegSt were extracted from Yamada et al.,128 who 
used this technique for coupling s-PEI to oxidized starch. The advantage of the DMTMM 
conjugation is the mild reaction condition at RT as compared to the DCC/HOBt system, 
which takes place at 50 °C – such an elevated temperature could result in an accelerated 
degradation of the polymer. 
 
 
Scheme 3.4: Mechanism of coupling: ethylenediamine with DMTMM. 
3.3.4 CHARACTERIZATION OF STARCH DERIVATIVES 
Proof of successful reaction 
The reaction was followed by conduction of FT-IR spectroscopy (shown for β-starch 
derivatives synthesized with DCC/HOBt in Figure 3.1 (A), and for δ-starch derivatives 
synthesized with DMTMM in Figure 3.1 (B). The typical peaks of the C=O stretching of the 
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carboxyl anion COONa at 1600 cm-1, and of the C=O stretching from the COOH group (after 
ion exchange) at 1732 cm-1, disappeared for PosStβ, and were replaced by two peaks at 1660 
cm-1 and at 1550 cm-1. These correspond to the amide bond formation: the amide I peak (1660 
cm-1) is mainly associated with the C=O stretching vibration, while the amide II (1550 cm-1) 
results from the N-H bending vibration and from the C-N stretching vibration. This is in 
principle also true for the reaction with DMTMM, however the stretching of the C=O arising 
from the carboxyl anion at 1594 cm-1 is still visible in the FT-IR spectrum, indicating a lower 
amount of amide bond formation for the PosStδDMTMM-derivative.  
 
Figure 3.1: FT-IR spectra of β-starch derivatives (A) and δ-starch derivatives (B). 
 
Further, 1H-NMR spectra were collected to analyze the purity of the samples and to determine 
the degree of substitution with ethylenediamine. NegSt (shown for NegStα in Figure 3.2 (A) 
showed δH values between 5.28 – 5.58 ppm that were assigned to the anomeric 1H atom, 
whereas the signals from 3.20 – 4.20 ppm were ascribed to the ring protons 2H, 3H, 4H, 5H, 
6H.127, 138  
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NegSt was afterwards coupled with ethylenediamine, which could also be observed by 1H-
NMR (shown for PosStα in Figure 3.2 (B). PosSt showed the typical pattern between 5.10 – 
5.62 ppm of the anomeric 1H atom. The ring protons were visible between 3.30 – 4.30 ppm. 
 
Figure 3.2: 1H-NMR spectra of synthesized starch derivatives in D2O: Oxidized starch 
(NegStα, (A) and coupled with ethylenediamine using DCC/HOBt (B and C). PosStγ was 
precipitated with EtOH rather than lyophilized followed by tangential flow filtration (PosStβ). 
PosStδDMTMM was produced from NegStδ coupled with ethylenediamine using DMTMM, and 
was precipitated with EtOH (D). 
 
Further, the value between 3.00 – 3.22 ppm was ascribed to the coupled ethylenediamine 
(NH-CH2-CH2-NH2). HOAc, used to protonate the synthesized PosSt, can be seen in the 
spectrum as an intense peak at 1.8 ppm. The peaks at 7.4, 7.6 and 7.8 ppm were ascribed to 
small impurities arising from the coupling reagents DCC/HOBt. Therefore, for the synthesis 
of PosStγ, the purification method was changed from lyophilization/tangential flow filtration 
to precipitation with ethanol. As DCC and HOBt are both soluble in ethanol, whereas starch 
derivatives are not, they can be separated through precipitation. This method was successful, 
as can be found in the 1H-NMR of PosStγ, shown in Figure 3.2 (C). Although the degree of 
substitution is less compared to PosStα, the previously noted peaks between 7 and 8 ppm were 
not visible. However, some traces of free ethylenediamine remained, suggesting that the 
washing after precipitation could still be improved. The same holds true for the product 
synthesized with DMTMM (Figure 3.2 (D).  
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Degree of substitution 
The degree of oxidation of NegSt was determined by a colorimetric assay, according to 
Blumenkrantz et al.,130 as this information is important for the following coupling reaction. 
Briefly, the Blumenkrantz assay detects the uronic acid content (carboxyl groups arising from 
the TEMPO C6-oxidation) by building a chromogen when heated in concentrated sulfuric 
acid/tetraborate and treated with m-hydroxybiphenyl. The degree of substitution of PosSt 
samples was calculated from 1H-NMR spectra. Both the degree of oxidation of different 
NegSt syntheses as well as the degree of substitution of PosSt is shown in Table 3.2. 
 
Table 3.2 
Degree of substitution of starch derivatives. Degree of oxidation of NegSt was determined 
with the Blumenkrantz assay (mean ± SD; n = 3), while the degree of substitution of PosSt 
was calculated from 1H-NMR spectra. 
 
 degree of oxidation (NegSt) / substitution (PosSt) [%]  
 α β γ δ δDMTMM 
NegSt 36 ± 1 52 ± 5 25 ± 2 21 ± 2 21 ± 2 
PosSt 33 47 10 11 19 
 
It can be seen that for different syntheses, the degree of oxidation varied. NegStα showed a 
degree of oxidation of 36 ± 1%, whereas NegStβ showed an increased degree of substitution 
of 52 ± 5%. The γ- and δ-samples showed a lower degree of oxidation between approximately 
25% and 20%. The degree of oxidation depended on the equivalent amount of NaOCl used 
for the synthesis. This is in accordance with Thiele,132 who described the degree of oxidation 
in relation to the equivalent amount of NaOCl - the more equivalents of NaOCl per starch 
monomer, the higher the degree of oxidation. For approximately 52% oxidation, 1.5 
equivalents of NaOCl were used, for 36% 1.25 equivalents were used, and for 25% and 21% 
oxidation, 1 and 0.75 equivalents were used respectively.  
For the substitution, 10 equivalents of ethylenediamine according to the degree of oxidation 
of NegSt were used. It can be seen that, the lower the degree of observed oxidation, the 
correspondingly lower the degree of coupling with ethylenediamine. Compared to the 
coupling with DCC/HOBt, the coupling with DMTMM was more efficient, showing a degree 
of substitution of 19%. 
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Molecular weight 
GPC measurements of α-starch derivatives showed a weight average molecular weight of 
around 76000 ± 4300 for PosSt (Table 3.3), which is in the same range as that of NegSt, 
showing a weight average molecular weight of 87 000 ± 1 800. However, for the synthesis of 
PosStβ, the weight average molecular weight decreased almost by half – this showed values 
of 43 000 ± 2 000, compared to NegStβ which had a weight average molecular weight of     
82 000 ± 1 900. It is likely that the elevated temperature of 50 °C combined with an increased 
reaction time led to degradation of the polymer backbone, leading to such a decrease. 
 
Table 3.3 
Mean average molecular weight of starch derivatives, determined with GPC (mean ± SD, n = 
2). 
 
 α β γ δ 
NegSt 86 799 ± 1 806 81 791 ± 1 889 n.a. n.a. 
PosSt 75 753 ± 4 282 43 402 ± 2 014 n.a. n.a. 
PosStDMTMM n.a. n.a. n.a. n.a. 
 
Unfortunately, the weight average molecular weights of the other polymers could not been 
determined, due to irreparable malfunction of the GPC. It is expected that at least for the 
PosSt samples, synthesized with DMTMM, the weight average molecular weight would be 
maintained, as the reaction was taking place at RT. 
 
3.3.5 Α-STARCH DERIVATIVES, USED FOR NANOPARTICLE PREPARATION 
In the following chapter, “Starch vs. chitosan nanoparticles – preparation and 
physicochemical characterization”, α-starch derivatives were used for the preparation of 
nanoparticles via charge complexed coacervation in aqueous medium. Therefore, 
material properties will shortly be summarized in this paragraph.  
The yield of the oxidation was 80.6% for NegStα and the reaction yield for the coupling with 
ethylenediamine was found to be 59.6%. Negatively and positively charged α-starch 
derivatives showed approximately the same weight average molecular weight, being 87 000 
for NegStα and 76 000 for PosStα. NegStα showed a degree of oxidation of around 36%, 
whereas the coupling reaction with ethylenediamine was found to be around 33%. Both 
polymers showed a stable amorphous solid state after lyophilization, which can be seen in 
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Figure 3.3. In comparison, the starting material of the synthesis, potato starch, showed a semi-
crystalline state, which is known to be characteristic of starch material.139  
 
Figure 3.3: XRPD pattern of potato starch (PS) and α-starch derivatives (NegStα, PosStα). 
 
For further characterization of the formulation as well as for cell interaction studies, PosSt 
was labeled with the fluorescent dye Bodipy® FL-C5 NHS Ester. The resulting polymer was 
orange in appearance as a dry powder with maximum fluorescence intensity at an excitation 
wavelength of 488 nm.  
 
3.4 CONCLUSION 
The NP formation via charge-mediated coacervation in aqueous medium requires water 
soluble materials. The synthesis and characterization of positively and negatively charged, 
water soluble starch derivatives was successfully carried out. Although the oxidation of potato 
starch was straight-forward, the conjugation of ethylenediamine with DCC/HOBt had some 
drawbacks. The medium for the coupling reaction consisted of 100% DMSO, which made 
purification using the Vivaflow 200 system challenging, as the Hydrosart® membrane (a 
stabilized cellulose-based membrane) is incompatible with DMSO. A pre-lyophilization step 
before the purification step was therefore necessary, which additionally proved to be both 
challenging (due to the high sublimation point of DMSO) and time consuming. An alternative 
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strategy to the pre-lyophilization step and purification with Vivaflow 200 was therefore 
found, namely the precipitation of PosSt with EtOH. With this time saving method, even the 
small amount of impurities arising from DCC/HOBt that were visible in the 1H-NMR 
spectrum could be removed. However, further improvement of the precipitation is necessary 
to remove residual free ethylenediamine. A more thorough washing procedure is suggested in 
this respect. Another drawback of the DCC/HOBt method is the elevated temperature of 50 
°C that is necessary for the coupling reaction. GPC measurements showed a decrease in the 
mean average molecular weight between PosStα and PosStβ from 76 000 to 43 000, 
respectively, indicating that the elevated temperature in combination with the prolonged 
reaction time of 72 h could result in an accelerated degradation of the polymer backbone. As a 
result, NegSt was coupled to ethylenediamine instead using DMTMM. Here, the reaction is 
taking place at RT in a mixture of water:DMSO. The product can be purified by precipitation 
with EtOH as solvent of choice.   
An important aspect for future work would be the testing of reproducibility of the synthesis to 
ensure a product of constant quality. Also scalability would be a variable to be explored. 
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4. STARCH VS. CHITOSAN NANOPARTICLES – PREPARATION 
AND PHYSICOCHEMICAL CHARACTERIZATION 
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4.1 INTRODUCTION 
The use of NPs as DDS for protein delivery is well-established, as they can offer protection 
during both storage, and administration, and are known to facilitate an enhanced permeation 
through epithelial barriers.140, 141 
The selection of an appropriate NP preparation method depends on both the carrier material as 
well as the drug (in this case the protein) to be encapsulated. There are several methods which 
can be utilized for NP preparation. In principle, they can all be described as either top-down 
or bottom-up methods.142, 143 The first case employs material on a large scale and involves the 
reduction of its lateral dimensions (that is, its particle size) with e.g. wet milling techniques. 
However, these methods involve a great amount of energy input and are highly inefficient.144 
On the other hand, bottom-up methods start with the material in a dissolved form, upon which 
nano- and microstructures are built up. Several approaches can be assigned to the bottom-up 
method, such as spray drying,145 supercritical fluid processes,146 nanoprecipitation,147, 148 and 
emulsion solvent evaporation.149-151 Each preparation method has its advantages and 
disadvantages. Most of these processes necessitate input of energy, by heating, sonication, or 
vortexing. Further, the use of organic solvents may be necessary, for example when DDS are 
prepared from polymers that are not water soluble. All such factors could potentially damage 
the structure of the DDS protein cargo, as the secondary, tertiary and quaternary levels of 
protein structure are very sensitive to the application of energy. Although often preparation 
methods for DDS are emulsion based, this approach can additionally lead to unfolding of the 
protein, as protein molecules migrate to the phase interface, arranging their hydrophilic 
domains to the water side and their lipophilic domains to the hydrophobic side. 
To avoid these issues and to ensure protein integrity, a preparation method for DDS was 
chosen that only applies the use of aqueous media, with no organic solvents and no harsh 
mixing conditions. Therefore, water soluble polymers were evaluated. Polysaccharides are 
among the most studied polymers for drug delivery applications.107 Amongst these, chitosan 
(CS) was chosen as reference material, as chitosan-based DDS are widely explored114-116, 152 
and can be prepared in aqueous solution by virtue of interaction of CS with a small ionic 
crosslinker tripolyphosphate (TPP).152 
Working in an aqueous environment, it should, however be noted that some proteins degrade 
under extreme pH conditions – and some even when their surrounding pH differs only a little 
from physiological pH - while others are sensitive to ionic strength. DDS preparation and 
loading with protein could be carried out in a buffered system; however, the presence of 
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buffer salts also has the potential to change the chemical properties of the DDS, as its 
formation is based on electrostatic interaction. 
The aim of this chapter was to compare the preparation and characterization of NPs composed 
of two different carbohydrate-based materials. CS NPs introduced by Calvo et al. in 1997 and 
often used for protein delivery152 acted as an evaluation tool for the preparation process, and 
as a guide to help establish appropriate analytical methods for the newly developed starch 
NPs. The synthesized water soluble anionic and cationic α-starch derivatives were used in 
order to enable NP formation via charge-mediated coacervation; these NPs were compared to 
CS NPs, prepared also via charge-mediated coacervation with TPP, which is also called ionic 
gelation in this special case. 
 
4.2 MATERIALS AND METHODS 
4.2.1 MATERIALS 
Protasan UPCL 113 (chitosan, CS) with a weight average molecular weight of 61268 ± 406 
and a degree of deacetylation of ~ 83% was bought from Novamatrix, Norway. Sodium 
tripolyphosphate (TPP) was purchased from Merck KGaA, Germany. Negatively (NegSt) and 
positively (PosSt) charged starches were synthesized in house. IgG1 and insulin were kindly 
donated by Boehringer Ingelheim (Germany) and Sanofi (France), respectively. Vancomycin 
hydrochloride (vanco), Ribonuclease A from bovine pancreas (RNAse A), α-amylase from 
porcine pancreas, chitosanase from Streptomyces (chitosanase), albumin from chicken egg 
white (OVA), albumin from bovine serum (BSA), and lysozyme from chicken egg white 
(Lyso) were bought from Sigma Aldrich  (USA). The Nrf2 peptide153 (peptide sequence: 
(LQL)DEETGEFLPIQ) was bought from Selleck Chemicals, U.S.A. 
Purified water was produced by a milliQ water purification system (Merck Millipore, USA). 
All other reagents were of analytical grade.  
 
4.2.2 PREPARATION AND LOADING OF CHITOSAN NANOPARTICLES 
CS NPs were prepared by ionic gelation of positively charged amine groups of CS with 
negatively charged phosphate groups of TPP in aqueous solution, in a procedure adapted from 
Calvo et al.113 Besides material concentration, the molar ratio of components, as well as the 
stirring speed (500 rpm, 1000 rpm) and injection rate (5 mL/min, 10 mL/min, 20 mL/min) for 
particle preparation using a syringe pump were investigated, as parameters potentially 
influencing the characteristics of resulting NPs. Further, the impact of the preparation medium 
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was explored, by utilizing either purified water, or 10 mM HOAc/OAc- buffer pH 5.0 with 
and without different amounts of NaCl (5 mM, 10 mM, 50 mM). Briefly, materials were 
dissolved in aqueous medium to obtain solutions of 1 mg/mL, 0.5 mg/mL and 0.25 mg/mL 
and filtered. Different molar ratios (20:1, 10:1, 2:1 and 0.5:1) of CS:TPP were studied by 
adding adequate volumes of TPP solutions (1, 0.5, 0.25 mg/mL) to CS solutions (1, 0.5, 0.25 
mg/mL) under gentle stirring at RT. NPs formed spontaneously and were analyzed after 10 
min of stirring for equilibration. The final pH value of all tested formulations was 5.0.  
In order to assess the use of CS NPs as DDS for proteins, five proteins varying in size and net 
charge, were chosen for loading experiments. These proteins were IgG1 (Mw: 150 kDa, 
isoelectric point (IEP): 8.5), BSA (Mw: 66 kDa, IEP: 4.7), OVA (Mw: 44 kDa, IEP: 4.5), 
Lyso (Mw: 14 kDa, IEP: 11.4) and Nrf2 (Mw: 1.3 kDa, IEP: 3.5). For the loading 
experiments, each protein sample was prepared as 5 mg/mL stock solution in purified water 
and added in various concentrations to the NP suspension to obtain final protein 
concentrations of 10.4 µg/mL, 20.7 µg/mL, and 41.3 µg/mL.  
 
4.2.3 PREPARATION AND LOADING OF STARCH NANOPARTICLES 
Starch NPs were prepared by charge-mediated coacervation between negatively charged 
carboxylate groups (NegSt) and positively charged amine groups (PosSt) of α-starch 
derivatives in aqueous solution. Briefly, materials were dissolved in purified water to obtain 
solutions of 1 mg/mL, 0.5 mg/mL, and 0.25 mg/mL, and filtered. Different molar ratios (3:1, 
1:1, 1:3) of PosSt and NegSt solutions were studied by adding adequate volumes of NegSt (1, 
0.5, 0.25 mg/mL) solution to PosSt solution (1, 0.5, 0.25 mg/mL) under gentle stirring at RT. 
NPs formed spontaneously and were analyzed after 10 min of stirring for equilibration. The 
final pH value was 7.4 for all tested formulations.  
For later characterization studies of the formulation as well as uptake studies, labeled starch 
NPs were prepared from solutions of 0.25 mg/mL and a molar ratio of 1:1 of PosSt:NegSt. 
Instead of PosSt alone, different mass ratios of PosSt:PosStF (100:0, 50:50, 10:90, 5; 95) were 
used for particle preparation. 
Four proteins varying in net charge and size were chosen for loading experiments, in order to 
assess the use of starch NPs as DDS. In detail, these proteins were vanco (Mw: 1.5 kDa, IEP: 
7.5), insulin (Mw: 6 kDa, IEP: 5.3), RNAse A (Mw: 14 kDa, IEP: 9.6), and IgG1 (Mw: 150 
kDa, IEP: 8.5). Each protein sample was prepared as 5 mg/mL stock solution in purified water 
(except insulin, which was dissolved in 0.01 N NaOH) and added to the NP suspension to 
obtain final protein concentrations of 17.2 µg/mL, 34.2 µg/mL, and 51.2 µg/mL. 
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4.2.4 CHARACTERIZATION OF NANOPARTICLES 
Physicochemical properties (particle size, PdI, and ζ-potential) of NPs in preparation medium 
were determined using the Zetasizer Nano ZSP (Malvern Instruments, UK) with a scattering 
angle of 173°. Particle sizes were intensity based z-average values and standard deviation was 
of at least 3 measurements. Storage stability of CS NPs was assessed by monitoring NPs for 
size, PdI and ζ-potential for 7 days. Samples were stored in the fridge (4 °C). 
Physicochemical stability of starch NPs was monitored for size, PdI and ζ-potential for 14 
days. Samples were stored either in the fridge (4 °C) or at RT (20 °C). Morphology of CS NPs 
was analyzed by scanning electron microscopy (SEM, JSM 7001F Field Emission SEM (Jeol, 
Japan)). Samples were placed on a silicon wafer on top of a carbon disc and sputtered with 
gold (layer thickness approx. 10 nm) prior to scanning. The accelerating voltage was 5 kV 
with a focal distance of 15 mm. Further, transmission electron microscopy (TEM) using a 
JEOL JEM 2011 microscope (Oxford Instruments, UK) was used for morphology analysis of 
CS and starch NPs. A 20 µL volume of sample was incubated on a copper grid for 30 min. 
After staining with 1% (w/v) of phosphotungstic acid (PTA) for 30 s, samples were dried 
overnight (excess fluid was directly removed with filter paper) and analyzed.  
To study the biodegradation of CS NPs, 10 mL of NP suspension was incubated at 50 °C with 
0.5 µL or 5 µL of chitosanase solution (0.1352 units/µL) for 2, 4, 6, 8, or 24 h under gentle 
stirring. As control, 10 mL of CS NP suspension was incubated at 50 °C under gentle stirring 
without enzyme. The biodegradation of starch NPs was studied by incubating 10 mL of NP 
suspension with 25 µL α-amylase solution (36.37 units/µL) at 37 °C for 2, 4, 6, or 8 h under 
gentle stirring. As a control in this case, 10 mL of starch NP suspension was incubated at 37 
°C under gentle stirring in the absence of α-amylase. Particle concentrations were then 
analyzed at several time points by nanoparticle tracking analysis (NanoSight LM 10, Malvern 
Instruments, UK). For these measurements, 0.5 mL was taken from each sample. Described 
results are the particle concentration (after correction for the dilution factor needed for 
valuable measurement) of treated and non-treated samples (each n=3).  
To study the stability of CS NPs and starch NPs upon aerosolization, they were nebulized 
with the Aeroneb®Lab nebulizer (Aerogen Ltd., Ireland) and collected to be analyzed for size, 
PdI and ζ-potential with the Zetasizer Nano ZSP (Malvern Instruments, UK). 
For the determination of protein encapsulation efficiency (EE) and loading rate (LR) in each 
case, NPs were separated from the dispersing medium containing non-encapsulated protein, 
after 15 min equilibration, by ultracentrifugation (45.000 x g for 90 min (CS NPs) or 60 min 
(starch NPs), 20 °C; Optima L-XP, Beckman Coulter, UK). The amount of free protein in the 
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supernatant was determined with the BCA (bicinchoninic acid) Assay Kit (Sigma Aldrich, 
USA). This assay relies on the formation of Cu2+-protein complexes with reduction of Cu2+ to 
Cu1+ under alkaline conditions. Bicinchoninic acid then forms a purple complex with the Cu1+ 
in alkaline conditions that can be detected by measuring the absorbance at 562 nm. EE and 
LR of proteins/peptides were defined and calculated according to following equations: 
 
 
 
 
 
 
 
For determination of the particle yield (mass NP), washing of the particles was performed 
with Vivaflow® 50 (100 kDa MWCO, PES (Polyethersulfone) membrane, Sartorius, 
Germany). A 50 mL (CS) or 40 mL (starch) volume of NP suspension was washed with 150 
mL or 120 mL of purified water, respectively, concentrated to 10 mL, freeze dried and 
weighed. 
 
4.3 RESULTS AND DISCUSSION 
The well-known system of CS NPs was chosen to get an idea of the preparation process and 
to establish analytical tools for the newly developed starch NPs. Further, the CS NP system 
was designated as a bench-mark for starch NPs. 
CS NPs were chosen, due to the abundance of literature available describing such systems, as 
well as the ability to prepare CS and starch-based NPs using a similar aqueous-based 
preparation process. CS is a well-known material and was a good starting point for the 
evaluation of analytical tools. It was designated as the 1st generation DDS for the COMPACT 
consortium to be replaced by starch NPs as a 2nd generation DDS once all characterization 
methods had been developed.   
 
4.3.1 PREPARATION OF CHITOSAN NANOPARTICLES 
CS is prepared via partial deacetylation from the natural polymer chitin, consisting of N-
acetylated glucosamine residues, occurring widely in nature as a structural polysaccharide 
present in the integument of crustacea and insects.154 Further, there is a vegetarian source of 
CS, obtained by extracting chitin from cell walls of fungi.155  
𝐸𝐸[%] =
𝑚𝑎𝑠𝑠(𝑝𝑟𝑜𝑡𝑒𝑖𝑛)𝑡𝑜𝑡𝑎𝑙 −  𝑚𝑎𝑠𝑠(𝑝𝑟𝑜𝑡𝑒𝑖𝑛)𝑓𝑟𝑒𝑒
𝑚𝑎𝑠𝑠(𝑝𝑟𝑜𝑡𝑒𝑖𝑛)𝑡𝑜𝑡𝑎𝑙
∗ 100 
𝐿𝑅 [%] =
𝑚𝑎𝑠𝑠(𝑝𝑟𝑜𝑡𝑒𝑖𝑛)𝑡𝑜𝑡𝑎𝑙 −  𝑚𝑎𝑠𝑠(𝑝𝑟𝑜𝑡𝑒𝑖𝑛)𝑓𝑟𝑒𝑒
𝑚𝑎𝑠𝑠𝑁𝑃
 ∗ 100 
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CS NPs were prepared by adding different amounts of the highly negatively charged small 
molecule TPP to a CS solution under stirring. Both solutions always had the same mass 
concentration.  
 
Particle preparation by manual injection  
First of all, the influence of the molar ratio and concentration of components on the 
physicochemical properties of formed CS NPs was investigated (Figure 4.1). It can be seen 
that NP formation depended highly on the molar ratio of the two components: a molar ratio of 
CS:TPP 20:1 led to a particle size between 182.1 ± 29.2 nm and 395.4 ± 36.1 nm, with 
corresponding PdI values at these sizes of 0.25 and 0.23, respectively. A molar ratio of 10:1 
was also shown to give good results with particle sizes ranging from 155.5 ± 2.7 nm to 395.8 
± 6.8 nm and PdIs between 0.15 and 0.36. In contrast, molar ratios of 2:1 and 0.5:1 resulted in 
aggregation of the material, with particle sizes between 800 and 4000 nm and high PdI values 
observed. This is in accordance with the determined ζ-potential values for these formulations, 
which are close to zero, indicating that an electrostatic stabilization of the NPs was not 
possible. However, this was possible for the formulations of molar ratios 20:1 and 10:1, with 
ζ-potential values around +45 mV and +35 mV, respectively. As a first result, it can therefore 
be concluded that the molar ratio of CS:TPP is important for NP formation, and should be 
between 20:1 and 10:1. A higher amount of negatively charged TPP leads to a loss in the ζ-
potential, resulting in an unstable system.  
As second parameter, the influence of material concentration was explored. Therefore, CS and 
TPP concentrations of 1, 0.5, and 0.25 mg/mL were investigated. For a molar ratio of 20:1, it 
can be seen that particle size increased with increasing material concentration: a particle size 
of 182.1 ± 29.2 nm was obtained for 0.25 mg/mL concentrations, whereas a particle size of 
290.6 ± 52.2 nm and 395.4 ± 36.1 nm was found for 0.5 mg/mL and 1 mg/mL concentrations, 
respectively. Similar results were obtained for a molar ratio of 10:1: the particle size for the 
lowest concentration was 155.5 ± 2.7 nm, whereas a particle size of 261.8 ± 0.2 was obtained 
for 0.5 mg/mL and a particle size of 395.8 ± 6.8 nm was obtained for 1 mg/mL. The ζ-
potential was not affected by the material concentration. The values rather depended on the 
molar ratio of CS:TPP, with ζ-potentials of around +45 mV for 20:1 and +30 - +35 mV for a 
molar ratio of 10:1. It can be concluded that particle size depends chiefly on material 
concentration, with a lower concentration leading to a smaller particle size. The ζ-potential, 
however, was mostly influenced by the molar ratio of components. This is in accordance with 
Calvo et al., who obtained similar results.113 
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Figure 4.1: Preparation of CS NPs with different material concentrations (1, 0.5, 0.25 
mg/mL), and molar ratios (20:1, 10:1, 2:1, 0.5:1 CS:TPP). (A) size (bar) and PdI (squares); 
(B) ζ-potential; TPP solution was applied by manual injection. 
 
Particle preparation with a syringe pump 
It could be seen that NP results obtained by manual injection were not always reproducible. 
To reduce the high standard deviations and to further improve reproducibility, the use of a 
syringe pump (Harvard Apparatus PHD ULTRA, Harvard Apparatus Inc., Holliston, USA) 
was explored. When using such a pump, the pressure, the added volume and the injection rate 
can be adjusted and controlled, which may lead to more reproducible results. For these 
experiments, a material concentration of 0.25 mg/mL of CS and TPP and two different molar 
ratios, 20:1 and 10:1, were chosen. Parameters such as stirring speed (500 rpm, 1000 rpm) and 
injection rate (5 mL/min, 10 mL/min, 20 ml/min) were varied and their effect on 
physicochemical properties of CS NPs studied. The results can be found in Figure 4.2.  
In comparison to the experiments performed with manual injection, the PdI of NPs formed 
using a syringe pump was always below 0.2, indicating a narrow particle size distribution. 
The particle size, however, did not depend on stirring speed or injection rate. For a molar ratio 
of 20:1, particle sizes were between 180 nm and 210 nm independent of injection rate and 
stirring speed. For a molar ratio of 10:1 it could be assumed that stirring has a minor 
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influence, as particle size was between 144.3 ± 0.2 nm and 161.3 ± 0.7 nm for a stirring speed 
of 500 rpm, whereas particle size decreased for a stirring speed of 1000 rpm, being between 
111.7 ± 0.2 nm and 120 ± 1.0 nm. However, these values were again independent of injection 
rates utilized in these experiments.  
 
 
Figure 4.2: Influence of stirring speed and injection rate on the preparation of CS NPs with 
0.25 mg/mL and two different molar ratios using the syringe pump. (A) size (bars) and PdI 
(squares); (B) ζ-potential. 
 
ζ-potential values were again only depending on the CS:TPP molar ratio, being around +50 
mV for a molar ratio of 20:1 and around +35 mV for a molar ratio of 10:1. It can be 
concluded that the syringe pump is a valuable tool for reproducible particle preparation. For 
further experiments, CS NPs were prepared with the syringe pump from 0.25 mg/mL 
solutions and a molar ratio of 10:1 (CS:TPP) under stirring at 500 rpm with an injection rate 
of 20 mL/min.  
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Particle preparation in buffer  
To investigate the influence of preparation medium and temperature, CS NPs were prepared 
in a 10 mM HOAc/OAc- buffer, pH 5.0 at different temperatures (4 °C, 20 °C, 45 °C). Results 
can be found in Table 4.1.  
 
Table 4.1 
Influence of preparation medium, temperature and NaCl concentration on physicochemical 
properties of CS NPs prepared from 0.25 mg/mL solutions with a molar ratio of 10:1 in a 10 
mM HOAc/OAc- buffer, pH 5.0. 
 
Temperature 
[°C] 
NaCl 
[mM] 
Size 
[d.nm] 
PdI ζ-potential 
[mV] 
4 - 88.1 ± 1.9 0.25 12.7 ± 0.9 
20 - 84.3 ± 1.6 0.24 24.1 ± 2.9 
45 - 80.9 ± 0.9 0.19 26.4 ± 0.8 
20 5 74.8 ± 0.2 0.21 20.2 ± 3.2 
20 10 73.7 ± 0.8 0.19 12.7 ± 0.4 
20 50 55.1 ± 0.1 0.09 16.3 ± 2.2 
 
It can be seen that the temperature had no clear effect on particle size, however for an 
elevated temperature, particle size distribution was somewhat improved with a PdI below 0.2 
for the formulation prepared at 45 °C. The ζ-potential was by contrast clearly influenced by 
the temperature, with values of +12.7 ± 0.9 mV for a preparation at 4 °C and values of +24.1 
± 2.9 mV and +26.4 ± 0.8 mV for the preparation at 20 °C and 45 °C, respectively. As the ζ-
potential measurement is temperature dependent, it could be assumed that for 4 °C the sample 
did not reach the correct measurement temperature yet, as the preparation temperature is not 
expected to alter the ζ-potential. To improve size distribution, NaCl was added in various 
concentrations to the buffer used for NP preparation (5 mM, 10 mM, 50 mM). It can be seen 
that, with increasing amounts of NaCl, the PdI decreased from 0.24 for the preparation in 
buffer without NaCl, to 0.21 for the preparation in 5 mM NaCl, to 0.09 for the preparation in 
50 mM NaCl. Particle size was also affected by the NaCl amount. Particles of 84.3 ± 1.6 nm 
were formed from preparation in buffer without NaCl, while 74.8 ± 0.2 nm particles resulted 
from the preparation in 5 mM NaCl, and 55.1 ± 0.1 nm NPs were the product of preparation 
in 50 mM NaCl. While some variations in ζ-potential was observed, as this measure depends 
both on the pH and ionic strength of the dispersing medium, it could not be compared under 
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conditions of varying NaCl content. The preparation in buffer clearly changed the particle size 
of CS NPs, being around 150 nm for the preparation in water and 90 nm for the preparation in 
buffer and even smaller for the preparation in buffer with additional salt concentration. 
To keep the formulation as simple as possible, it was decided to minimize additional material 
contributions from buffer components or salts. The preparation in water was used for further 
evaluation of the CS NPs system. 
 
4.3.2 CHARACTERIZATION OF CHITOSAN NANOPARTICLES 
Storage stability  
To investigate storage stability of CS NPs, short term particle stability after preparation was 
studied for 7 days. Therefore, CS NPs prepared from 0.25 mg/mL and a molar ratio of 10:1 
were stored at 4 °C. Samples were taken at several time points and analyzed for their size, PdI 
and ζ-potential (Figure 4.3). It can be seen that particle size, PdI and ζ-potential were stable 
during storage and could be prepared in advance before running further experiments. 
 
 
Figure 4.3: Storage stability of CS NPs prepared from 0.25 mg/mL and a molar ratio of 10:1 
(CS:TPP), stored at 4 °C. (A) size (bars) and PdI (squares); (B) ζ-potential. 
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Morphology  
Attempts were made to evalute the morphology of CS NPs by SEM. In contrast to PLGA 
NPs, where this technique has nicely been explored, the application of SEM for imaging of 
CS NPs was found to be of limited use. SEM images showed a polymer layer (Figure 4.4 (A) 
with some particulate structures, more clearly visible at higher levels of magnification (Figure 
4.4 (B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Images of CS NPs, prepared from 0.25 mg/mL solutions in a molar ratio of 10:1 
(CS:TPP). SEM images (A-B). TEM images without staining (C) and with 1% PTA staining 
(D). 
 
This behavior indicates an instability of the system probably occuring as a result of the drying 
process utilized during SEM sample preparation - as CS NPs are known to show a gel-like 
structure, such sample drying can be expected to result in particle aggregation. In more detail, 
for imaging, the sample is placed on a SEM wafer, water is evaporated and the dry image is 
analyzed after sputtering with gold. However, during drying, space becomes limited, with 
particles coming closer to each other. Once a particle comes in contact with another particle, 
their surfaces literally stick together. NP repulsive forces, resulting from their positive ζ-
potentials, are overcome with restricted space and direct contact of the NPs. Another 
technique was therefore employed for imaging of CS NPs, namely TEM. Here, the sample is 
placed on a copper grid, allowed to dry and analyzed. The same phenomenon could be 
observed as for SEM imaging (Figure 4.4 (C). However, NPs could be stabilized with 1% 
2 µm 
1 µm 
A 
B 
C 
D 
TEM SEM 
47 
 
PTA (Figure 4.4 (D). After incubation of the NPs on the grid for 10 min, the residual solvent 
was removed by blotting with tissue paper and the grid was incubated on a 1% PTA droplet 
for 30 s. Although a polymer layer can still be observed, PTA working as a negative stain in 
this case builds a small dark layer around the particles, stabilizing them and making them 
“visible”. 
 
Biodegradation 
The biodegradation of a nanoparticulate system and the analysis of its degradation products is 
of great importance, when considering the application of such a system in vivo. 
For this reason, the biodegradability of CS NPs by chitosanase was tested, using an adapted 
protocol from Sun et al.156 Chitosanase is an enzyme, produced by many micro-organisms, 
including bacteria such as actinomycetes, as well as fungi.154 While chitosanase is not a 
human enzyme, the test should act as tool to further develop a similar enzymatic method for 
the starch NPs. 
CS NPs were incubated at 50 °C with or without chitosanase. For the samples treated with 
chitosanase, either 0.5 µL or 5 µL enzyme solution was added (0.0676 units and 0.676 units, 
respectively). At certain time points, samples were taken and particle concentration was 
determined with the help of nanoparticle tracking analysis. Compared to a control group (CS 
NPs stored at 50 °C without enzyme), the particle concentration was determined. It can be 
seen from Table 4.2 that the particle concentration of the control group decreased from 77.8 ± 
1.4 x E8 particles/mL before the incubation to 61.9 ± 12.5 x E8 particles/mL after 24 h of 
incubation. This could be due to the elevated temperature of 50 °C, resulting in a higher 
moving speed of the particles, and leading to merging of particles as a result of this higher 
kinetic energy. Nevertheless, the difference in particle concentration between the control 
group and samples incubated with chitosanase was very clear. The 0.5 µL chitosanase 
samples showed a decrease in particle amount from 80.4 ± 1.9 x E8 particles/mL to 5.3 ± 1.9 x 
E8 particles/mL already after 24 h of incubation. This effect was even more pronounced for 
the samples treated with 5 µL chitosanase. Here, the particle amount of 82.99 ± 4.1 x E8 
particles/mL was reduced to 0.6 ± 0.2 x E8 particles/mL after 24 h of incubation. Already after 
2 h the particle concentration was reduced to 1.8 ± 0.9 x E8 particles/mL, indicating a very 
fast degradation mechanism of the CS NPs. 
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Table 4.2 
Biodegradation of CS NPs by chitosanase at 50 °C, analyzed as particle concentration after 2, 
4, 6, 8, or 24 h; determined by nanoparticle tracking analysis (mean ± SD; n=3). 
 
 CS NPs 
[x E8 particles/mL] 
CS NPs + 0.5 µL chitosanase  
[x E8 particles/mL] 
CS NPs + 5 µL chitosanase  
[x E8 particles/mL] 
before 77.8 ± 1.4 80.4 ± 1.9 82.99 ± 4.1 
2 h 68.8 ± 3.9 13.3 ± 3.6 1.8 ± 0.9 
4 h 72.2 ± 4.2 12.1 ± 1.2 0.9 ± 0.3 
6 h 75.2 ± 5.9 9.1 ± 3.7 0.8 ± 0.4 
8 h 79.4 ± 6.2 8.7 ± 2.8 0.7 ± 0.2 
24 h 61.9 ± 12.5 5.3 ± 1.9 0.6 ± 0.2 
 
Loading of CS nanoparticles 
To investigate the use of CS NPs as DDS, five different proteins/peptides were chosen to 
study the loading capacity of CS NPs. The selected proteins - Nrf2 (Mw: 1.3 kDa, IEP: 3.5), 
Lyso (Mw: 14 kDa, IEP: 11.4), OVA (Mw: 44 kDa, IEP: 4.5), BSA (Mw: 66 kDa, IEP: 4.7), 
and IgG1 (Mw: 150 kDa, IEP: 8.5) – represent proteins/peptides with different net charges 
and molecular weights. For this experiment, CS NPs prepared from 0.25 mg/mL solutions and 
a molar ratio of 10:1 (CS:TPP) were chosen. For the determination of protein EE and LR of 
the CS NPs, they were separated from the dispersing medium, containing the free protein, 
after 15 min equilibration, by ultracentrifugation. EE and LR were determined indirectly, by 
measuring the amount of free protein in the produced supernatant with a colorimetric method 
(BCA assay). The BCA assay was chosen as detection method of choice due to its broad 
application spectrum.  
Although a direct method of quantification is always favored, the dissolution of the NPs 
without harming the cargo (in this case the protein) has to be ensured when such a method is 
employed. Different dissolution strategies were in fact tried, such as dissolution with e.g. HCl, 
NaOH, and 500 mM NaCl; however, either particles could not be completely dissolved, or the 
pH or ionic strength of the solubilizing agent led to aggregation of the protein. 
As a result, an indirect method for quantification was preferred. Ultracentrifugation was 
chosen as a separation method, as other methods such as Vivaspin® or Centrisart® (membrane 
based methods), in which the protein has shown interactions with the membrane, made a 
quantitative analysis impossible. Before quantifying the EE and the LR, the 
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ultracentrifugation method had to be validated. In this respect, three parameters had to be 
guaranteed: a) a NP suspension had to form a quantitative pellet during ultracentrifugation, 
meaning complete removal of NPs from the supernatant; b) a protein solution had to show 
similar concentrations in the supernatant before and after ultracentrifugation to assure no 
precipitation of the protein under the employed ultracentrifugation conditions; c) the 
applicability and linearity of the BCA assay in the measured protein concentration range had 
to be verified.  
A quantitative pellet of CS NPs was formed with ultracentrifugation at 45 000 x g and 20 °C 
for 60 min. Further, the supernatant was analyzed by nanoparticle tracking analysis, and no 
particles could be observed. The pellet which was formed by CS NPs after ultracentrifugation 
can be seen in Figure 4.5 (A), with visualization by SEM. Further all tested concentrations of 
protein solution before (“conc theory”) and after ultracentrifugation (“conc measured”) were 
determined with the BCA assay. The results of such measurement for a representative 
employed protein concentration of 40 µg/mL are shown in Figure 4.5 (B). It can be seen that 
the theoretical concentration and the concentration after ultracentrifugation is almost the 
same, thus no aggregation and sedimentation of the protein/peptide occurred. In a third step, 
the applicability and linearity range of the BCA assay was determined. It could be shown that 
blank NP supernatant showed a slight impact on the absorbance reading as determined with 
the BCA assay. However, these values were constant and could be subtracted from the 
measurement values of samples. 
 
 
 
Figure 4.5: Validation of the indirect quantification method. (A) SEM image of the pellet 
formed by CS NPs after ultracentrifugation at 45 000 x g, 60 min, and 20 °C; (B) 
concentration of protein solutions before ultracentrifugation (conc theory) and after 
ultracentrifugation determined from the supernatant (conc measured). 
 
NPs were washed with the Vivaflow® 50 system (100 kDa MWCO, PES membrane, 
Sartorius, Germany), freeze dried and weighed, for the determination of the LR. In contrast to 
Vivaspin® or Centrisart®, this membrane based, crossflow filtration method, also known as 
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tangential flow filtration, is very mild. It is stated in the Cross flow filtration method 
handbook that “a pressure difference across the filter drives components that are smaller than 
the pores through the filter. Components larger than the filter pores are retained and pass 
along the membrane surface, flowing back to the feed reservoir.”157 With this method, NPs 
stay intact and do not show a blockage of the membrane as happened for the other two 
systems. This was verified by dynamic light scattering (DLS): before washing with the 
Vivaflow® 50 system, CS NPs showed a particle size of 151.1 ± 1.0 nm and a PdI of 0.14. 
After washing, particle size increased to 182.6 ± 3 nm with a PdI of 0.18. This slight increase 
in size can be explained by the concentrating effects of washing on the sample: For washing, 
50 mL of nanoparticle suspension was used, but this volume was concentrated to 10 mL for 
freeze drying.  
Physicochemical properties of loaded CS NPs from post loading experiments with different 
proteins/peptides can be found in Table 4.3. Further, EE and LR are shown.  
Regarding size distribution, all formulations showed good PdI values, lower than 0.2, 
indicating a narrow particle size distribution. Blank particles showed a particle size of 155.5 ± 
2.7 nm and a ζ-potential of +31.5 ± 0.8 mV. In contrast to that, all formulations demonstrated 
a decrease in particle size varying extent when loaded with different proteins. Also a decrease 
in the ζ-potential could be seen following loading with proteins. The loading with OVA, 
however, is an exception, as both particle size and ζ-potential stayed constant.  
The high EE determined for OVA and BSA of up to 82.8 ± 1.6% and 91.7 ± 4.6%, as well as 
the high LR of 23.0 ± 1.3% and 25.6 ± 1.3%, respectively, can be ascribed to the hydrophobic 
character of these proteins at pH 5.0. The IEP of these proteins is 4.5 (OVA) and 4.7 (BSA), 
meaning that both proteins are close to their IEP at the pH of the CS NP suspension. 
Nevertheless, compared to OVA, BSA-loaded NPs showed a decrease in particle size as well 
as a decrease in ζ-potential, indicating a different binding mechanism as compared to OVA. 
Concerning the encapsulation of the negatively charged Nrf2 (at pH 5.0), an encapsulated 
mass of around 50-60 µg could not be further enhanced, meaning that such a system has a 
maximum LR of approximately 3%.  
It can be seen that for some formulations (marked with *), the EE and LR could not been 
determined. This holds true for all the IgG formulations, as well as the formulation loaded 
with 125 µg Lyso. For a higher mass of Lyso, however, an EE of up to 23.9 ± 0.9% and a LR 
of 6.6 ± 0.3% could be obtained. Surprisingly, Lyso was able to be encapsulated, although its 
IEP (11.4) is even higher than that of IgG (8.5), meaning a higher positively charge than the 
antibody at pH 5.0. 
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Table 4.3 
Physicochemical properties of protein-loaded CS NPs as well as encapsulation efficiency 
(EE) and loading rate (LR), as determined indirectly with the BCA assay after separating 
loaded NPs from free protein via ultracentrifugation; *loading could not be determined; 
(mean ± SD, n=3). 
 
CS NPs 
(loaded 
with) 
mass
initial 
protein 
[µg] 
Size 
[d.nm] 
PdI ζ-potential 
[mV] 
mass
encaps 
protein 
[µg] 
EE 
[%] 
LR 
[%] 
blank - 155.53 ± 2.7 0.15 +31.5 ± 0.8 - - - 
IgG1 (Mw 150 kDa, IEP 8.5) 
 125 133.8 ±  8.7 0.13 +25.8 ±  2.3 * * * 
 250 102.5 ±  10.1 0.17 +23.3 ±  1.6 * * * 
 500 106.3 ±  20.3 0.18 +22.4 ±  4.0 * * * 
BSA (Mw 66 kDa, IEP 4.7) 
 125 126.1 ±  9.4 0.13 +21.3 ±  1.7 144.1 ± 8.5 113.7 ± 6.7 7.9 ± 0.5 
 250 89.6 ±  3.5 0.17 +23.5 ±  1.9 209.4 ± 7.7 83.8 ± 3.1 11.5 ± 0.4 
 500 134.4 ±  3.3 0.17 +21.4 ±  3.7 463.8 ± 23.1 91.7 ± 4.6 25.6 ± 1.3 
OVA (Mw 44 kDa, IEP 4.5) 
 125 154.4 ±  24.2 0.15 +31.0 ±  1.9 120.4 ± 7.3 94.2 ± 5.7 6.6 ± 0.4 
 250 158.5 ±  8.5 0.14 +31.0 ±  1.1 228.6 ± 13.3 90.5 ± 5.3 12.6 ± 0.7 
 500 163.7 ±  26.0 0.18 +30.1 ±  4.3 417.9 ± 8.2  82.8 ± 1.6 23.0 ± 0.5 
Lyso (Mw 14 kDa, IEP 11.4) 
 125 116.9 ± 11.8 0.13 +21.4 ±  6.3 * * * 
 250 135.8 ±  5.8 0.12 +24.3 ±  2.7 48.0 ± 10.4 19.2 ± 4.2 2.7 ± 0.6 
 500 139.1 ±  23.6 0.11 +25.1 ±  3.6 119.5 ± 4.7 23.9 ± 0.9 6.6 ± 0.3 
Nrf2 (Mw 1.3 kDa, IEP 3.5) 
 125 131.6 ± 21.6 0.13 +31.7 ± 0.2 53.5 ± 19.8 42.6 ± 15.7 2.9 ± 1.1 
 250 114.1 ± 10.8 0.16 +24.6 ± 1.3 28.0 ± 10.4 11.1 ± 4.1 1.5 ± 0.6 
 500 105.8 ± 5.3 0.18 +24.8 ± 0.7 64.3 ± 12.4 12.8 ± 2.5 3.5 ± 0.7 
 
Apparently, a negative charge is not important for binding of the protein/peptide to the 
positively charged CS NPs. It seems that the most important factor influencing the binding is 
rather hydrophobicity or an approximately neutral charge at the desired pH – an observation 
which is entirely logical when considering the hydrophilic aqueous environment.    
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Stability of chitosan nanoparticles upon aerosolization 
To determine their applicability for pulmonary delivery, CS NPs aerosolization properties and 
their stability during nebulization were studied by determining the physicochemical properties 
of the NPs before and after nebulization. CS NPs with a size of approximately 146.8 ± 1.4 nm 
and a PdI of 0.155 showed a ζ-potential of approximately +32.7 ± 3.7 mV before 
nebulization. After nebulization, however, particle size increased to 173.3 ± 1.8 nm and a PdI 
of 0.195 was found, together with a ζ-potential of +30.8 ± 1.8 mV. Furthermore, the 
nebulization process required a very long time frame, which additionally showed that the 
nebulization of CS NPs for pulmonary delivery is not efficient. 
 
4.3.3 PREPARATION OF STARCH NANOPARTICLES 
Starch NPs were prepared via charge-mediated coacervation in aqueous solution at RT. This 
process was adapted from Calvo et al.,113, 152 who prepared CS NPs from the interaction 
between CS and the small TPP. In contrast to the CS system, the starch NP formation 
involved the interaction of two polymeric materials of similar molecular weight. Partial 
charge neutralization due to the reaction of positively charged amine groups of PosSt with 
negatively charged carboxyl groups of NegSt led to the spontaneous formation of starch NPs, 
after mixing the two oppositely charged polymers under stirring. An advantage of the starch 
NP system is the isohydric pH of the nanoparticle suspension of 7.4 as well as the interaction 
of two polymers probably leading to more stable particles. The general advantage of 
coacervation is the mild character of this procedure as organic solvents, high temperatures, 
and sonication are not necessary for the NP preparation. Further, no additional stabilizers 
necessary for example during nanoprecipitation have to be used in this case. Therefore, it is 
very well suited as method to prepare NPs for loading with proteins and peptides.  
The important parameters influencing particle properties, known from the CS NP preparation, 
were also investigated for the starch NP formation. The influence of polymer concentration (1 
mg/mL, 0.5 mg/mL, 0.25 mg/mL), and different molar ratios (1:3, 1:1, 3:1 PosSt:NegSt) were 
studied, by adding NegSt to PosSt with the help of a syringe pump under stirring. Important 
physicochemical properties of the formed NPs in relation to the used material concentration 
and molar ratio are described in Table 4.4. 
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Table 4.4 
Physicochemical characteristics of starch NPs related to material concentration (1, 0.5, 0.25 
mg/mL) and molar ratio of components (1:3, 1:1, 3:1) used for charge-mediated coacervation.  
 
A narrow particle size distribution for the formulations is indicated by the consistently low 
PdI (always below 0.2). Particle size ranged from approximately 140-350 nm, depending on 
both the material concentration and molar ratio of components. The smallest particle size of 
138.9 ± 0.3 nm was obtained for a molar ratio of 1:3, and 0.25 mg/mL material  
concentrations. Keeping the molar ratio constant, but increasing the material concentrations to 
0.5 and 1 mg/mL resulted in increased particle sizes of 160.5 ± 0.6 and 181.6 ± 1.7 nm, 
respectively. As mentioned, varying the molar ratio also influenced particle size. NPs 
prepared from material concentrations of 0.25 mg/mL showed an increase in particle size 
from 138.9 ± 0.3 nm to 152.0 ± 0.2 nm and further to 209.2.8 nm for molar ratios of 1:3, 1:1 
and 3:1, respectively, thus indicating that the particle size increased also with the content of 
PosSt. 
The ζ-potential ranged from -35 to -10 mV in the investigated molar ratios, and in fact only 
depended on the molar ratio of PosSt and NegSt. For a molar ratio of 1:3 the ζ-potential was 
approximately -35 mV. A molar ratio of 1:1 resulted in a ζ-potential of around -25 mV, and 
starch NPs prepared in a molar ratio of 3:1 showed a ζ-potential of around -10 mV. Therefore, 
the greater the PosSt content of the formulation, the closer the ζ-potential was to 0.  
 
Formulation PosSt conc 
[mg/mL] 
NegSt conc 
[mg/mL] 
PosSt:NegSt 
[molar ratio] 
Size 
[d.nm] 
PdI ζ-potential 
[mV] 
Starch 1-1:3 1 1 1:3 181.6 ± 1.7 0.104 -31.1 ± 0.3 
Starch 1-1:1 1 1 1:1 206.9 ± 0.7 0.078 -22.2 ± 0.1 
Starch 1-3:1 1 1 3:1 346.9 ± 6.6 0.211 -10.3 ± 0.1 
Starch 0.5-1:3 0.5 0.5 1:3 160.5 ± 0.6 0.088 -33.4 ± 1.6 
Starch 0.5-1:1 0.5 0.5 1:1 179.0 ± 1.6 0.077 -23.5 ± 0.8 
Starch 0.5-3:1 0.5 0.5 3:1 230.5 ± 4.2 0.084 -9.1 ± 0.1 
Starch 0.25-1:3 0.25 0.25 1:3 138.9 ± 0.3 0.105 -37.0 ± 3.1 
Starch 0.25-1:1 0.25 0.25 1:1 152.0 ± 0.2 0.077 -24.1 ± 0.6 
Starch 0.25-3:1 0.25 0.25 3:1 209.3 ± 2.8 0.035 -8.5 ± 0.3 
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4.3.4 PREPARATION OF LABELED STARCH NANOPARTICLES 
For later characterization and cell interaction studies, starch NPs were prepared as described, 
but with different amounts of labeled PosStF. Results can be found in Table 4.5. It could be 
seen that the lower the PosStF content was present in the formulation, the lower the resulting 
ζ-potential, whereas particle size and PdI were constant. The hydrophobic character of the 
label probably caused the change in the ζ-potential. For later experiments, a 50:50 ratio of 
PosStF:PosSt was chosen to ensure similar physicochemical properties as the particles without 
label whilst at the same time a high fluorescence for analysis.   
 
Table 4.5 
Characteristics of starch NPs prepared with different amounts of labeled PosStF in a ratio of 
1:1 (PosSt(F):NegSt) and a concentration of 0.25 mg/mL; bold: formulation used for uptake 
studies (Chapter 6). 
 
PosSt
F
 
[%] 
PosSt 
[%] 
Size 
[d.nm] 
PdI ζ-potential 
[mV] 
100 0 132.5 ± 1.17 0.088 -26.4 ± 2.80 
50 50 145.2 ± 0.7 0.1 -26.4 ± 2.8 
10 90 147.1 ± 0.75 0.051 -22.7 ± 0.95 
5 95 146.4 ± 0.72 0.064 -18.3 ± 0.12 
 
 
4.3.5 CHARACTERIZATION OF STARCH NANOPARTICLES 
Storage stability  
To investigate the influence of the surface charge of the nanoparticles on storage stability, 
starch NPs prepared from 0.25 mg/mL formulations with a molar ratio of 1:3, 1:1 and 3:1 
were chosen. Starch NP formulations showed different storage stabilities, when stored after 
preparation (Figure 4.6). Whilst Starch 0.25-1:3 and Starch 0.25-1:1 showed good stability 
with respect to size over 14 days, the formulation Starch 0.25-3:1, with a ζ-potential close to 
zero showed aggregation tendencies at both storage temperatures. For this formulation the 
weak surface charge was not able to electrostatically stabilize the NP suspension via repulsive 
forces.158 Starch 0.25-1:1 showed best stability and was therefore chosen for further 
experiments. 
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Figure 4.6: Stability study of various starch NP formulations prepared from 0.25 mg/mL 
solutions, stored either at RT or at 4 °C (F); (A) size; (B) PdI; (C) ζ-potential.  
 
Morphology 
TEM images of starch NPs, prepared from 0.25 mg/mL solutions, incubated on a copper grid 
and stained with 1% PTA are shown in Figure 4.7. Black particles with a spherical, solid and 
consistent shape could be observed for all formulations. Image analysis indicated that sizes 
were comparable to size measurements determined by DLS. However, similar to CS NPs, 
starch NPs tended to aggregate during the drying process on the copper grid, forming a 
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polymer layer probably due to their gel-like, sticky character (data not shown). Therefore, 
starch NPs were stained and stabilized with 1% PTA during the drying process.  
The formulation of Starch 0.25-1:3 (Figure 4.7 (C) only showed few particles whereas a 
considerably greater amount of NPs could be found for formulations Starch 0.25-3:1 and 
Starch 0.25-1:1. The efficient interaction of the highly negatively charged starch NPs (ζ-
potential of -37.0 ± 3.1 mV) with the slightly negatively charged TEM grids during the 
incubation time was probably hindered by repulsion.   
Figure 4.7: TEM images of starch NPs, positively stained with 1% PTA. (A) Starch 0.25-3:1; 
(B) Starch 0.25-1:1; (C) Starch 0.25-1:3. 
 
Biodegradation 
With respect to the use of NPs in the field of nanomedicine, one important point to address is 
the biodegradation of the system. As known, safety of NPs is not only a matter of size, but 
also depends on a variety of other factors such as dose frequency, toxicity of raw material, 
and importantly on their persistence in the body. The longer NPs stay in the human body 
without any biodegradation, the higher might be the risk of adverse effects, e.g. due to 
unintentional activation of the immune system.34  
In general, degradation products of NPs also have to be determined to be safe, otherwise these 
could lead to a non-specific immune response as well. However, by choosing starch and 
starch derivatives as material for the preparation of a DDS, this issue has already been 
considered. Maintenance of degradability should lead eventual breakdown to glucose and 
glucose units (or oligomers) with ethylendiamine side chains, which should be readily 
excreted due to low molecular weight. The latter is further reduced by using a NP system, 
consisting of both positively and negatively charged starch derivatives. To test the 
biodegradability of the starch NP system, not only by unspecific degradation mechanisms, but 
also by specific enzymatic degradation, Starch 0.25-1:1 samples were incubated in a proof of 
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concept study at 37 °C with or without α-amylase, an enzyme found in the human body (e.g. 
in the saliva, the pancreatic juice, the serum159, or the lung160). After certain time points, 
samples were taken and particle concentration was determined by nanoparticle tracking 
analysis. Compared to a control group (starch NPs stored at 37 °C without enzyme), a 
decrease in particle concentration could be observed already after 2 h incubation with α-
amylase at 37 °C (Table 4.6). Yamada et al. found that modified starch-PEI derivatives were 
still able to be degraded by α-amylase, although the degradation was slower compared to the 
degradation of unmodified starch.128 The synthesized starch derivatives in the current work 
showed a smaller change in molecular structure than the starch-PEI derivatives in comparison 
to unmodified starch. Moreover, the incubation of starch NPs with α-amylase showed that 
even after charge-mediated coacervation, the two starch derivatives were able to be degraded 
by the human enzyme α-amylase. The fluctuations in particle numbers for the control group 
can be ascribed to the analytical method. Only a limited amount of particles can be measured 
due to the high dilution necessary for this method. Thus, NTA does not allow for exact 
particle counting but rather gives an order of magnitude. The fluctuations seen within the 
control group are therefore likely the result of the intrinsic measurement error. The trend 
nevertheless is clear. 
 
Table 4.6 
Biodegradation of starch NPs by α-amylase incubated at 37 °C; analyzed as particle 
concentration after 2, 4, 6, or 8 h; determined by nanoparticle tracking analysis; (mean ± SD, 
n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Loading of starch nanoparticles 
As the starch NPs should act as DDS for the delivery of proteins, their loading capacity was 
evaluated, by loading of four different proteins. The selected proteins - vanco (Mw: 1.5 kDa, 
IEP: 7.5), insulin (Mw: 6 kDa, IEP: 5.3), RNAse A (Mw: 14 kDa, IEP: 9.6), and IgG1 (Mw: 
 Starch NPs 
[x E8 particles/mL] 
Starch NPs + α-amylase 
[x E8 particles/mL] 
before 44.3 ± 2.9 44.5 ± 0.2 
2 h 56.1 ± 8.0 2.7 ± 0.6 
4 h 46.1 ± 1.7 1.7 ± 1.1 
6 h 55.4 ± 10.4 1.7 ± 0.8 
8 h 50.5 ± 3.8 0.9 ± 0.6 
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150 kDa, IEP: 8.5) – represent a range of IEP and molecular weights. Starch NPs from 0.25 
mg/mL solutions and a molar ratio of 1:1 were chosen, showing best stability and a negatively 
surface charge of around -25 mV. Table 4.7 shows the physicochemical properties of loaded 
starch NPs as well as EE and LR, determined indirectly with the BCA assay after separating 
loaded NPs from free protein via ultracentrifugation. Here, the same procedure for validation 
was applied as for the CS NPs: the ultracentrifugation at 45 000 x g and 20 °C for 90 min 
showed no remaining NPs in the supernatant, as determined by nanoparticle tracking analysis. 
Further, tested protein solutions showed stable concentration readings before and after 
ultracentrifugation, indicating that no aggregation or sedimentation of the proteins occurred. 
The supernatant of starch NPs, similar to CS NPs, showed a low absorbance in the BCA that 
was stable and could therefore be subtracted from the calculations.  
EE and LR differed for all four proteins, and the EE was affected by the initial amount of 
protein added: the lower the protein amount, the higher the EE. However, the LR was 
enhanced by increasing the initial amount of added protein. Calvo et al. observed the same 
phenomenon for the encapsulation of BSA into CS NPs.113 A narrow PdI could be observed 
for all formulations, except for the formulation loaded with 500 µg IgG1. An increase in size, 
combined with a decrease in ζ-potential indicated that the loading with IgG1 was successful. 
It seemed that the loading could be increased from approximately 4.5% (125 µg and 250 µg 
IgG1) up to 12.0% for the 500 µg formulation. However, when taking into account the broad 
size distribution of NPs (indicated by a PdI of 0.39), such data must be interpreted cautiously. 
As the EE was obtained via indirect measurement, protein aggregation could have biased the 
results. A saturation for IgG1-loaded starch NPs could be already found for the 125 µg 
formulation, as no difference was observed between the encapsulated mass and the LR of the 
125 µg loaded NPs and the 250 µg loaded NPs. For these formulations, the encapsulated mass 
was found to be 63 and 72 µg, respectively, and the LR was determined as 4.4 and 4.9%, 
respectively. Starch NPs loaded with RNAse A showed no saturation, as the loading could be 
increased from 4.9% for the 250 µg loaded formulation up to 9.6% for the 750 µg 
formulation; however, the EE dropped from 27.9% for the 250 µg loaded NPs to 18.1% for 
the 750 µg loaded NPs. The same could be observed for insulin: an EE of 24.9% was seen 
following loading with 250 µg of insulin, a value which dropped to 15.9% following loading 
with 750 µg insulin. In contrast, an increase in LR be observed from 4.3% to 8.2% for such 
formulations. The most promising loading however was achieved for vanco, which showed a 
LR of up to 22.8% for the 750 µg loaded formulation with at the same time a high EE of 
43.5%.  
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Table 4.7 
Physicochemical properties, EE and LR of starch nanoparticles loaded with different amounts 
of IgG1, RNAse A, insulin or vancomycin. Results represent mean ± SD, n=3. 
 
 
starch 
NP 
(loaded 
with) 
mass
initial 
protein 
[µg] 
Size 
[d.nm] 
PdI ζ-potential 
[mV] 
mass
encaps 
protein 
[µg] 
EE 
[%] 
LR 
[%] 
blank - 157.7 ± 2.2 0.08 -23.7 ± 0.7 - - - 
IgG1 (Mw 150 kDa, IEP 8.5) 
 125 179.6 ± 6.1 0.10 -18.0 ± 0.2 63.2 ± 14.7 50.6 ± 11.7  4.4 ± 1.0 
 250 237.4 ± 15.6 0.17 -13.1 ± 0.3 71.9 ± 1.9 28.8 ± 0.8 4.9 ± 0.1 
 500 556.5 ± 49.5 0.39 -11.6 ± 0.9 174.3 ± 2.4 35.9 ± 0.5 12.0 ± 0.2 
RNAse A (Mw 14 kDa, IEP 9.6) 
 250 171.5 ± 0.3 0.07 -21.6 ± 0.6 72.0 ± 3.4 27.9 ± 1.3 4.9 ± 0.2 
 500 172.9 ± 1.3 0.05 -17.7 ± 2.4 103.5 ± 3.1 20.1 ± 0.6 7.1 ± 0.2 
 750 195.0 ± 31.5 0.13 -20.7 ± 0.5 139.8 ± 21 18.1 ± 2.7 9.6 ± 1.4 
insulin (Mw 6 kDa, IEP 5.3) 
 250 157.6 ± 0.7 0.09 -22.7 ± 1.2 62.4 ± 3.1 24.9 ± 1.2 4.3 ± 0.2 
 500 162.3 ± 0.4 0.06 -21.0 ± 0.3 73.9 ± 4.7 14.8 ± 0.9 5.1 ± 0.3 
 750 160.3 ± 0.9 0.07 -20.4 ± 0.5 119.2 ± 4.3 15.9 ± 0.6 8.2 ± 0.3 
vanco (Mw 1.5 kDa, IEP 7.5) 
 250 163.9 ± 0.4 0.08 -23.4 ± 0.7 205.2 ± 7.7  81.1 ± 3.0 14.2 ± 0.5 
 500 164.7 ± 0.8 0.05 -21.2 ± 0.3 258.6 ± 0.2 51.1 ± 0.1 17.8 ± 0.1 
 750 164.5 ± 0.6 0.06 -21.2 ± 0.4 330.1 ± 4.1 43.5 ± 0.5 22.8 ± 0.3 
 
The differences in EE and LR can be ascribed to the differences in IEP and molecular weight 
of the various proteins and peptides. Calvo et al., amongst others, described the phenomenon 
of particle protein loading as a function of electrostatic interactions between protein and 
polysaccharide.113 As the loading of the proteins into the starch NPs is a result of the 
electrostatic interactions between negatively charged NPs and protein, the IEP of each protein 
at the pH of the starch NP suspension (pH 7.4) has to be taken into account. Both IgG1 and 
RNAse A are positively charged at pH 7.4, whereas insulin is negatively charged and 
vancomycin is neutral. A high EE and loading for IgG1 and RNAse A would therefore be 
expected. However, IgG1 and RNAse A loaded starch NPs showed rather low LR of 4.9% 
and 9.6%, respectively. This low loading, which was slightly higher in the case of RNAse A, 
could be a result of the fact that the system loaded with IgG1 was already saturated in the case 
of the 250 µg formulation, due to steric hindrance. IgG1 is an antibody with a molecular 
weight of around 150 kDa that needs more space, when binding to the NP surface than e.g. 
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RNAse A with a molecular weight of around 14 kDa. Insulin showed a similar behavior to 
RNAse A: a loading of 8.2% could be achieved for the 750 µg formulation, although insulin 
is negatively charged at pH 7.4. Vancomycin, which is neutral at pH 7.4, showed the highest 
loading of 22.8% probably due to a combined effect of low water solubility at this pH, and the 
small molecular weight of 1.5 kDa.  
In order to evaluate protein integrity during the loading, sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) was performed. For such investigations, 
IgG1 was chosen as model protein and SDS-PAGE was run on a precast 10% polyacrylamide 
gel at 10 mA. Results can be found in Figure 4.8. It can be seen that the band of IgG1 loaded 
into starch NPs (lane 1) is at the same level as IgG1, stored at 4 °C (lane 3), indicating that no 
protein aggregation or loss of molecular weight occurred during the loading of the starch NPs 
with IgG1. The smearing in lane 1 can be ascribed to some interaction between blank starch 
NPs and the stain Coomassie Blue, as this was also visible for blank starch NPs (lane 2). 
Further studies showed, that the smearing was due to some unspecific interaction between 
PosSt and the staining.    
 
Figure 4.8: SDS-PAGE of IgG1 loaded starch NPs (lane 1), blank starch NPs (lane 2) and 
IgG1 standard (lane 3); samples were stained with Coomassie Blue.  
 
 
Aerosolization properties of starch nanoparticles 
To determine their applicability for pulmonary delivery, the aerosolization properties and 
stability of starch NPs during nebulization was studied. Physicochemical properties of the 
starch NPs were measured before and after nebulization. Further, the nebulization of labeled 
starch NPs and of starch NPs loaded with IgG1 was studied; results can be found in Table 4.8. 
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Table 4.8 
Physicochemical properties of various starch NP formulations before and after nebulization. 
 
 
Starch NPs showed similar physicochemical properties before and after nebulization, which 
was observed to run smoothly. Labeled starch NPs showed similar size and PdI values before 
and after nebulization, however, ζ-potential decreased from about -26 mV to about -15 mV. 
This could be ascribed to the hydrophobic label of the polymer, which might change the 
hydrophobicity of the NPs and thus the tightness of the surface binding of the ion layers, 
contributing to the ζ-potential. The physiochemical properties of starch NPs loaded with IgG1 
were seen to change upon nebulization, observed as an increase in size from 184 nm up to 212 
nm and an increase in PdI from 0.21 to 0.25. Although the ζ-potential did not change before 
and after nebulization, the stability of IgG1 NPs during nebulization was not deemed to be 
satisfactory, indicating a destabilization of the loaded nanoparticles during nebulization.  
For uptake studies (Chapter 6), the deposited amount of starch NPs on a Transwell® 
membrane was studied by applying different volumes of starch NP suspension with the 
Aeroneb®Lab nebulizer, followed by weighing and calculation of the amount of deposited 
starch NPs. The results can be found in Figure 4.9. It can be seen that increasing the applied 
volume resulted in an increase in the deposited mass. The volume that was chosen for uptake 
studies was 250 µL, meaning a deposited mass of starch NPs of approximately 41.1 ± 0.7 µg. 
 
Starch NPs Size 
[d.nm] 
PdI ζ-potential 
[mV] 
before 147.9 ± 2.4 0.074 -21.8 ± 1.1 
after 152.4 ± 1.6 0.058 -23.5 ± 1.3 
labeled before 145.2 ± 0.7 0.1 -26.4 ± 2.8 
labeled after 145.2 ± 2.2 0.089 -14.9 ± 6.62 
IgG1 loaded before 184.0 ± 2.9 0.21 -18.5 ± 1.3 
IgG1 loaded after 212.3 ± 1.8 0.25 -19.3 ± 2.4 
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Figure: 4.9: Deposited starch NP amount on a Transwell® membrane, after nebulization of 
different volumes of starch NP suspension with the Aeroneb®Lab nebulizer. 
 
 
4.4 COMPARISON OF CHITOSAN AND STARCH NANOPARTICLES 
Regarding the preparation process, both nanoparticle types were able to be prepared in 
aqueous medium. Compared to CS NPs, starch NPs were prepared from two polymers instead 
of a polymer interacting with a highly charged small compound. The parameters influencing 
physicochemical properties of NPs were similar for both NP types. The material concentration 
was the most important factor with respect to influence on particle size, whereas the molar 
ratio of components was important for the surface charge. Both particle types showed particle 
sizes of around 150 nm, but differed in their ζ-potential. CS NPs showed a positive surface 
charge, whereas starch NPs showed a negative surface charge. Due to the fact that the systems 
are based on electrostatic interactions, the preparation medium was, not surprisingly, found to 
influence particle properties. As the labeling of CS was not successful, labeled CS NPs could 
not be prepared. The preparation of labeled starch NPs, however, was successful, with particle 
properties being similar to the unlabeled starch NPs. 
Regarding their morphology, both particle types showed a spherical appearance with a gel-
like character. It has to be mentioned that the addition of PTA facilitated a negative staining 
of the CS NPs, whereas the starch NPs were positively stained with PTA (being taken up into 
the particles). 
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The chosen starch NP formulation (Starch 0.25-1:1) showed better storage stability, although 
CS NPs storage stability was only evaluated for a short period of time and therefore is hard to 
compare. Also, both NP types were able to be degraded by their specific enzyme.  
The loading behavior was also similar for both types of NPs. Molecules with an IEP close to 
the pH of the NP suspension showed the best LR. 
Aerosolization properties differed a lot between the two particle types. Whilst CS NPs were 
not stable during nebulization, starch NPs and also labeled starch NPs were stable during 
nebulization. Loaded starch NPs, however, showed destabilization tendencies. 
 
4.5 CONCLUSION 
CS NPs were used as a well-known and well-described model DDS to evaluate a mild 
preparation process to be further employed for the production of starch NPs, and to develop 
analytical methods suitable for characterization of the newly developed starch NPs. For the 
preparation process, key parameters were found to be the polymer concentration, influencing 
the size of the NPs, as well as molar ratio of employed components, which influence the 
surface charge of the NPs. Due to their gel-like structure, CS NPs were not stable during 
drying, which was a challenge for imaging the CS NPs. One possible solution for studying the 
morphology of CS NPs was found in TEM imaging after 1% PTA staining of the CS NPs. 
Storage stability of CS NPs in the fridge was evaluated for 6 days. Particles were stable 
during that time. The biodegradation of CS NPs with the help of an enzyme (chitosanase) was 
successfully demonstrated.  
The derivatization of potato starch into water soluble, positively (PosSt) and negatively 
charged (NegSt) starches enabled the formation of starch NPs in aqueous medium via charge-
mediated coacervation. As determined by TEM images after 1% staining with PTA, starch 
NPs showed a spherical shape. Physicochemical properties of NPs (namely size and surface 
charge) could be tuned by varying the molar ratio and concentration of the two components. 
Starch NPs were demonstrated to be biodegradable by α-amylase. Further, starch NPs were 
loaded with proteins and peptides of different net charges and molecular weights. Vanco was 
found to be the best suitable candidate, with a LR of 23% and an EE of 44%, probably 
favored by the combination of the low molecular weight and the hydrophobicity of the 
peptide at the pH of the NP suspension. It can therefore be concluded that starch NPs, 
prepared by the utilized mild and easy technique, have the potential to be further explored as 
platform for pulmonary delivery of proteins and peptides. 
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5.  AEROSOL DELIVERY OF NANOPARTICLES TO THE DEEP 
LUNG – NANOPARTICLES EMBEDDED IN MICROPARTICLES 
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5.1 INTRODUCTION 
The pulmonary application of proteins and peptides is a promising non-invasive route of 
administration. Systemic delivery via the lungs is an interesting approach as a large absorptive 
surface area, a high vascularization and a thin air-blood-barrier support the uptake of APIs 
from this site. Additionally, the avoidance of the first-pass effect, known to be present in the 
case of oral delivery, shows further advantages for pulmonary administration.89 Local delivery 
to the lungs may also present a number of benefits, and as such, COMPACT has chosen local 
lung delivery as one of their preferred routes of administration. This is of importance for 
diseases such as asthma, chronic obstructive pulmonary disease (COPD), lung cancer, cystic 
fibrosis (CF), idiopathic pulmonary fibrosis (IPF) and pulmonary infections. The direct 
application to the site of action is favored, due to reduced systemic side effects and a rapid 
onset of action. The actual target of course depends on the disease, and was chosen in the 
context of COMPACT to be the alveolar epithelium. This site is heavily affected in IPF, in 
which repeated cycles of epithelial cell injury may lead to an activation of alveolar epithelial 
cells, resulting in an abnormal wound repair with exaggerated accumulation of fibroblasts and 
extracellular matrix.161-164 A first model drug, that could actually function as API in the 
context of IPF is the intracellularly-active peptide Nrf-2.153 Achieving uptake of such a 
peptide into non-phagocytic, epithelial cells is however considerably more challenging 
compared to e.g. macrophages, which are known to engulf nearly everything (in accordance 
with their physiological function). The previously developed nanoparticle formulation 
(Chapter 4) shows a good size range suitable for the uptake into epithelial cells of the deep 
lung, which requires nanoparticle carriers below 200 nm in size.165, 166  
Amongst other factors, the deposition of particles in the lung is influenced by the physical and 
chemical properties of the particles, which can be easily addressed, by controlling the 
preparation parameters of the particles. It is known, that particle deposition occurs due to 
three major mechanisms: impaction, sedimentation and diffusion.83 Very large particles (> 8 
µm daero) deposit already in the mouth and throat. Medium sized particles (daero ~ 4 - 10 µm) 
tend to deposit in the bronchioles, whilst smaller particles (20-50 nm < daero < 2-5 µm) deposit 
in the alveolar region.101, 167-169 As can be seen, the size of developed nanoparticles (~150 nm) 
is not ideally suited for respiration170  and delivery to the deep lung.  
Thus, the previously developed formulation needs further optimization in order to allow for 
efficient deposition in the deep lung. Besides applying APIs by nebulizers, and metered dose 
inhalers (MDI), dry powder inhalers (DPI) are favored. These systems show numerous 
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advantages, being propellant-free, portable and easy to operate, and showing an improved 
stability of the formulation as a result of existence in a dry state.171-173  
Spray drying is a mild, commonly used method for preparation of dry powders.168, 174 It has 
been applied to a variety of substances, such as antibiotics,175 vaccines,176 and peptides.177 The 
Nano Spray Dryer (Büchi B-90) is furthermore a good choice, as it is known to facilitate the 
preparation of particles in a size range of a few µm, interesting for deep lung delivery. 
Different particle types can be produced by spray drying. Hollow Trojan microparticles, as 
prepared by Tsapis et al., consist of a NP layer building the microparticle.103 Various porous 
particle types were introduced by Yang et al.178 and Ungaro et al.179 Also matrix particles are 
known, where the nanoparticles are embedded in a microparticle matrix.180, 181  
An advanced carrier system was designed for deep lung deposition of nanoparticles developed 
as nano- in microparticle dry powder formulation. This system was proposed to a) escape 
macrophage clearance and b) mediate alveolar epithelial cell uptake of the NPs. Selection of 
excipients used for microparticle formation was made based on their possession of high water 
solubility. Consequently, in this chapter, the advanced carrier system for pulmonary 
application was prepared from CS and Starch NPs, spray dried with different excipients, i.e. 
lact, treha, and manni. Various characterization methods were used to assess the properties of 
the microparticles: the most important investigation being the redispersion behavior of NPs 
after disintegration of the microparticles, followed by assessment of morphology, powder 
crystallinity, and localization of NPs in the microparticles, as well as particle size, and 
aerodynamic properties.  
 
5.2 MATERIALS AND METHODS 
5.2.1 MATERIALS 
Partially hydrolyzed potato starch (Mw 1 300 000 g/mol, approx. 33% amylose content) was a 
gift from AVEBE (Netherlands). Negatively (NegSt) and positively (PosSt) charged starches 
were synthesized in house. Chitosan UP CL 113 (CS) was bought from NovaMatrix 
(Norway). Sodium tripolyphosphate (TPP) was purchased from Merck (Germany). IgG1 was 
kindly donated by Boehringer Ingelheim (Germany). Mannitol (manni), trehalose dihydrate 
(treha) and α-lactose monohydrate (lact) were bought from Sigma Aldrich (USA). G-Blocks 
(guluronic acid oligomers, consisting of more than 90% guluronic acid residues and some 
mannuronic acid residues, dp10 and d22) were a kind gift from the Department of 
Biotechnology, Norwegian University of Science and Technology (NTNU). Alexa Fluor 647 
carboxylic acid (succinimidyl ester) and Bodipy FL-C5 NHS Ester (succinimidyl ester) were 
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obtained from Life Technologies (USA). Purified water was produced by a milliQ water 
purification system (Merck Millipore, USA). All other reagents were of analytical grade.  
 
5.2.2 PREPARATION OF MICROPARTICLES 
Scale-up of nanoparticle preparation 
For upscaling of CS NPs, the preparation was performed as described earlier (Chapter 4), but 
with an increased volume: NP formation therefore occurred spontaneously after adding 10 mL 
of TPP solution to 50 mL of CS solution under stirring at 300 rpm (molar ratio 10:1, 
CS:TPP). The final pH value was 5.5.  
Upscaling of starch NPs was also facilitated by an increase of volume: 20 mL of NegSt were 
added to 20 mL of PosSt under stirring at 700 rpm (molar ratio 1:1). The final pH value was 
7.4. For loaded starch NP samples, 150 µL of IgG1 solution (5 mg/mL) was added to 40 mL 
of starch NP suspension. Stirring speed and injection rate were adjusted for both CS and 
starch NP formulations to obtain NPs of similar physicochemical properties compared to NP 
prepared in Chapter 4. 
 
Microparticle preparation  
Either blank NP suspension or NP suspension with excipient was spray dried with a nano 
spray dryer (Büchi B-90, Büchi, Switzerland). Lact, treha or manni was added to the NP 
suspension prior to spray drying, in mass ratios of NP:excipient 1:5, 1:10 and 1:20. 
Additionally, the influence of microparticle matrix forming G-Blocks (dp10, dp22) on the 
physicochemical properties of NP suspensions was tested. Different spray caps (4 µm, 5.5 µm 
and 7 µm) and inlet temperatures (90 °C, 70 °C, and 50 °C) were investigated for spray 
drying. The spray dryer was equilibrated with water prior to every spray drying run. The spray 
drying process for further particle analysis was performed at 70 °C inlet temperature, an outlet 
temperature of maximum 40 °C and a gas flow of 130 L/min, using the 5.5 µm spray cap. The 
spray rate was always 100% and samples - typical batch size was 40 or 50 mL feed volume - 
were kept on ice during the spray drying process. For NGI experiments, 10 µL sodium 
fluorescein solution (FluNa, 5 mg/mL) was added to each sample and spray drying was 
performed under light protection. Samples were stored in a desiccator until usage.  
 
5.2.3 NANOPARTICLE RELEASE FROM MICROPARTICLES 
Release of NPs from the microparticle matrix was tested in a proof of concept study by 
dissolving approximately 1 mg of microparticles in 1 mL of purified water. After 10 s 
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vortexing, the particle size and PdI of released NPs was determined by DLS using the 
Zetasizer Nano ZSP (Malvern Instruments, UK) with a scattering angle of 173 °. 
 
5.2.4 MORPHOLOGY  
Morphology of microparticles was examined by SEM (JSM 7001F Field Emission SEM 
(Jeol, Japan)). Samples were immobilized on a carbon disc and sputtered with gold (layer 
thickness approx. 10 nm) prior to scanning. The accelerating voltage was 5 kV. In case of the 
Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) deposition study, 
samples were directly deposited on SEM carbon discs and analyzed as mentioned above. 
 
5.2.5 PARTICLE SIZE DISTRIBUTION  
Particle size distribution was determined by image analysis of SEM images, using the Fiji 
Software (Fiji is a distribution of ImageJ available at http://fiji.sc). Particle sizes were 
measured, grouped into different intervals and plotted as number of particles [%]. More than 
100 particles were analyzed per image. Additionally, particle size distribution was analyzed 
by static laser light diffraction using the HORIBA LA-950 (HORIBA, Japan) powder feeder 
attachment. Vibration and air suction allowed the powder to pass through a laser light beam 
and to be analyzed directly as dry powder without the need of applying a non-solvent.  
 
5.2.6 POWDER CRYSTALLINITY 
For X-ray powder diffraction (XRPD) experiments, samples were analyzed by a 
diffractometer of the type Bruker D8 Advance, equipped with an 1D-detector 'Lynxeye' using 
variable divergence slit and Cu-Kα radiation. X-ray diffraction is based on radiation scattering 
and interference. Diffraction occurs when light is scattered by a periodic array with long-
range order, producing constructive interference at specific angles. The scattering of X-rays 
from atoms produces a diffraction pattern, which contains information about the atomic 
arrangement within the crystal. The conditions for constructive interference are described by 
Braggs Law, where n is the order of the diffracted beam, λ is the wavelength of the x-ray 
radiation, d is the distance between the parallel lattice planes from which the waves are 
scattered and θ is the angle between the x-rays and the lattice plane:182 
 
𝑛 ∗ 𝜆 = 2 ∗ 𝑑 ∗ 𝑠𝑖𝑛𝜃 
According to Bragg’s law, constructive interference for a set of atomic planes with d-spacing 
only occurs when the incident angle is θ. When the scattered waves interfere constructively, 
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they remain in phase, as the path length of each wave is equal to an integer multiple of the 
wavelength. Such an occurrence yields a peak in the diffractogram.  
The position and intensity of peaks in a diffraction pattern are determined by the crystal 
structure. The absence of peaks in the diffractogram or the presence of so-called halos 
indicates a completely amorphous material, which does not have a periodic array with long-
range order, and so does not produce a diffraction pattern.182 
 
5.2.7 LOCALIZATION OF NANOPARTICLES IN MICROPARTICLES 
The internal composition of the carrier system was observed by a confocal laser scanning 
microscope (Zeiss LSM710, Zeiss, Germany). Lasers at 405 nm (4′,6-Diamidino-2-
phenylindole, DAPI), 488 nm (starch NPs) and 633 nm (IgG1) were used for detection. 
Labeled starch NPs were spray dried with treha (mass ratio 1:20) and DAPI (12.5 ng/mL). For 
loaded particles, 150 µL labeled IgG1 (5 mg/mL) was added to the labeled starch NP 
suspension beforehand. Aliquots of the spray dried powders were fixed on a glass slide. 
Confocal images were analyzed using the Zen 2012 software (Carl Zeiss Microscopy GmbH).  
IgG1 was labeled with Alexa Fluor 647 carboxylic acid (succinimidyl ester) according to the 
manufacturers’ protocol (life technologies, USA). Purification was performed with PD-10 
Desalting Columns (GE Healthcare, UK). 
 
5.2.8 AERODYNAMIC PROPERTIES 
The mass median aerodynamic diameter (MMAD), the geometric standard deviation (GSD), 
and the fine particle fraction (FPF) of microparticles prepared by spray drying of NPs with 
excipient in a mass ratio 1:20 and 10 µL FluNa (5 mg/mL) for analysis were determined with 
the Next Generation Impactor (NGI). For NGI experiments, the flow rate was adjusted to 60 
L/min and the time of aspiration was set to 4 s. The powder inhaler (Handihaler®, Boehringer 
Ingelheim, Germany) was loaded with a hard gelatin no.3 capsule, filled with 10 mg of 
powder (n = 3). After inhaler actuation, particle deposition on the NGI was determined by 
correlating fluorescence intensity to deposited mass. Therefore, a standard curve was prepared 
from each sample and fluorescence intensity was measured at λex= 485 nm and λem = 530 nm. 
The fluorescent dye FluNa was equally distributed throughout the formulation. FPF is defined 
as the part of the inhaled dose with an aerodynamic diameter < 5 µm in %. Further important 
parameters are the MMAD and the GSD. The MMAD is correlated to the detected mass 
within the NGI and is the mass median aerodynamic diameter, meaning that 50% of the 
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particles are smaller than this value and 50% are larger. The GSD gives an idea of the particle 
distribution. 
 
5.2.9 PADDOCC DEPOSITION 
The deposition of microparticles was studied with the help of the PADDOCC (Pharmaceutical 
Aerosol Deposition Device on Cell Cultures), which is a deposition device for dry powder, 
developed in-house.183, 184 Particles were analyzed qualitatively and quantitatively for 
following cell interaction studies (Chapter 6). Deposition behavior and morphology was 
analyzed after direct deposition on carbon disc wafers, by SEM. Particle deposition was 
determined quantitatively by correlating fluorescence intensity to deposited mass. For 
quantification, microparticles, co-spray dried with FluNa were used; a standard curve was 
prepared from each sample and fluorescence intensity was measured at λex= 485 nm and λem = 
530 nm. 
 
5.3 RESULTS AND DISCUSSION 
5.3.1 PREPARATION OF MICROPARTICLES 
Scale-up of nanoparticle preparation  
For preparing the microparticles from the NP suspension via spray drying, the preparation 
method of NPs was up-scaled. As an increase in concentration of the solutions led to an 
increased size of the NPs (Chapter 4), the process was up-scaled by increasing the volume but 
keeping the concentration constant at 0.25 mg/mL. Different beaker types and injection rates 
were tested and the impact on physicochemical properties of NPs is shown in Table 5.1.   
Both NP types showed a size around 150 nm, with a narrow particle size distribution. They 
differed, however, in their ζ-potential, with CS NPs showing a positive ζ-potential of 
approximately +35 mV and starch NPs showing a negative ζ-potential of approximately -20 
mV. 
It could be concluded that the NP preparation process was suitable for up-scaling by 
increasing the volume. However, a good solvent mixture has to be assured, by selection of a 
suitable beaker type, magnetic stirrer and injection rate, depending on the kind of syringe to 
be employed in the preparation process. Following investigation and control of these process 
parameters, the physicochemical properties of NPs stayed constant as compared to the 
original preparation process. 
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Table 5.1  
Characteristics of NPs in process upscaling studies prepared from 0.25 mg/mL solutions and a 
molar ratio of 1:1 (PosSt:NegSt) and 10:1 (CS:TPP) with varying process parameters; bold: 
formulations used for microparticle preparation. Beaker type 1123: 150 mL; beaker type 
1122: 100 mL; beaker type 1169: 50 mL; all from VWR, USA). 
 
Beaker type Syringe volume 
[mL] 
Injection rate 
[mL/min] 
Size 
[d.nm] 
PdI ζ-potential 
[mV] 
CS NPs      
1122 10 30 175.9 ± 1.5 0.159 +35.1 ± 0.9 
1122 20 60 199.0 ± 1.5 0.163 +35.2 ± 0.5 
1123 10 20 136.1 ± 0.4 0.151 +35.5 ± 2.8 
Starch NPs      
1169 20 20 180.8 ± 1.5 0.055 -19.5 ± 1.3 
1169 20 40 157.9 ± 1.6 0.071 -17.9 ± 2.3 
1169 20 60 145.1 ± 0.7 0.066 -18.1 ± 3.5 
 
Microparticle preparation 
Microparticles were prepared from aqueous CS NP or starch NP suspensions (Table 5.1, 
bold) spray dried with a nano spray dryer with or without different excipients. An influence 
of the spray cap on the size of microparticles was disproved and the 5.5 µm spray cap was 
chosen for all following experiments. To ensure a dry product while at the same time ensuring 
mild preparation conditions feasible for protein encapsulation, an inlet temperature of 70 °C 
was selected. Although this temperature seems to be quite high, the most important 
temperature influencing product stability is in fact the outlet temperature, which was always 
below 40 °C in this case. To further ensure a mild preparation process, samples were kept on 
ice during spray drying. To determine NP stability during the pumping process, 
physicochemical properties of NPs were determined before spray drying and almost at the end 
of the spray drying process by taking samples from the remaining NP suspension. Size and ζ-
potential of NPs remained the same prior to and at the end of spray drying, meaning that the 
pumping process as well as temperature differences did not influence particle properties over 
the duration of the spray drying process, which usually took approximately 2 – 2.5 h for the 
applied volumes.  
NP suspensions were spray dried with excipient; therefore, the influence of the excipient on 
physicochemical properties of NPs was investigated. Here, a focus was placed on excipients 
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that were highly water soluble, in order to easily release the NPs after deposition in the deep 
lung. Further, excipients with GRAS status were favored, resulting in a choice of excipients 
being lact, treha, and manni. Solid excipient was either added after NP preparation and stirred 
for 10 min for equilibration, or NPs were directly prepared in excipient solution. For the 
latter, each material for NP preparation (i.e. CS, TPP, NegSt, PosSt) was dissolved in an 
excipient solution instead of purified water. As no differences between the two preparation 
methods was observed, it was decided to add the solid excipient after NP preparation. The 
influence of excipients on physicochemical properties of NPs can be found in Table 5.2. As 
can be seen, the addition of excipients, i.e. manni, lact, and treha did not change the 
physicochemical properties of NPs. Particles were in general around 150 nm with a PdI of 
around 0.16 for CS NPs and 0.07 for starch NPs. The ζ-potential was approximately +35 mV 
and -25 mV for CS NPs and starch NPs, respectively. 
 
Table 5.2 
Influence of excipient on physicochemical properties of NPs, after applying to the NP 
suspension as dry powder; measured after stirring for 10 min for equilibration. Dp10 and dp22 
are G-Blocks, with the number indicating their oligomer length. Manni: mannitol, lact: 
lactose, treha: trehalose. 
 
 Size  
[d.nm] 
PdI ζ-potential  
[mV] 
CS NPs + manni 1:20 149.4 ± 1.9 0.171 +37.1 ± 1.4 
CS NPs + lact 1:20 150.3 ± 1.5 0.175 +36.6 ± 0.9 
CS NPs + treha 1:20 135.9 ± 1.5 0.152 +36.4 ± 1.2 
Starch + manni 1:20 153.3 ± 0.4 0.085 -23.0 ± 0.2 
Starch + lact 1:20 152.7 ± 1.9 0.065 -23.4 ± 0.3 
Starch + treha 1:20 154.1 ± 1.5 0.083 -23.6 ± 0.8 
CS + dp22 1:0.4 588.5  ± 120.7 0.733 +11.0 ± 0.2 
CS + dp10 1:0.4 6471 ± 545 0.630 +1.7 ± 0.1 
CS + dp10 1:1 2710 ± 1224 0.897 -14.6 ± 0.2 
CS + dp10 1:1.8 337.6 ± 3.5 0.369 -21.6 ± 0.3 
CS + dp10 1:3.6 6584 ± 2282 0.675 +0.5 ± 0.1 
Starch + dp10 1:0.4 150.0 ± 1.4 0.077 -32.2 ± 1.7 
Starch + dp10 1:3.6 128.9 ± 0.7 0.097 -34.7 ± 2.2 
Starch + dp22 1:3.6 127.7 ± 0.4 0.106 -36.4 ± 2.4 
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Additionally, the approach of using smart excipients was followed by testing G-Blocks 
(guluronic acid oligomers, dp10 and dp22) for building the microparticle matrix. This 
material was evaluated for mucosal delivery of NPs and it could be shown that applying the 
G-Blocks together with NPs improved particle mobility in mucus due to a reduced mucus 
barrier function.97, 185 The idea of additionally selecting G-Blocks as part of the microparticle 
preparation was that this could potentially improve bronchiolar uptake of particles that impact 
in the upper lung, where mucus is present as a non-cellular barrier. CS NPs showed signs of 
aggregating upon G-Block addition, with large particles between a few hundred nanometers 
up to the µm range being formed. From the ζ-potential values, which are often around 0±10 
mV, it can be concluded that (partial) charge neutralization let to aggregation of the particles. 
An interaction between the positively charged surface of CS NPs and the negatively charged 
G-Blocks acids can be assumed. In contrast, starch NPs with added G-Blocks showed 
particles around or smaller than 150 nm with a PdI below 0.1 and a ζ-potential around -35 
mV. Here, the NP suspension was not negatively influenced by aggregation, probably due to 
the fact, that both starch NPs and G-Blocks acids were negatively charged. Nevertheless, 
there was an influence of G-Blocks, as can be seen by the increase in ζ-potential magnitude 
from approximately -25 to -35 mV, indicating that G-Blocks might have been associated with 
the particle surface. As a conclusion, non-charged excipients for spray drying were favored, 
as they did not influence physicochemical properties of NPs.  
A first result regarding powder properties after spray drying was powder flowability, which 
differed for the various formulations. Although manni samples were more difficult to collect 
from the collecting electrode of the spray dryer, the powder flow appeared to be more regular 
compared to lact or treha samples – in these cases material was easy to remove from the 
electrode, however particles showed signs of aggregation during the collection process. Here, 
adhesion interaction between the particles was more pronounced than for manni samples. This 
is in accordance with literature data, in which manni has been reported to show good powder 
flowability.186 
 
5.3.2 RELEASE OF NANOPARTICLES FROM MICROPARTICLES 
The successful release of NPs from the microparticle matrix was one of the main 
requirements for the formulation. In vivo, this is an important point to be addressed, so it was 
the first parameter to be explored. The uptake of particles into cells is amongst other factors 
size dependent. For example, Desai et al. have shown that the uptake of NPs into Caco-2 cells 
is significantly greater compared to their microparticle counterparts.141, 187 In general, it is 
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known that NPs in a size range between 100 - 200 nm are taken up by cells via endocytosis. 
Thus, NPs released from the microparticle matrix should have a size around or below 200 nm, 
and a narrow size distribution. 
In a proof of concept study, approximately 1 mg each of the microparticle formulations was 
dissolved in 1 mL aqueous solution and vortexed for 10 s (to speed up the dissolution 
process). Released NPs were measured for their size and size distribution. Results for 
different formulations can be found in Figure 5.1, where CS NP formulations are shown in 
(A) and starch NP formulations are shown in (B). It could be seen that blank NPs, spray dried 
without excipient, were not able to be redispersed. This was the case for CS NPs, which 
showed aggregates in the µm size range and a PdI close to 1. Compared to that, starch NPs 
showed an improved behavior, nevertheless, the size distribution was not satisfactory. During 
the drying process, the gel-like NPs probably came into contact with each other, forming 
larger particles.  
 
 
Figure 5.1: Dissolution behavior of microparticles, and comparison of physicochemical 
properties of NPs before spray drying and after being released from the microparticles. (A) 
CS NPs spray dried with different amounts of excipient. (B) Starch NPs spray dried with 
different amounts of excipient. 
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Adding different excipients in a mass ratio 1:5 (NP:excipient) could not improve the 
redispersion behavior of both NP types. However, a mass ratio of 1:20 led to a good 
redispersion of NPs with physicochemical properties being similar to the NP suspension 
before spray drying. The excipient served as drying protectant, probably due to steric 
hindrance, so that the NPs were not able to merge into larger particles. One exception is 
manni, which could still not improve the dissolution behavior of CS NPs in a mass ratio of 
1:20. Loaded starch NPs with 150 µL IgG1 solution (5 mg/mL) also showed a good 
redispersion when spray dried with treha in a mass ratio NP:excipient of 1:20. The size of 
these loaded NPs after redispersion was 243.0 ± 9.2 nm with a PdI of 0.2.  
As a result, a mass ratio of 1:20 NP:excipient was chosen for further experiments. The 
material of choice was determined to be manni or treha, showing good protection of the NP 
suspension during spray drying. 
 
5.3.3 MORPHOLOGY  
The morphology of all spray dried samples was examined using SEM. Representative images 
of spray dried NPs without excipient and with excipient in a mass ratio of 1:20 (NP: 
excipient) are shown in Figure 5.2. It could be seen that both types of NPs, when spray dried 
without excipient, were very small and had an undefined shape. In contrast, NPs spray dried 
with excipient were larger and of defined shape. Depending on the kind of NP, the 
morphology differed: microparticles prepared from CS NPs spray dried with different 
excipients had a spherical and smooth surface, whereas starch NPs spray dried with excipient 
additionally had wrinkled shapes.  
Iskandar et al. have shown that morphology of spray dried particles depends on parameters 
such as droplet size of the material to be spray dried, viscosity of the droplet, size of the sol in 
the droplet, drying temperature, gas flow rate and addition of surfactant. From a theoretical 
perspective they concluded that the structural stability of the droplet and the hydrodynamic 
effects during the drying process might play important roles in controlling the morphology of 
the resulting particles.188 As spray drying parameters, such as droplet size (determined by the 
spray cap), gas flow rate and drying temperature was kept constant, the differences in 
morphology are likely chiefly influenced by formulation parameters in this case. 
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Figure 5.2: SEM images of spray dried NPs without (A) or with 1:20 excipient: manni (B) 
lact (C) treha (D); column on the left: CS NPs (1); column on the right: starch NPs (2); scale 
bar: 1 µm. 
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Spray drying of blank NPs led to a collapse of the droplet during the drying process, resulting 
in particles of undefined shape. Adding an excipient, however, increased the mass fraction in 
the droplet, stabilizing the droplet due to its internal stiffness, meaning that prepared particles 
showed a more defined shape and were almost spherical. A review from Vehring presented a 
classification based on dimensionless numbers (e.g. Peclet number) that can be used to 
estimate how excipient properties in combination with process parameters influence the 
morphology of engineered particles.189 The differences in shape of microparticles have to do 
with the NP type, as process parameters and excipients were kept constant. It could be 
assumed that starch NPs have a different Peclet number compared to CS NPs, resulting in a 
different diffusion behavior in the droplet, leading to a different particle shape.  
 
5.3.4 PARTICLE SIZE AND PARTICLE SIZE DISTRIBUTION 
Particle sizes were measured with the Fiji Software, grouped into different intervals and 
plotted as number of particles [%] (Figure 5.3). More than 100 particles were analyzed per 
image. Therefore, images were divided into sections and only particles completely visible 
were chosen for measurement. It can be seen that CS NPs, spray dried without excipient are 
mostly in the nanometer size range (87%), and mostly around 400 – 800 nm, with 13% of 
particles being between 1-2 µm. This is in accordance with the redispersion behavior 
observed after spray drying: during the drying process, the gel-like NPs come into contact 
with each other, forming larger particles. This differed for the starch NPs. Here, only 59% of 
NPs were found to be below 1 µm, 33% were between 1-2 µm in size, and 8% were between 
2-4 µm. As the redispersion of starch NPs spray dried without excipient was easier to achieve 
than the CS NPs, it could be assumed that the starch NPs do not show this gel-like character 
to such an extent as the CS NPs do.  
For the samples spray dried with excipient, this looked different. The particle fraction below 1 
µm was decreased, whereas the fractions of a few µm in size increased. Adding more mass 
for the spray drying process with at the same time a constant volume, led to increased particle 
size and improved the redispersion behavior. It could be assumed that the excipient is building 
a matrix into which the NPs are embedded.   
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Figure 5.3: Particle size distribution of optimized microparticles spray dried with various 
excipients, compared to NPs, spray dried without excipient. 
 
Additionally, particle size was measured with the HORIBA LA-950 using static laser light 
diffraction and the dry powder feeder apparatus. As can be seen in Figure 5.4 (A), the sample 
is applied as dry powder and dispersed either via pressurized air or sucked up via low 
pressure. With the help of a laser light beam, particle size is determined while the powder is in 
the air stream passing the measurement window. Applying pressurized air is a rather harsh 
and fast method, and as such a certain amount of sample mass is necessary to be able to detect 
particles in the air stream. Using low pressure instead is a mild method, where particles are 
passing through the measurement window with less speed, thus less amount of sample is 
needed. However, the ability to de-agglomerate particles is less effective in this case. 
The dry feeder apparatus is a useful tool to analyze the particle size of a powder, as there is no 
need to apply a non-solvent, which could influence the physicochemical properties of the 
microparticles. In general, a mass of a few grams is needed to give a good signal when the 
sample is dispersed via pressurized air. The yield of the spray drying process, however, was 
usually between 150 - 200 mg. Deciding for a manual measurement and applying a low 
pressure instead of pressurized air made possible a detection of the particles within the air 
stream. Nevertheless, the mild dispersion method was not able to de-agglomerate particles of 
all samples, as can be seen in Figure 5.4 (B), where the cumulative volume of particles [%] is 
shown. The two manni formulations showed a good particle size distribution between 2 and 
10 µm, with the CS NPs spray dried with manni 1:20 being slightly smaller than the starch 
NPs spray dried with manni 1:20. The other formulations showed large aggregates up to the 
mm size range. This behavior is in accordance with the differences in powder flowability 
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observed during sample collection after the spray drying process. As known from the SEM 
images, particle size was below 10 µm, indicating that the mild low pressure during 
measurement was not able to de-agglomerate the particles. This further approved manni as 
excipient, showing good powder flowability. 
 
Figure 5.4: Particle size distribution of microparticles (mass ratio 1:20), determined with the 
HORIBA LA-950. 
 
 
5.3.5 POWDER CRYSTALLINITY 
To fully characterize a powder formulation, its solid state form should be analyzed. This was 
done by XRPD. Microparticles were prepared in a mass ratio 1:20 (NP:excipient) and results 
can be found in Figure 5.5. For lact and treha samples, there was only a halo visible, 
indicating that the samples were amorphous. Manni samples instead showed distinct patterns, 
typical for crystalline material, and indicating the existence of long-range molecular order. 
Analyzing the spectrum resulted in approximately 17% α-form, 25% β-form, and 59% δ-form 
for Starch_manni and 13% α-form, 84% β-form, and 3% δ-form for CS_manni. Bulk material 
of manni before spray drying showed 100% β-form. Hulse et al. found structural variations of 
spray dried manni depending on the supplier. There were basically two different polymorphic 
forms, being either α-form or β-form or a mixture of both.190 Comparing the samples of 
CS_manni and Starch_manni showed that the NP type had an effect on the recrystallization 
behavior of manni. In Starch_manni, the original β-form transformed mainly into the δ-form 
and also into the α-form, although to a lower extent, so that only 25% of the β-form was left. 
In CS_manni, the β-form was better preserved, so that only a low amount transferred into the 
α-form and even less into the δ-form. As Hulse et al. did not find the δ-form, this polymorph 
could be a result of the included NPs, which is also underlined by the different amount of δ-
form being present for the two different formulations. A similar influencing effect was seen 
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by Hulse et al., who co-spray dried proteins (trypsin and lysozyme) with manni and analyzed 
the influence of protein on manni polymorphism.191   
 
Figure 5.5: XRPD diffractograms of microparticles. 
 
5.3.6 LOCALIZATION OF NANOPARTICLES IN MICROPARTICLES 
From SEM images, it was not possible to visualize the localization of NPs within the 
microparticles. Confocal microscopy however is able to distinguish between different 
fluorescent labels, each representing an independent structure. Therefore, labeled starch NPs 
were spray dried as usual after adding treha (mass ratio 1:20, NP:excipient) and the 
fluorescent dye DAPI (12.5 ng/mL). Particles were analyzed by confocal microscopy, with 
Figure 5.6 representing a cross-section of microparticle. It can be seen that the NPs are 
distributed throughout the whole microparticle, rather than building a ring at the surface. 
Sham et al.180 obtained similar results for dry powder comprised of polycyanoacrylate NPs 
and lact. In this study, NPs were also embedded in a microparticle matrix, however, the NPs 
appeared in clusters, rather than being distributed equally throughout the microparticle. 
Another study into embedding NPs in microspheres was performed by Grenha et al. They 
showed that CS NPs were equally distributed throughout the whole microparticle matrix. 
However, they have seen that manni also completely coated the microparticle, giving a wall-
like structure.181    
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Figure 5.6: Confocal images of labeled starch NPs (green), co-spray dried with treha (mass 
ratio 1:20) and DAPI (blue). (A) DAPI, representing the microparticle matrix, (B) Bodipy 
(green label), representing the NPs; (C) fluorescence overlay; (D) additional overlay with 
light microscopic image; scale bar: 2 µm. 
 
Furthermore, the composition of starch NPs loaded with 150 µL labeled IgG1 and spray dried 
with treha and DAPI was investigated (cross-section shown in Figure 5.7). IgG1 was labeled 
for such investigations with Alexa Fluor 647 carboxylic acid (succinimidyl ester) according to 
the manufacturer’s protocol. From the confocal images it could be concluded, that also here, 
the loaded starch NPs are distributed throughout the microparticle. In addition, the 
visualization of several microparticles provides proof of a rather equal distribution of NPs 
throughout the sample.  
 
Figure 5.7: Fluorescence images of labeled starch NPs, loaded with labeled IgG1 and co-
spray dried with treha (mass ratio 1:20) and DAPI. (A) DAPI, representing the microparticle; 
(B) Bodipy, representing the nanoparticles; (C) Alexa Fluor 647, representing IgG1; (AB) 
overlay of (A) and (B); (BC) overlay of (B) and (C); (ABC) overlay of (A), (B) and (C); scale 
bar: 10 µm. 
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5.3.7 AERODYNAMIC PROPERTIES 
The aerodynamic properties of a formulation intended for pulmonary application are essential 
to both characterize and optimize, as a high deposition in the deep lung depends on the 
physical and chemical properties of the particles amongst other factors (e.g. breathing of the 
patient, lung physiology). Parameters to be determined are the MMAD, the GSD and the FPF. 
The FPF, being defined as the part of the inhaled dose being < 5 µm in aerodynamic diameter, 
gives an indication of the amount of the applied dose reaching the deep lung. The MMAD 
indicates the median aerodynamic diameter within the measured particle population and is 
correlated to the detected mass within the NGI. Additionally, the GSD gives an idea of 
particle distribution and homogeneity of the sample. 
In general, when speaking about the size of particles, it is the geometric diameter that is being 
referred to. However, the inhalation process is characterized by the flight behavior of a 
particle, which depends not only on its size, but also on its density (and shape). Therefore, the 
aerodynamic diameter was introduced as a more meaningful measure. Assuming an 
appropriate MMAD between 1-5 µm, a high deposition in the deep lung is expected.192, 193  
Aerodynamic properties of different formulations can be found in Table 5.3.  
 
Table 5.3 
Mass Median Aerodynamic Diameter (MMAD), Geometric Standard Deviation (GSD), and 
Fine Particle Fraction (FPF) of  microparticles prepared by spray drying of NPs with excipient 
in a mass ratio 1:20. Parameters were determined with the Next Generation Impactor (NGI); 
for analysis, sodium fluorescein (FluNa) was added before the spray drying process; (mean ± 
SD, n = 3). 
 
 MMAD [µm] GSD [µm] FPF [%] 
CS_manni 3.8 ± 0.3 3.2 ± 0.1 52.5 ± 7.9 
CS_lact 4.0 ± 0.5 1.8 ± 0.6 27.4 ± 7.0 
CS_treha 3.4 ± 0.6 2.6 ± 0.3 42.7 ± 5.4 
Starch_ manni 2.1 ± 0.3 4.9 ± 0.5 41.3 ± 2.9 
Starch_ lact 2.5 ± 0.3 4.2 ± 0.4 36.7 ± 3.9 
Starch_ treha 2.1 ± 0.2 7.0 ± 0.5 40.5 ± 3.5 
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Formulations based on CS NPs showed an MMAD around 3.5 µm with a narrow GSD. In 
comparison, the starch NP formulations were smaller, with an MMAD around 2 µm. 
Nevertheless, the GSD was higher compared to the CS NP formulations. This is in accordance 
with the SEM images, showing a broader size distribution for the starch NP formulations than 
the CS NP formulations. The FPF was dependent on the excipient used for microparticle 
preparation. Here, manni samples showed the best results with around 40% FPF for 
Starch_manni and around 50% for CS_manni. These findings are in agreement with those 
reported in literature, where an FPF between 5 and 50% is common, varying as a result of the 
type of carrier194, 195 and drug morphology196 rather than as a function of the utilized 
inhalation device.197 
 
5.3.8 PADDOCC DEPOSITION 
Qualitative and quantitative deposition of microparticles was studied with the PADDOCC 
(Photo 5.1), which is a set-up, consisting of (A) an air-flow control unit (Akita®, Activaero, 
Germany), (B) an aerosolization unit (fitting a HandiHaler®, Boehringer Ingelheim, 
Germany), and (C) a custom-made sedimentation chamber, holding three Snapwell® inserts 
containing monolayers of pulmonary epithelial cells.183, 184 The device should mimic the 
process of aerosol drug delivery by sedimentation as a deposition mechanism, and should 
allow for evaluating the interaction of a specific formulation with the pulmonary epithelial 
cells. 
 
Photo 5.1: Setup of the PADDOCC. (A) Air-flow control unit; (B) aerosolization unit; (C) 
sedimentation chamber, holding three Snapwell® inserts. The latter two components are 
placed in a heating chamber, for performance of the cell experiments at 37 °C.  
 
Before studying the interaction of the microparticle formulations with the pulmonary 
epithelia, the deposition of the formulations with the PADDOCC onto SEM wafers, in the 
absence of a cell monolayer, was examined qualitatively and quantitatively. More than 90% 
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of the total formulation mass was released from the capsule for all experiments. In a first step 
the deposition was analyzed qualitatively: Figure 5.8 shows SEM images of deposited 
microparticle formulations.  
 
Figure 5.8: SEM images of microparticles, deposited with the PADDOCC onto SEM wafers. 
CS NPs spray dried with excipient: (A) manni; (B) lact; (C) treha. Starch NPs spray dried 
with excipient: (D) manni; (E) lact; (F) treha. All samples were spray dried in a mass ratio 
1:20 (NP:excipient); scale bar: 10 µm. 
 
It could be seen that only small particles were deposited and that, although some 
agglomeration occurred, particles were spread over the entire surface of the SEM wafers. It 
seemed that a greater degree of deposition occurred on the case of the sample starch_manni 
(D), compared to other formulations. This was in accordance with the particle size 
measurements and the powder flowability observations made during formulation collection 
from the spray dryer.  
In a second step, the quantitative deposition of the formulations was studied; results can be 
found in Figure 5.9.  
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Figure 5.9: Quantitative deposition of microparticles prepared by spray drying of NPs with 
excipient in a mass ratio 1:20. For analysis, FluNa was added before the spray drying process. 
Deposited mass is calculated per Transwell® area (1.12 cm2). A mass of 10 mg of particles per 
capsule was used for deposition studies.  
 
Two trends could be observed from these experiments: the deposited mass depended on the 
excipient, with manni showing the highest deposited mass and treha showing the lowest 
deposited mass. Further, the NP type was of importance, as formulations consisting of starch 
NPs showed a higher deposition than formulations of CS NPs. These results are underlined by 
the qualitative analysis, shown by the SEM images. Comparison of these results to those 
obtained for particle size measurements with the dry feeder apparatus of the HORIBA LA-
950 is further possible. With respect to size measurements facilitated by the dry feeder 
apparatus, lact and treha aggregates were not able to be redispersed within the air stream for 
measurement purposes. This observation can be correlated to the findings of the PADDOCC 
experiments, where lact- and treha-containing particles probably impacted as larger 
aggregates in the PADDOCC device, mimicking the in vivo aerosol deposition situation, 
before reaching the Snapwell® region. Manni samples, however, showed good dispersion 
behavior within the air stream and reached the Snapwell® region in high doses. Starch_manni 
showed better deposition behavior than CS_manni. As mentioned before, the different 
formulations showed different flow properties as well as different cohesive natures, probably 
leading to the different deposition. In summary, manni showed potential as an excipient for 
bringing high particle amounts to the deep lung, which is in accordance with literature,195 
whereas spry dried particles resulting in amorphous lact and treha, showed poor dispersibility 
leading to low predicted particle deposition in the alveolar region.  
 
 
86 
 
5.4 CONCLUSION 
The successful spray drying process was mainly influenced by the working of the spray cap, 
together with the piezo driven mesh used for droplet formation. A dysfunction of the spray 
cap resulted in a poor yield or bad product quality. An inlet temperature of 70 °C ensured a 
dry product and resulted in an outlet temperature below 40 °C indicating a low thermal 
burden for the encapsulated protein. Adding different non-charged excipients (manni, lact,  
and treha) did not change the physicochemical properties of the NP suspension. Also so-
called smart excipients, i.e. G-Blocks, were tested. However, these molecules are negatively 
charged; as such they were seen to be appropriate as excipients for starch NPs, but showed 
aggregation after addition to CS NP suspensions. It can therefore be concluded that non-
charged excipients are favored for the microparticle preparation. 
Spray drying the NP suspension without excipient resulted in particles with an indistinct 
shape. Adding an excipient led to particles distinctly spherical in shape, with specific 
morphology depending mostly on the NP composition - spray dried CS samples with different 
excipients showed rather smooth and round surfaces, while spray dried starch samples with 
different excipients showed rather wrinkled shapes. NPs spray dried without excipient were 
not able to be redispersed. Depending on the amount of excipient, NPs were able to be 
redispersed in aqueous solution (mass ratio 1:20, NP:excipient).  
The particle size distribution clearly depended on the specific excipient employed. Samples 
spray dried with manni showed the narrowest particle size distribution, whereas samples spray 
dried with lact or treha showed a broad size distribution.  
Also crystallinity of the samples depended on the kind of excipient used. Manni samples 
showed a crystalline appearance after spray drying, whereas lact and treha samples were 
completely amorphous.  
The internal structure of the microparticles was evaluated by confocal fluorescence 
microscopy, using the formulation of Starch_treha (loaded with IgG1) as model formulation 
to get an idea of whether the NPs are located at the surface, or rather spread throughout the 
excipient matrix. It was seen that the latter phenomenon occurred with starch NPs being 
present throughout the entire microparticle and not only at the surface. The same was true for 
the formulation loaded with IgG1.  
The aerodynamic properties of the formulations differed with respect to measure of MMAD, 
GSD and FPF. The MMAD was slightly larger for the CS NP formulations, whereas the GSD 
was higher for the starch NP formulations, independent of the used excipient. The FPF, 
however, depended rather on the excipient than on the NP type, with the highest FPF between 
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40% and 50% noted for Starch_manni and CS_manni formulations, respectively. The 
deposition with the PADDOCC worked for all formulations, however differences between the 
formulations were found. Quantitatively speaking, the manni samples looked best, from 
which Starch_manni showed the highest deposited amounts. 
In summary, taking into consideration all tested excipients, there is no clear advantage of one 
special excipient. Lact and treha showed a good redispersion behavior of NPs, however their 
amorphous and highly cohesive character was detrimental for their delivery to the deep lung. 
Manni showed a high degree of deposition and good redispersion in the case of starch NPs, 
however, its influence on protein stability has to be further evaluated. A mixture of treha and 
manni as matrix builder for the microparticle preparation could be proposed. Assessing the 
NP type, starch NPs clearly show an advantage for both important parameters - redispersion 
of the NPs after microparticle dissolution and high deposition in the deep lung - compared to 
CS NPs. Due to that fact, starch NPs were further evaluated for their cell uptake ability 
(Chapter 6).  
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6.  IN VITRO BIOPHARMACEUTICAL EVALUATION OF THE 
NOVEL CARRIERS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The author of the thesis made the following contribution to this chapter:  
 
 
Planned, designed and performed experiments related to particle preparation and 
characterization, cytotoxicity and endoLISA assays as well as uptake studies, analyzed data 
from the mentioned studies, interpreted the experimental data and wrote the manuscript, if not 
stated otherwise. 
  
The cell culture was performed by Stephanie Kletting.  
 
The immunogenicity studies were performed by Anne Marit de Groot at Utrecht University. 
She analyzed data from the mentioned studies and interpreted the experimental data.  
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6.1 INTRODUCTION 
After successful DDS preparation, in vitro biopharmaceutical evaluation of the prepared 
system, including cytotoxicity and immunogenicity assessment as well as the conduction of 
first uptake studies is crucial, before testing the uptake and efficacy of the developed DDS in 
vivo.  
As the carrier system introduced in this thesis was developed for pulmonary delivery, the 
various cellular and non-cellular barriers of the lung must be considered during in vitro DDS 
assessment. These include the epithelial barriers of the upper and the deep lung, mucus as a 
non-cellular barrier and clearance mechanism of the upper lung, as well as macrophages 
patrolling in the deep lung. One of the main barriers to be overcome by the DDS is the 
epithelial barrier of the alveolar region, as these are the specific cells to be targeted by the 
DDS. Nevertheless, interactions could still occur between DDS + macrophages (clearance 
mechanism in the deep lung), but also between DDS + barriers of the upper lung. As a result, 
cytotoxicity testing of the DDS was performed not only with alveolar epithelial cells, but also 
with macrophages and bronchiolar epithelial cells.  
For pulmonary delivery, various cell culture models of the respiratory system are available. 
Regarding epithelia, A549 cells are a well-established cell line of the alveolar region. 
Additionally, Calu-3 cells and 16HBE14o- cells are commonly used to mimic the epithelia of 
the upper airways.198 Further, THP-1 cells have been utilized as a model for macrophages, 
present as a clearance system in the deep lung. While advanced systems, such as co-
cultures,199, 200 or triple-cultures201-203 are available, in the context of the current work, 
monocultures composed of the above mentioned cells were of interest for a first evaluation. 
In this chapter cytotoxicity studies of the source materials used for NP preparation were 
performed on A549 cells, as there is a lack of data related to the pulmonary toxicity of such 
materials. Formulation into nano-sized carriers could alter material toxicity, as well as the 
form of deposition. Thus, both CS and starch NPs were evaluated regarding their cytotoxicity 
in different cell lines. Such testing is of additional importance as recently the OECD guideline 
for the testing of chemicals for subchronic inhalation toxicity was updated, and now includes 
also NPs.204 Additionally, microparticles were evaluated regarding their cytotoxicity in 
different cell lines under liquid covered conditions (LCC) as well as air-liquid-interface 
(ALI), as the deposition under ALI will lead to a different local concentration of the applied 
particles. Immunogenicity experiments with microparticles were conducted by the University 
of Utrecht, a collaboration partner in COMPACT. Due to some surprising results, an 
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endoLISA was performed to investigate any potential source of contamination with 
endotoxins.  
As intracellular delivery was of specific importance in this thesis, investigation of the uptake 
of the particles is necessary in order to assess and ensure efficacy of the DDS-associated 
protein/peptide; therefore, ALI uptake studies of starch NPs on alveolar and bronchial 
epithelia cell lines, i.e. A549 and 16HBE14o-, were conducted. Microparticles were also 
deposited on A549 cells, and NP uptake was studied to see whether microparticles could be 
dissolved on epithelial cells cultivated under ALI.  
Unless stated otherwise, α-starch derivatives, named NegSt and PosSt, were used for 
experiments. 
 
6.2 MATERIALS AND METHODS 
6.2.1 MATERIALS  
Protasan UPCL 113 (chitosan, CS) was bought from Novamatrix, Norway. Sodium 
tripolyphosphate (TPP) was purchased from Merck KGaA, Germany. Negatively 
(NegSt) and positively (PosSt) charged starches were synthesized in house. IgG1 was 
kindly donated by Boehringer Ingelheim (Germany). Mannitol (manni), trehalose 
dihydrate (treha) and α-lactosemonohydrate (lact) were bought from Sigma Aldrich 
(USA). 
A549 cells (No. CCL-185) and Calu-3 cells (No. HTB-55) were purchased from American 
Type Culture Collection (ATCC). 16HBE14o- cells were a kind gift from Dr. Dieter C. 
Gruenert (Department of Otolaryngology, University of California, San Francisco, CA, USA). 
THP-1 cells (No. ACC-16) were bought from DSMZ. Cell culture medium (RPMI 1640), 
minimum essential medium eagle (MEM), fetal bovine serum (FBS), phosphate buffered 
saline (PBS), Hank’s balanced salt solution (HBSS) and sodium pyruvate were obtained from 
Life Technologies (USA), and non-essential amino acids (NEAA) from GE Healthcare Life 
Sciences. Thiazolyl blue tetrazolium bromide (MTT reagent) was bought from Sigma 
Aldrich (USA). TritonTM X-100 was purchased from Sigma Aldrich (U.S.A.). The 
endoLISA® assay endotoxin test kit was purchased from Hyglos GmbH (Germany). Purified 
water was produced by a milliQ water purification system (Merck Millipore, USA). 
All other reagents were of analytical grade.  
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6.2.2 CELL CULTURE 
A549 and THP-1 cells were cultivated in RPMI 1640 medium. Calu-3 and 16HBE14o- cells 
were cultivated in MEM medium containing 1% NEAA, and 1% sodium pyruvate (Calu-3) or 
300 mg glucose (16HBE14o-), respectively. All media contained 10% FBS (v/v). For cell 
viability assays and uptake studies, 1% (v/v) penicillin/streptomycin (P/S, 10 000 U/mL, 
Gibco life technologies, USA) was added to media.  
 
6.2.3 CELL VIABILITY 
Cell viability was evaluated by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay. This colorimetric assay is based on the reduction of the tetrazolium 
dye MTT to its insoluble formazan, by mitochondrial enzymes. The formazan crystals can be 
dissolved in DMSO and show a purple color, the intensity of which depends on the metabolic 
activity of cells. Thus, quantification of the absorbance of solubilized formazan crystals gives 
an indication of how many viable cells are present, in relation to a positive and negative 
control.  
For assessing the cytotoxicity of materials used for NP preparation, 2x104 A549 cells were 
seeded into 96 well plates under LCC. After reaching approximately 90% confluence, the cell 
medium was removed and the cells were washed once with 200 µL HBSS (composed of 1.12 
mM CaCl2, 0.49 mM MgCl2-6H2O, 0.41 MgSO4-7H2O, 5.33 mM KCl, 0.44 mM KH2PO4, 
4.17 mM NaHCO3, 137.93 mM NaCl, 0.34 mM Na2HPO4, 5.55 mM D-glucose, pH 7.4). 
Afterwards, the cells were incubated with material solutions of CS, TPP, NegSt, or PosSt 
dissolved in HBSS (4 h incubation) or RPMI (24 h incubation).  
NP toxicity was studied using A549 (2x104) and THP-1 (1x105) cells, seeded into 96 well 
plates (LCC). Cells were incubated with NP suspensions, diluted with RPMI medium 
(concentrations of 133, 67, 33, 17, and 8 µg/mL) for 4 h and 24 h, respectively.  
To evaluate the microparticles, A549 and Calu-3 cells were seeded into 96 well plates to 
enable LCC investigations, as well as cultivated on Transwell® plates (3460, 1.12 cm2, 
Corning, USA) to enable ALI investigation. The particles were applied after 
dissolution/redispersion of NPs in RPMI (A549) or MEM (Calu-3) in the case of LCC or after 
PADDOCC deposition (10 mg per capsule, in the case of ALI cultures) and incubated for 4 h 
or 24 h.  
In all cases, following incubation of cells with NP materials, NPs or microparticles, cells were 
washed once with 200 µL HBSS buffer. A 100 µL volume fresh HBSS buffer, containing 
10% (v/v) MTT reagent (5 mg/mL) was then added and incubated for a further 4 h. HBSS 
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buffer was aspirated and 100 µL DMSO was added and incubated for 20 min. Absorbance 
was then measured at 550 nm with the Tecan Infinite® 200 microplate reader (Tecan 
Deutschland GmbH, Germany). All incubation steps were done at 37 °C, under gentle shaking 
and light protection. Cell viabilities were calculated in comparison to negative controls 
(untreated cells as 100% value of cell viability) and positive controls (1% TritonTM X-100 
solution as 0% value of cell viability).  
 
6.2.4 IMMUNOGENICITY 
Immunogenicity experiments were carried out by our project partner from Utrecht University. 
Assays were performed according to Zeng et al.205 as follows: 
 
Toll-like receptor activation assay 
Toll-like receptor (TLR) reporter cell lines (HEK-BlueTM-hTLR2, -hTLR3, -hTLR4, -hTLR7, 
and -hTLR9 reporter cells) were cultured as instructed by the manufacturer (InvivoGen, 
France). The TLR reporter cell lines were stimulated with the unloaded or loaded (IgG1) 
microparticles at concentrations of 1, 0.5, 0.1 and 0.05 mg/mL or with the solvent alone, in a 
total volume of 100 µL for 16 h at 37 °C. As positive controls, the following agonists were 
used: PAM3SCK (100 ng/mL) for TLR2, polyinosinic-polycytidylic acid [poly(I:C)] (5 
μg/mL) for TLR3, lipopolysaccharide (LPS)-EK (10 ng/mL) for TLR4, CL264 (5 μg/mL) for 
TLR7 and ODN2006 (10 μg/mL) for TLR9 (all from InvivoGen). To detect the reporter 
protein, secreted alkaline phosphatase (SEAP), 20 μL of the supernatant was added to 180 μL 
of QUANTI-BlueTM substrate (InvivoGen) and incubated for 1 h at 37 °C. Levels of SEAP 
were determined by measuring the absorbance using a microplate reader at 650 nm. Relative 
SEAP levels were defined as the sample level divided by the solvent control level. 
 
Dendritic cell maturation assay  
Femurs and tibia of adult CB6F1/CrL mice (6-12 weeks old) were flushed with culture 
medium (Iscove’s Modified Dulbecco’s Medium) supplemented with 5% (v/v) FBS (Lonza, 
Verviers, Belgium), 50 μM 2-mercaptoethanol (Sigma-Aldrich), penicillin and streptomycin, 
and the cells were seeded in 12-well plates at a concentration of 4.5x105 cells in 1 mL culture 
medium (adapted from Lutz et al.206). Dendritic cells were expanded with 20 ng/mL murine 
recombinant granulocyte macrophage colony stimulating factor (rGM-CSF) (Cytogen, The 
Netherlands). On day 2, the volume of complete growth medium was doubled and on day 5, 
an additional 20 ng/mL rGM-CSF was added. On day 7, bone marrow dendritic cells were 
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stimulated with PBS (1:250), LPS (10 ng/mL) or the unloaded or loaded (IgG1) 
microparticles at concentrations of 1, 0.5, 0.1 and 0.05  mg/mL for 16 h at 37 °C in a 
humidified CO2 incubator. Staining of surface markers with the indicated antibodies was 
performed in the presence of Fc block (2.4 G2) for 30 min on ice. Anti-CD11c (N418) and I-
Ad/I-Ed (M5/114) were purchased from eBioscience (San Diego, CA, USA), and anti-CD40 
(3/23) and -CD86 (GL1) were obtained from BD Biosciences (Breda, the Netherlands). 
Samples were measured on a FACS CantoII (BD Biosciences, San Jose, CA, USA) and 
analyzed using the FlowJo software. Ethical approval for the mouse experiments was obtained 
from the Animal Experiment Committee of Utrecht University, The Netherlands. 
 
6.2.5 ENDOLISA 
Endotoxin amounts were determined with an endoLISA® endotoxin test kit from Hyglos 
GmbH (Germany). Materials were dissolved or particles were dispersed in endotoxin-free 
water at 1 mg/mL. LPS standard was freshly prepared as follows: the lyophilized LPS 
standard was dissolved completely in 2.06 mL endotoxin-free water (500 EU/mL). It was 
vortexed at 1 400 rpm for 10 min and a dilution row was prepared with concentrations of 500, 
50, 5, 0.5, 0.05, and 0 EU/mL. Each sample was vortexed thoroughly before pipetting. A 100 
µL volume of sample was added to a coated 96 well plate, followed by 20 µL of 6x binding 
buffer. The wells were sealed with cover foil and incubated at 37 °C for 90 min with 
continuous mixing at 450 rpm. Afterwards, the plate was washed carefully 3 times with 150 
µL wash buffer per well. Then, 100 µL assay reagent was added to each well. Fluorescence 
was measured at λex = 380 nm and λem = 440 nm and set as time point zero. The plate was 
incubated at 37 °C for another 90 min, following which the fluorescence was again 
determined and designated as time point 1. Endotoxin amount was calculated afterwards 
according to the standard curve. 
 
6.2.6 UPTAKE STUDIES 
For the evaluation of starch NP uptake into A549 and 16HBE14o- cells, 1x105 and 0.6x105 
cells/well, of the respective cell lines were seeded on Transwell® membranes (3460, 1.12 
cm2). After 24 h, A549 cells were set on ALI, i.e. medium was aspirated and 500 µL of fresh 
medium was added to the basolateral compartment only. Two days later, 250 µL of labeled 
starch NPs were deposited onto A549 cells with the Aeroneb®Lab nebulizer (Aerogen Ltd., 
Ireland) and incubated at 37 °C or 4 °C, respectively. Regarding the 16HBE14o- cells, an ALI 
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was established after 48 h in culture. After reaching 90% confluence, 250 µL starch NPs were 
nebulized in the same procedure as for deposition on A549 cells.  
For studying the uptake of the microparticles, A549 were seeded in Snapwell® plates (3801, 
1.12 cm2; Corning, USA) and 10 mg of labeled starch NPs in manni (mass ratio 1:20) were 
deposited with the PADDOCC at 37 °C.  
In all cases, after 1 h, 4 h, and 24 h of incubation, cells were washed with PBS and fixed with 
3% paraformaldehyde (PFA) for 30 min at RT. After fixation, cells were permeabilized with a 
BSA/saponin/PBS solution, followed by an anti-phalloidin staining (1:143 and 1:100 in 
16HBE14o- in BSA/saponin/PBS; actin) for 30 min. After washing, the samples were 
counterstained with DAPI (1:50 000 in PBS; nuclei) and subsequently mounted with DAKO 
mounting medium (DAKO, USA). The samples were analyzed by a confocal laser scanning 
microscope (Zeiss LSM710, Zeiss, Germany). Lasers at 405 nm (DAPI), 488 nm (starch NPs) 
and 633 nm (actin) were used for detection. Microscopic images of fixed samples were 
acquired at 1024 × 1024 resolution, using a 63X water immersion objective. Confocal images 
were analyzed using Zen 2012 software (Carl Zeiss Microscopy GmbH) and Fiji Software 
(Fiji is a distribution of ImageJ available at http://fiji.sc). 
 
6.3 RESULTS AND DISCUSSION 
6.3.1 CYTOTOXICITY SCREENING 
Material used for nanoparticle preparation 
The use of cell lines in general is advantageous in comparison to primary cells, as the latter 
are donor dependent and often lack reproducibility. That is particularly true for lung tissue 
extracted from patients in a diseased state (lung cancer, CF, etc.) for which variations between 
each patient are known. A549 cells were chosen as an epithelium model of the deep lung. 
This was deemed to be a necessary model for investigation, as intracellular delivery to the 
alveolar region requires uptake into such cells; assessment of the toxicity of applied materials 
to such cells is therefore of great importance. A549 cells constitute a human pulmonary 
adenocarcinoma-derived cell line,207 which is both an easily accessible and well-established 
model of the alveolar region for first tests. For evaluating cell viability on exposure to NP 
materials, A549 cells were incubated with CS, TPP, NegSt and PosSt (α-starch derivatives) 
for 4 h and 24 h at 37 °C. Materials were dissolved in HBSS (4 h) or RPMI (24 h) and added 
in various concentrations to the A549 cells. Results can be found in Figure 6.1 with (A) 
representing 4 h of incubation and (B) representing 24 h of incubation. 
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Figure 6.1: Viability of A549 cells after incubation with material used for NP preparation 
(CS, TPP, NegSt, and PosSt); after 4h incubation, samples dissolved in HBSS (A) and after 
24 h incubation, samples dissolved in RPMI (B). Data represent two independent experiments 
(n=3, each). 
 
After 4 h of incubation it could be seen that positively charged polymers were more toxic than 
negatively charged materials, which is in accordance with literature, showing that positively 
charged materials are more toxic compared to negatively charged ones.128, 208 A cell viability 
of 71 ± 6 % was found for the lowest concentration (0.05 mg/mL) of PosSt, which slowly 
decreased with increasing concentration up to 5 mg/mL. In contrast to PosSt, a cell viability 
of 135 ± 8 % was observed for the lowest tested concentration of CS, indicating that the cells 
were under stress. Here, a drastic decrease in cell viability was observed for concentrations of 
around 0.4 mg/mL and greater. In comparison, Huang et al., found that the cytotoxicity of CS 
only significantly increased at concentrations higher than 0.7 mg/mL, and that the cytotoxicity 
was independent of CS molecular weight; toxic effects could also be reduced by reducing the 
degree of CS deacetylation. Additionally, no difference was observed in the cytotoxicity of 
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CS applied as a raw material or as NP suspension.209 The cytotoxic effects in the current work 
could be at least partially ascribed to the low pH of the CS solution. This highlights an 
advantage of the starch material, in that it does not alter the pH of the applied medium. 
Negatively charged materials showed similar cell viabilities for concentrations up 2.5 mg/mL, 
however, whilst NegSt showed a good cell viability of 85 ± 6 % for the highest tested 
concentration, a high concentration of TPP led to a decrease in cell viability to 33 ± 12 %. 
This could be attributed to an increase in osmolality with increasing concentration of TPP. A 
1 mg/mL concentration of TPP was still isotonic (osmolality of around 286 mOsm/kg), 
whereas 2.5 mg/mL already showed an increase up to approximately 310 mOsm/kg and 5 
mg/mL showed an osmolality of approximately 330 mOsm/kg.  Polymeric materials showed 
no effect on osmolality so that samples were always isotonic. 
A general drop in cell viability could be found for the 24 h incubation (Figure 6.1 B), as the 
assay also detected a drop in cell proliferation rather than purely toxicity. In contrast to this, 
CS showed more or less constant cell viabilities of around 70-80%. This could be explained 
by the fact that CS was not soluble in RPMI medium and was applied as suspension, meaning 
that significant interaction with the A549 cells was possibly not taking place.   
 
Cytotoxicity of nanoparticles 
NPs were evaluated for their cytotoxicity using A549 cells, as an uptake of NPs by alveolar 
epithelial cells was the objective. Knowing from the previously conducted formulation studies 
that the molar ratio of NP components strongly influences the ζ-potential, it was aimed here to 
understand the effect of surface charge on cytotoxicity. Thus, three different starch NP 
formulations were studied, employing molar ratios of 3:1, 1:1, and 1:3 PosSt:NegSt, prepared 
from 0.25 mg/mL solutions. For comparison, CS NPs (0.25 mg/mL, molar ratio 10:1 CS:TPP) 
as well as NegSt, PosSt, and a water soluble potato starch (PSs) as control were tested in a 
concentration range from 8 to 133 µg/mL. Viability data of A549 cells after treatment with 
aforementioned samples for 4 h (A) and 24 h (B) are shown in Figure 6.2.  
At the routinely-employed 4 h measurement time point, as suggested by the manufacturers, 
A549 cells incubated with PSs, or NegSt both showed cell viabilities of around 100%. 
Treatment with PosSt resulted in a decrease in cell viability to 65.4 ± 5.5% for the highest 
tested concentration. Such results were comparable to the experiments performed on source 
material (Figure 6.1). Similar results were also obtained for Starch 0.25-3:1 NPs with cell 
viabilities of around 71.3 ± 1.9%. Decreasing the PosSt amount in the NP formulation led to 
an increase in cell viability, which is not surprising bearing in mind that positively charged 
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polymers usually show higher toxicities.128, 208 CS NPs showed a similar behavior to Starch 
0.25-1:1 NPs for the 4 h incubation, while after the 24 h incubation period, a decrease in cell 
viability to 60.9 ± 2.2 % was noted for the highest tested concentration. This is in contrast to 
the cell viability studies performed by Grenha et al., who found a minimum cell viability of 
80% for their tested CS NP suspension.114 However, the CS they were using was of higher 
molecular weight (150 000 - 400 000 g/mol) compared to the CS used in this thesis, with a 
molecular weight of approximately 50 000 - 150 000 g/mol. Although the aforementioned 
Huang et al. found that the molecular weight does not influence toxicity of CS,209 it may 
change the pH of the applied NP suspension so resulting in cell damage. 
 
 
Figure 6.2: Viability of A549 cells after exposure to starch NPs, starch derivatives (PosSt, 
NegSt), or a soluble potato starch (PSs) for 4 h (A) or 24 h (B). Data represent two 
independent experiments (n = 3, each). 
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It can be concluded that, the greater the amount of positively charged material present in the 
starch NP formulation, the lower the observed cell viability. In addition, the chosen starch NP 
formulation Starch 0.25-1:1 showed similar or even better cell viabilities after 4 h and 24 h 
compared to the tested CS NP formulation. In the applied dose of 40 µg for uptake 
experiments, starch NPs showed cell viabilities of 80% or higher. 
Additionally to the A549 epithelial cell line, THP-1 cells, representing alveolar macrophages, 
were used to study the cytotoxicity of NP formulations. In this respect, the formulations CS 
0.25 10:1 (CS NP) and Starch 0.25-1:1 (Starch NP) were chosen. Figure 6.3 shows the cell 
viabilities of THP-1 cells after 4 h, 8 h, and 24 h treatment with CS NPs or starch NPs. 
 
 
Figure 6.3: Viability of THP-1 cells after exposure to CS NPs, or starch NPs (Starch 0.25-
1:1) for 4 h (■), 8 h (♦) or 24 h (○). Data represent two independent experiments (n = 3, each). 
 
For the THP-1 cells, it could be seen that CS NPs showed better cell viabilities compared to 
starch NPs after 4 h of incubation. CS NPs showed constant cell viabilities around 135%, 
indicating that the THP-1 cells were under stress. High viabilities can be a sign of positive 
stimulation; however, they are often also seen before cell viability decreases, demonstrating a 
type of rescue mechanism of the cell. Starch NPs showed a decrease in cell viability to 66.1 ± 
6.9 % for the highest tested concentration. The differences in cell viability of the two 
formulations after 4 h could perhaps be ascribed to differences in uptake kinetics, as the 
results obtained after 8 h and after 24 h of incubation were similar, with CS NPs showing 
slightly higher cell viabilities.  
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Cytotoxicity of microparticles 
Microparticles, consisting either of starch NPs or CS NPs embedded in a microparticle matrix 
of manni, lact, or treha, were tested for their cytotoxicity using A549 and Calu-3 cells. These 
two cell types were chosen for investigation as microparticles would be required to pass 
through the whole respiratory system before deposition in the deep lung (represented by A549 
cells), meaning that they could also interact with epithelial cell lines of the upper lung 
(modeled by Calu-3 cells).  
Therefore, microparticles were dissolved in medium and applied under LCC to A549 or Calu-
3 cells and incubated for 4 h and 24 h, respectively. The results can be found in Figure 6.4. 
 
 
Figure 6.4: Cell viability after incubation with microparticles. Calu-3 cells after (A) 4 h 
incubation; (B) 24 h incubation; A549 cells after (C) 4 h incubation; (D) 24 h incubation; 
concentration [µg/mL] - representative of NP amount in microparticles. 
 
The x-axis represents the concentration of NP in microparticles, to make a comparison to 
Figure 6.2 possible. It was observed that cell viability was independent from the NP material, 
and depended rather on the kind of excipient used for microparticle preparation. Manni 
samples led to a more pronounced decrease in cell viability compared to lact or treha samples. 
No big difference between the two cell lines was found, with the exception of the 24 h time 
point, at which Calu-3 cells seemed to show better cell viabilities compared to A549 cells. 
This is most likely caused by the longer doubling time of Calu-3 cells, leading to a lower 
uptake of particles in comparison to A549 cells within the same time interval, and less 
pronounced effects resulting from particle-induced downregulation of cell proliferation. The 
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differences in excipient tolerability could be attributed to their chemistry, as no differences in 
osmolality were found between the samples. Treha and lact are disaccharides of glucose or 
glucose and galactose monomers, respectively and as such are probably positively influencing 
the cells’ metabolism.   
The cytotoxicity of microparticles was further tested by the University of Copenhagen, a 
COMPACT project partner, using the MTS assay with an incubation time of 1 h. Particles 
showed slightly increased viability, but in general no toxicity was observed (data not shown). 
Further, cytotoxicity was tested under ALI conditions by applying microparticles (10 mg per 
capsule) with the PADDOCC. The results of these investigations are shown in Figure 6.5. It 
could be seen that within cell lines, the differences in cell viabilities between the formulations 
are negligible, although differences in deposited amounts of sample expected to reach cells 
were found in Chapter 5 (Figure 5.9). Calu-3 cells seemed to show higher cell viabilities, 
compared to A549 cells, which is in accordance with results found for LCC (Figure 6.4). As 
mentioned before, this could be due to the fact that Calu-3 cells have a longer doubling time 
compared to A549 cells. 
 
 
Figure 6.5: Cell viability of A549 and Calu-3 cells after deposition of microparticles (10 mg 
per capsule) with the PADDOCC and incubation at 37 °C for 4 h; cell viability determined 
with the MTT assay. 
 
6.3.2 IMMUNOGENICITY SCREENING  
To prevent an undesirable inflammatory and immunological response (in which CD4+ T cells 
may be activated and B cell-derived antigens may be formed) and to prevent the premature 
elimination of the DDS from the body, the immunogenicity of microparticles was tested based 
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on induction of dendritic cell maturation and TLR activation (extracellular: hTLR2, 4; 
intracellular: hTLR 3, 9) via NFκB.  
Antigen-presenting cells, such as dendritic cells, recognize pathogens via pattern-recognition 
receptors. These receptors can recognize peptidoglycan-, RNA- or DNA-associated patterns, 
which are characteristic for pathogens but absent in eukaryotic cells. TLRs are widely studied 
pattern-recognition receptors, and as such in the present experiment the potential activation of 
four different human TLRs (TLR2, TLR3, TLR4, and TLR9) was measured. Additionally, 
dendritic cell maturation was studied. These two assays were used in combination. The human 
TLR reporter assay was used as it is a straightforward and relatively quick human based 
assay, and allows for prediction of which TLR pathway may be activated in vivo. Moreover, 
the dendritic cell maturation assay links the innate and adaptive immune system, and gives a 
prediction regarding whether T cells could become activated in response to administration of 
a specific material. 
Cells were stimulated with microparticles or IgG1 for 16 h in triplicates; results for 
extracellular hTLR2 (A), and hTLR4 (B) can be found in Figure 6.6, whereas results for 
intracellular hTLR3 (B), and hTLR9 (D) can be found in Figure 6.7. In general, no inhibition 
(small diagrams) should be observed, as this could lead to a false negative result. If inhibition 
of the agonist by the sample occurs, the activation (large diagrams) of hTLR cannot be 
interpreted.  
Regarding the hTLR2, no inhibition i.e. SEAP activity was measured and no activation from 
IgG1 and CS particles was observed. Starch particles also showed no inhibition of hTLR2, but 
demonstrated a concentration dependent activation, i.e. DDS particles consisting of starch 
activated TLR more than IgG, thus being more immunogenic than the drug itself.  
Regarding the hTLR4, inhibition in combination with CS particles was lower than the agonist, 
meaning that TLR4 activation data is also inconclusive. The negatively charged agonist 
(LPS)-EK could have been bound by the positively charged CS NPs, hTLR4 is in fact 
activated by CS particles. Starch particles, however, showed no inhibition of hTLR4 - a 
concentration dependent activation of hTLR4 starch particles to a greater extent than IgG was 
observed, meaning that the starch particles were more immunogenic than the drug itself. 
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Figure 6.6: Immunogenicity. Inhibition (small images) and activation (large images) of TLR. 
Percentage of SEAP activity compared to maximum (TLR agonist) is displayed on the y-axis. 
Statistical significance was measured using two-way ANOVA. Statistical analysis was 
performed between drug/DDS and positive control (inhibition) or between drug (IgG) and 
DDS with corresponding concentration, e.g. DDS with concentration of 0.05 mg/mL was 
compared to IgG with a concentration of 0.25 µg/mL (activation). Samples that are 
statistically lower compared to positive control, have inhibited the TLR signaling 
pathway/TLR receptor. Therefore, the data in the activation graph is n.a. It could not be 
concluded if there was an activation/inhibition present. (A) hTLR2; (B) hTLR4. 
 
For the hTLR3, a concentration dependent inhibition of hTLR3 (i.e. SEAP activity) measured 
in combination with CS particles was determined, meaning that the data of hTLR3 activation 
is inconclusive. It is likely, that the agonist for this hTLR, poly(I:C), a nucleotide which is 
negatively charged, was bound by the CS NPs. Thus, it could not be concluded if hTLR3 is 
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activated by CS particles. The same holds true for the starch particles. As part of the NPs 
consist of cationic starch derivatives, they could have bound the agonist poly(I:C), although to 
a lower extent, due to the negative net charge. 
 
 
Figure 6.6: Immunogenicity. Inhibition (small images) and activation (large images) of TLR. 
Percentage of SEAP activity compared to maximum (TLR agonist) is displayed on the y-axis. 
Statistical significance was measured using two-way ANOVA. Statistical analysis was 
performed between drug/DDS and positive control (inhibition) or between drug (IgG) and 
DDS with corresponding concentration, e.g. DDS with concentration of 0.05 mg/mL was 
compared to IgG with a concentration of 0.25 µg/mL (activation). Samples that are 
statistically lower compared to positive control, have inhibited the TLR signaling 
pathway/TLR receptor. Therefore, the data in the activation graph is n.a. It could not be 
concluded if there was an activation/inhibition present. (A) hTLR3; (B) hTLR9. 
 
For the hTLR9, no inhibition (i.e. SEAP activity) was measured in combination with CS 
particles, and no activation of hTLR9 was observed; in some cases, the CS DDS particles 
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showed significantly lower SEAP activity compared to corresponding IgG concentrations. 
Also starch particles showed no inhibition and no activation of hTLR9; also here, the starch 
DDS showed significantly lower SEAP activity compared to corresponding IgG 
concentrations in some cases. 
It could be concluded, that starch microparticles were more likely to activate TLR than CS 
microparticles. However, only an activation of extracellular hTLR, i.e. 2 and 4, was observed, 
whereas intracellular hTLR3 and hTLR 9 were not activated. As an activation of the TLR is a 
hindrance for pulmonary applications, these results were followed up by an endotoxin assay 
(Chapter 6.3.3) to identify the source of TLR activation. 
For the murine bone marrow-derived dendritic cells (BMDC) maturation assay, cells were 
stimulated with microparticles or IgG1 for 20 h in duplicates. Results can be found in Figure 
6.8. 
 
 
Figure 6.8: BMDC maturation assay. CD40+CD86/MHCII+CD11c frequency as a 
percentage of the parent population is displayed on the y-axis. Statistical significance was 
measured using two-way ANOVA. Statistical analysis was performed between drug (IgG) 
and DDS with corresponding concentration, e.g. DDS with concentration of 0.05 mg/mL was 
compared to IgG with a concentration of 0.25 µg/mL.  
 
 
Chitosan particles showed no increased maturation of dendritic cells. In some cases however, 
the percentage of CD40+CD86+ cells was lower compared to the corresponding IgG1 
concentration. In the case of starch particles, there was an increased maturation of dendritic 
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cells especially at the two highest concentrations (0.1, 0.5 and 1 mg/ml). The effect was also 
concentration dependent: the percentage CD40+CD86+ cells increased with increasing 
concentration. 
 
6.3.3 ENDOLISA 
Due to the results from the immunogenicity data, an endoLISA was performed to see whether 
the material itself was immunogenic or whether any endotoxin impurities may have been 
present, leading to false positive results. Therefore, all synthesized starch derivatives were 
tested as well as CS and TPP. To identify the source of any potential contamination within the 
preparation steps, also NPs, as well as microparticle formulations were also applied. The 
results can be found in Figure 6.9.  
 
Figure 6.9: Endotoxin concentration in material samples (dissolved in endotoxin-free water) 
as well as NP or microparticle formulations (dispersed in endotoxin-free water). For particle 
preparation α-starch derivatives were used. 
 
It could be seen that no endotoxins were found for CS material or for CS formulations. This is 
in accordance with the statement of the manufacturer, who guarantees an ultra-low level of 
endotoxins in this material. Negatively charged starches showed only very little amounts of 
endotoxin, independent of the degree of starch oxidation. In contrast, PosStα, with a degree of 
substitution of 33%, showed a very high endotoxin concentration of approximately 45 
EU/mL. All other PosSt derivatives, however, showed only a low concentration of 
endotoxins. This was independent of the degree of substitution, as PosStβ with a degree of 
substitution of around 47% showed only around 1 EU/mL. This further decreased for PosStγ 
and PosStδ. Starch NPs, consisting of 50% PosStα, showed a concentration of 31 EU/mL. 
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starch microparticles consisting of starch NPs and excipient (mass ratio 1:20) showed again a 
decreased concentration of approximately 3 EU/mL.  
As the found endotoxin concentration was independent of the degree of substitution 
(comparison of PosStα and PosStβ), a direct activation from the starch material itself could be 
excluded. It was however interesting that a lower endotoxin concentration was observed when 
comparing the PosStδ derivative to the PosStα derivate. This result could indicate that the 
synthesis time point and storage time could have had an influence, as PosStα was synthesized 
at least one or two years before PosStβ. The other PosSt derivatives were all synthesized over 
a short period of time. The strong immune activation observed in the TLR assays and the DC 
maturation assay was thus most likely due to the contamination of the cationic starch 
derivative during storage and not by one of the preparation steps. It could be concluded, that 
the conditions for storage of PosSt are very important to control. This gives some perspective 
to eliminate this problem in further studies. During the experiments, PosSt was kept light 
protected at RT. Storage at 4 °C or even -20 °C could show an improvement. Also storage in a 
desiccator under low relative humidity could show an advantage. Keeping this in mind, the 
cytotoxicity data as well as immunogenicity data should be interpreted with care and ideally 
be performed for carriers prepared from newly synthesized starch derivatives. 
 
6.3.4 UPTAKE STUDIES 
Nanoparticles 
In order to evaluate uptake of starch NPs into A549 cells, PosSt was labeled with a green 
fluorescent dye (Bodipy® FL C5 NHS Ester, for synthesis see Chapter 3), following which 
starch NPs were prepared from 0.25 mg/mL solutions in a ratio of 1:1. The size of these 
labeled starch NPs was 145.2 ± 0.1 nm, with a PdI of 0.1, indicating a narrow size 
distribution. The ζ-potential was -26.4 ± 2.8 mV. As a control, A549 cells were grown under 
ALI conditions without treatment. Starch NPs were stable during nebulization (with a slight 
decrease in the ζ-potential, Chapter 4), and were deposited onto A549 cells and further 
incubated for 1 h, 4 h and 24 h at 4 °C or 37 °C. Endocytosis, as an energy-driven uptake 
mechanism, is highly reduced in cells when incubated at 4 °C. If NPs are taken up by the cells 
at 4 °C, it can be concluded that the uptake is not mediated by an energy-dependent 
mechanism. The binding and uptake of starch NPs by A549 cells can be seen in Figure 6.10 as 
z-stacks. Usually, the thickness of the samples is greater than that of a single focal plane. Z-
stacks are created by incrementally stepping through the sample and taking images at different 
focal planes. The advantage of this technique is that the complete sample can be visualized. 
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For this study, the ability to create z-stacks means that NP localization with respect to surface 
binding vs. uptake into cell can be visualized, as indicated in Figure 6.10 as either an arrow 
(extracellular NPs) or arrow head (intracellular NPs).  
Particles (green) showed an uptake already after 1 h of incubation at 37 °C. There was also 
some uptake after 1 h of incubation at 4 °C, although to a lower extent under these conditions, 
suggesting that at least a part of the uptake mechanism is energy dependent, i.e. normally 
occurs by endocytosis. The cell-associated fluorescence as observed at 4 °C could be either 
due to mere binding to the cell membrane or indicate some nonspecific, energy independent 
uptake. Such nonspecific uptake is known for A549 cells, suggesting that this could be a cell-
dependent phenomenon.91 
 
 
Figure 6.10: Confocal laser scanning microscopy (CLSM) images of 250 µl nebulized starch 
NP onto A549 cells, cultivated at the ALI. (A) after 1 h incubation at 37°C; (B) after 1 h 
incubation at 4°C; (C) after 4 h incubation at 37°C; (D) after 4 h incubation at 4°C; (E) after 
24 h incubation at 37°C; (F) A549 without treatment, incubated at 37°C.  Cells were washed 
with PBS, fixed with 3% PFA and stained. Blue: DAPI; red: actin; green: starch NP; scale bar: 
10 µm; arrow: extracellular NPs; arrow head: intracellular NPs; (n=2).  
 
To investigate this possibility further, the interaction of starch NPs with 16HBE14o- cells, a 
cell line generated by transformation of normal human bronchial epithelial cells that does not 
show carcinoma-like properties,210, 211 was also tested at 37 °C. The size of starch NPs in this 
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case was 114.6 ± 2 nm, with a PdI of 0.12 and a ζ-potential of -28.1 ± 0.6 mV. The results of 
this study can be found in Figure 6.11. No particle uptake was seen after 1 h of incubation. 
However, after 4 h and 24 h of incubation, particles could be internalized. In this case, the 
confocal microscopy analysis provides qualitative data only - uptake amount should not be 
compared between the two cell types since the particle batch and the instrument settings (e.g. 
laser power) were not identical. From the images it seemed that the uptake into A549 was 
more pronounced; however, the experiment on the 16HBE14o- cells was only performed 
once, and it is suspected that the result may be influenced by a problem with the level of 
particle fluorescence, as an A549 cells experiment was run in parallel and showed the same 
effect. Nevertheless, an interaction of starch NPs with non-cancer pulmonary cell lines could 
be suggested. 
 
 
Figure 6.11: CLSM images of 250 µl nebulized starch NP onto 16HBE14o- cells, cultivated 
at the ALI at 37 °C. (A) after 1 h incubation; (B) after 4 h incubation; (C) after 24 h 
incubation; (D) control; cells were washed with PBS, fixed with 3% PFA and stained. Blue: 
DAPI; red: actin; green: starch NP; scale bar: 10 µm. 
 
In summary, starch NPs were able to be internalized by A549 cells, and, from a preliminary 
study also potentially taken up by cells of a non-cancer cell line, 16HBE14o-. Thus, NPs 
should be able to be internalized once released from the microparticles following lung 
deposition. 
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Microparticles 
To investigate the uptake of starch NPs when applied as dry powder formulation, 
microparticles (Starch_manni 1:20) were deposited on A549 cells with the PADDOCC (10 mg 
per capsule). The uptake was studied after 1 h, 4 h and 24 h of incubation at 37 °C and can be 
found in Figure 6.12. Compared to the starch NP uptake on A549 cells, fewer particles can be 
found for the application of the microparticles. This is reasonable, due to the fact that only 
1:20 of the microparticles consisted of starch NPs and that only a limited amount of the 
applied fraction reached the cells after deposition with the PADDOCC. Nevertheless, particles 
can be found already after 1 h of incubation, suggesting that the microparticles were rapidly 
dissolved, releasing the starch NPs. Also after 4 h and 24 h of incubation, particles were 
internalized. In contrast to the direct application of starch NPs, where NPs could be found 
throughout the sample, microparticles were not homogenously distributed, but rather showed 
some high deposition and low deposition spots.  
 
 
Figure 6.12: CLSM images of Starch_manni 1:20 deposited with the PADDOCC (10 mg per 
capsule) onto A549 cells, cultivated at the ALI at 37 °C. (A) after 1 h incubation; (B) after 4 h 
incubation; (C) after 24 h incubation; (D) control; cells were washed with PBS, fixed with 3% 
PFA and stained. Blue: DAPI; red: actin; green: starch NP; scale bar: 10 µm. 
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6.4 CONCLUSION 
The cytotoxicity screening on A549 cells revealed that positively charged materials were 
more toxic, compared to negatively charged materials. NegSt, however, showed a higher 
tolerance compared to TPP, probably due to the effect of TPP on osmolality. On A549 cells, 
starch NP formulations showed a decrease in cell viability with increasing PosSt amount, thus 
a final formulation consisting of a molar ratio of 1:1 (PosSt: NegSt) was chosen. Additionally, 
starch NPs were comparable or better than the standard CS formulation. This behavior was 
different for the cytotoxicity on THP-1 cells, where CS NPs showed an advantageous 
behavior after an incubation of 4 h. Following 24 h of incubation, however, it was revealed 
that both particle types showed more or less comparable effects. Cytotoxicity testing of 
microparticles under LCC revealed a detrimental effect of manni samples, independent of the 
NP formulation. However, this effect was not pronounced under ALI conditions. It could be 
suggested that Calu-3 cells were less sensitive than A549 cells, due to their longer doubling 
time, thus leading to a lower endocytic uptake of particles per unit time.  
Immunogenicity data indicated that the starch delivery system was more immunogenic 
compared to the CS NPs, thus not suitable for application in vivo. However, CS NPs often 
interfered with the assay, due to presumed binding of the agonist to CS NP surfaces, meaning 
that an accurate analysis of the results was not possible. Additionally, results obtained from 
the endotoxin assay suggested that the observed apparent immunogenicity of the starch 
system could be due to suboptimal storage conditions of PosStα, leading to incorporation of 
immunogenic endotoxin impurities. It could be shown that the endotoxin concentration was 
independent of the degree of substitution of PosSt and also that the closer the starch derivative 
synthesis was to the performed endoLISA experiment, the lower the found endotoxin 
concentration. An alternative could therefore be the use of newly synthesized PosSt 
derivatives for DDS and additional cytotoxicity and immunogenicity screenings, or the 
removal of endotoxin impurities. The latter is challenging, as endotoxins are heat resistant, 
meaning that samples must be stored at 200 °C for at least 4 h or treated with 1 M NaOH in 
order to facilitate endotoxin removal. An alternative approach could be the application of 
EndoTrap® from Hyglos, which is a chromatography based method for endotoxin removal. In 
comparison to starch derivatives, CS and its formulation did not show any endotoxin 
impurities, due to the fact that the material was bought in high quality from Novamatrix, who 
also guaranteed a very low content of endotoxins. These findings show, how important a 
detailed material characterization is, with regards to material purity and presence of 
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impurities, especially with respect to new materials that cannot be bought from a 
manufacturer.  
The uptake of starch NPs after aerosolization onto A549 cells and 16HBE14o- cells indicate 
that starch NPs could be suitable for intracellular protein/peptide delivery. Also the 
application of the dry powder formulation led to an uptake of starch NPs in A549 cells that 
was already visible after 1 h of incubation, demonstrating that the microparticles were able to 
quickly dissolve and release the NPs.  
In a next step, intracellular protein/peptide delivery by loaded starch NPs should be evaluated, 
as well as a competitive particle uptake between macrophages and epithelial cells. Results of 
those experiments are included in the thesis A new cell line-based coculture model of the 
human air-blood barrier to evaluate the interaction with aerosolized drug carriers by 
Stephanie Kletting. 
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 7.  SUMMARY AND OUTLOOK 
 
Protein and peptide delivery is a demanding task. The pulmonary route of administration in 
particular, requires special attention regarding formulation strategy and a good knowledge of 
the used materials, in order to facilitate effective delivery of proteins and peptides. 
The aim of this thesis was focused on the development of a novel nanotechnology enabled 
DDS suitable for pulmonary protein and peptide delivery, using novel excipients. 
In this context, the synthesis and characterization of starch derivatives was performed, 
including an optimization of product purification performed by precipitation of the material, 
as well as introducing an alternative coupling agent, DMTMM. 
NP preparation from synthesized starch derivatives via charge mediated coacervation in 
aqueous medium was successfully performed, offering a mild preparation method for loading 
with proteins and peptides. This procedure was seen to be most successful for NP loading 
with vanco, with an EE of ~43% and a LR of ~23% obtained in this case. No organic 
solvents, no harsh preparation conditions, and no additional excipients, e.g. for stabilization 
purposes, had to be used for such NP preparation. 
A carrier system for the delivery of NPs to the deep lung was further developed. The market 
situation shows that APIs for inhalation are usually applied as physical mixture with larger 
carrier particles acting as a vehicle for deep lung deposition. This often results in a high 
fraction of particles that do not reach the lung, as de-agglomeration in the air-stream is 
required. The developed carrier system instead consists of a fast dissolving carrier matrix with 
aerodynamic properties, suitable for deep lung deposition, which incorporates the NPs and 
facilitates a fast NP release in the deep lung.  
In vitro experiments revealed opportunities but also drawbacks of the developed DDS. It 
could be shown that starch NPs applied without but also with the microparticle carrier system 
were able to be taken up by alveolar epithelial cells (A549), ensuring an intracellular delivery 
of the cargo. However, immunogenicity data revealed a contamination with endotoxins, 
which could to a certain extent also explain the obtained cytotoxicity data.  
In summary, these findings underline the close interplay between knowledge of the material 
used for drug delivery preparation, and in vitro testing approaches, in addition to the 
development of a suitable DDS for APIs from a technological viewpoint. Additionally, in the 
case of proteins and peptides as API, a sound knowledge of their characteristics is also 
necessary.  
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Although a few questions could be answered in the current work, several open questions still 
remain and could form the basis of future work. In the course of material synthesis an 
alternative coupling reagent was found in DMTMM, and an improvement in the purification 
method could be shown; however, scalability from milligram to gram, and further to 
kilogram, is of interest from an industrial point of view. Furthermore, although a possible 
explanation for the apparent immunogenicity of the system was found – namely, 
contamination with endotoxins – the application of different elimination techniques (e.g. with 
EndoTrap®) followed by further evaluation with the endoLISA are of importance to 
substantiate this hypothesis. Cytotoxicity and immunogenicity data should also be repeated in 
conjunction with such investigations. 
NP preparation and loading was successful with model proteins. The loading with an actual 
disease-relevant cargo with subsequent efficacy testing is however of interest. The release 
kinetics of such a cargo from NPs could be investigated.  
The microparticles (and especially Starch_manni) showed a high degree of deposition in the 
deep lung, and a considerable uptake of starch NPs, when deposited as dry powder 
formulation. However, release studies of the NPs in lung relevant medium (e.g. simulated 
lung fluid) as well as real-time imaging of the dissolution of the microparticles on pulmonary 
epithelial cells are of interest. Further, particle uptake by epithelial cells vs. macrophages 
should be evaluated (e.g. with a co-culture model). 
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8.  LIST OF ABBREVIATIONS 
 
ALI air-liquid-interface 
ANOVA analysis of variance 
API active pharmaceutical ingredient 
AT-I alveolar type I cell 
AT-II alveolar type II cell 
BCA bicinchoninic acid 
BMDC murine bone marrow-derived dendritic cells 
BSA bovine serum albumin 
CLSM confocal laser scanning microscopy 
COMPACT collaboration on the optimization of macromolecular pharmaceutical access to 
cellular targets  
CS chitosan 
DAPI 4‘,6-diamidin-2-phenylindol 
DCC N,N’-dicyclohexylcarbodiimide  
DDS drug delivery system 
DLS dynamic light scattering 
DMSO dimethyl sulfoxide 
DMTMM 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride 
DPI dry powder inhaler 
DSMZ  Deutsche Sammlung von Mikroorganismen und Zellkulturen 
EE encapsulation efficiency 
efpia European Federation of Pharmaceutical Industries and Association 
EMA European Medicines Agency 
FACS fluorescence-activated cell sorting 
FBS fetal bovine serum 
FDA (US) Food and Drug Administration 
FPF fine particle fraction 
FT-IR fourier transform infrared spectroscopy 
GPC gel permeation chromatography 
GRAS generally recognized as safe 
GSD geometric standard deviation 
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HBSS  Hank’s balanced salt solution 
HOBt 1-hydroxybenzotriazole 
hTLR human toll-like receptor 
IEP isoelectric point 
IMI Innovative Medicines Initiative 
IPF idiopathic pulmonary fibrosis 
lact lactose 
LCC liquid covered condition 
LPS lipopolysaccharide 
LR loading rate 
Lyso lysozyme 
manni mannitol 
MDI metered dose inhaler 
MEM minimum essential medium eagle 
MMAD mass median aerodynamic diameter 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
FluNa sodium fluorescein 
NaOCl sodium hypochlorite 
NCS nanotoxicology classification system 
NEAA non-essential amino acids 
NegSt negatively charged starch derivative 
NGI next generation impactor 
NMR nuclear magnetic resonance 
NP nanoparticle 
OVA ovalbumin 
PADDOCC pharmaceutical aerosol deposition device on cell culture 
PBS phosphate buffered saline 
PdI polydispersity index 
PFA paraformaldehyde 
PosSt positively charged starch derivative 
PTA phosphotungstic acid 
RNAse A ribonuclease A  
RPMI Roswell Park Memorial Institute (cell culture medium) 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
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SEAP secreted embryonic alkaline phosphatase 
SEM scanning electron microscopy 
TEM transmission electron microscopy 
TEMPO (2,2,6,6-tetramethylpiperidin-1-yl)oxidanyl 
TPP sodium tripolyphosphate 
treha trehalose 
vanco vancomycin  
XRPD x-ray powder diffraction  
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